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ABSTRACT 
The work embodied in this thesis was designed to explore the interaction between the 
renin -angiotensin -aldosterone system (RAAS) and the autonomic nervous system. It 
was stimulated by the observations that the neurohormonal suppression of the RAAS 
by ACE inhibitors in chronic heart failure (CHF) is inadequate, and that high residual 
levels of circulating aldosterone have been shown to have detrimental autonomic 
modulating effects independent of angiotensin II in experimental models. 
The effects of aldosterone blockade with spironolactone therapy were 
examined in CHF patients already established on ACE inhibitors. It was observed that 
spironolactone has beneficial parasympathomimetic properties, improving heart rate 
variability and reducing heart rate, particularly during the early morning hours of the 
day when ACTH -induced aldosterone secretion is maximal. The interaction between 
the RAAS and the parasympathetic tone was explored further in a series of normal 
volunteer studies. Although the effects of ACE inhibitors are well recognised, not 
much is known about the parasympathomimetic properties of direct angiotensin II or 
aldosterone receptor antagonism. In this thesis, it was demonstrated that losartan, an 
angiotensin II receptor antagonist, and enalapril, an ACE inhibitor, were equally 
effective in improving the vagally- mediated baroreflex response in salt depleted 
normotensive subjects. It was also demonstrated that direct intravenous aldosterone 
administration impaired the baroreflex response to vasopressor agents in healthy 
subjects. 
The observed vagomimetic effects of aldosterone blockade may have 
important therapeutic implications, suggesting the possibility that spironolactone may 
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have anti -ischaemic or anti -arrhythmic properties. However, aldosterone blockade did 
not appear to have any significant impact on either autonomic tone or ischaemic 
events when administered to patients with ischaemic heart disease but preserved LV 
function. The reasons for the latter remain unclear but may reflect differences in 
disease -state (less neurohormonal activation, and a larger proportion of these patients 
was established on beta -blockers -which may influence autonomic tone - and only a 
minority was taking concomitant ACE inhibitors, compared to the CHF cohort). In 
CHF however, spironolactone was shown to improve QT dispersion, a surrogate 
marker of arrhythmic activity and sudden cardiac death. Mechanisms in which 
aldosterone may contribute towards dispersion of the QT intervals on the 
electrocardiogram are probably multifactorial. Aldosterone increases cardiac afterload 
(by increasing vascular tone and potentiating vascular smooth muscle hypertrophy) 
and it is demonstrated that cardiac afterload would increase QT dispersion through 
mechano- electrical feedback. Vagal tone modulation itself however did not contribute 
towards QT dispersion. 
These studies demonstrate how inextricably linked the RAAS and the 
autonomic nervous system is. In particular, the detrimental autonomic effects of 
aldosterone in CHF have been highlighted. The findings of these studies highlight 
possible mechanisms and provide valuable insights as to why further therapeutic 
mileage is gained by the addition of an aldosterone antagonist in CHF patients who 
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The past two decades have seen tremendous advances in our understanding of the 
renin -angiotensin -aldosterone system (RAAS) and the pathophysiology of chronic 
heart failure (CHF). Indeed, angiotensin -converting enzyme (ACE) inhibitors have 
revolutionized the management of CHF. 
In recent years, ACE inhibitors have been shown to reduce the morbidity and 
mortality rates not only in CHF, but also in asymptomatic left ventricular dysfunction 
and in post- myocardial infarction patients [Cohn et al 1991, Pfeffer et al 1992, 
Rutherford et al 1994, CONSENSUS -1 1987, SOLVD 1991, AIRE 1993, Kober et al 
1995]. However, despite these beneficial effects, the morbidity and mortality rates of 
CHF remains high [CONSENSUS -1 1987, SOLVD 1991]. It may however be 
possible to obtain more therapeutic mileage from the concept of inhibiting the RAAS 
than is being obtained currently in normal clinical practice. There are two main 
reasons for this. Firstly, the doses of ACE inhibitors currently used in clinical practice 
are often lower than those used in major survival trials [Cleland and Poole- Wilson 
1995]. These low doses used in clinical practice may not be optimally effective and 
higher doses may be required to inhibit the RAAS optimally. High doses of ACE 
inhibitors appear to suppress the RAAS more effectively than low doses [Davidson et 
al 1996]. Secondly, even when used at the highest tolerated doses, ACE inhibitors 
themselves may not completely suppress the RAAS. In a significant proportion of 
these patients on chronic ACE inhibition, the plasma aldosterone (and to a lesser 
extent, Angiotensin II [Ag II] ) levels rise again despite initial suppression, after as 
little as three months of treatment [Staesson et al 1981, Barghi et al 1993]. There is a 
growing body of evidence to suggest that the neurohormonal re- activation, especially 
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that of aldosterone, has adverse effects on the cardiovascular system, such as the 
modulation of the cardiac autonomic tone. In fact, aldosterone blockade has recently 
been shown to reduce both morbidity and mortality among severe CHF patients 
already established on ACE inhibitors [Pitt et al 1999]. These observations form the 
core of this thesis. The potential adverse effects of the neurohormonal "escape" of the 
RAAS axis despite ACE inhibitors, are explored in the studies carried out in this 
thesis. 
By way of an introduction, I shall first of all, present an overview of the 
RAAS axis, with particular attention paid to the potential mechanisms and clinical 
significance of the neurohormonal reactivation despite ACE inhibitors in CHF. 
Whereas the adverse effects of Ang II are well documented, the potential adverse 
effects of aldosterone on the cardiovascular system are less well known. The current 
literature on the role of aldosterone escape in CHF is also reviewed, highlighting 
where relevant, the unresolved issues which prompted the studies constituting this 
thesis. 
1.1 Overview of the Renin -Angiotensin - Aldosterone System and its inhibition: 
Evidence from the large mortality trials 
The organisation the RAAS system is shown in Fig 1.1. In low cardiac output 
states like heart failure, there is activation of the RAAS system, which operates in 
concert with the sympathetic nervous system to maintain arterial pressure. Firstly, 
stimulation of the ß 1- adrenoceptors in the juxtaglomerular apparatus of the kidneys as 
a result of heightened adrenergic drive is a principal mechanism responsible for the 
release of renin in CHF. Secondly the reduced cardiac output and vasoconstriction of 
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heart failure lead to a redistribution of blood flow away from the kidney. The 
decreased renal perfusion and the subsequent activation of the baroreceptors in the 
renal vascular beds also increase renin secretion. Plasma renin activity is further 
increased in CHF by diuretic therapy and salt restriction (which result in a reduction 
of sodium presented to the macula densa), and activation of left atrial volume 
receptors. 
The increased plasma renin activity leads to the formation of Mg II. Among 
the components of the RAAS, Ang II has the most potent and best -studied effects 
(see Table 1.1). It is a potent vasoconstrictor, up to 40 times stronger than 
noradrenaline, and contributes to the excessive elevation of systemic vascular 
resistance in CHF. In addition Ang II increases sympathetic outflow. It enhances 
peripheral sympathetic transmission; it augments output of norepinephrine from nerve 
terminals and block reuptake of norepinehrine. It also stimulates vasopressin and 
aldosterone release. 
Aldosterone secretion is regulated by the RAAS system, potassium ion and 
ACTH. It has potent sodium retaining properties. Renin and aldosterone secretions 
respond dynamically to even small changes in sodium balance. Aldosterone is also a 
primary regulator of potassium balance, providing hameostasis over a wide range of 
variation in potassium intake. In addition to these well known renal effects, there is 
now increasing evidence emerging from animal studies and clinical observations that 
aldosterone may have other adverse direct cardiac and vascular effects. Recent 
experiments have uncovered aldosterone binding sites in the heart, vascular wall and 
the brain in addition to the well -known renal receptors in the distal nephron. These 
potentially harmful effects are reviewed separately in Sections 1.3 -1.6. 
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It is clear by looking at the adverse effects of Ang II and aldosterone, that 
there is much to be gained by neurohormonal suppression of the RAAS in CHF, 
which would reduce systemic vascular resistance, diminish afterload and improve 
cardiac output. Indeed a number of large well -designed randomised trials have 
demonstrated that ACE inhibitors improve survival in these patients regardless of 
aetiology or severity of symptoms. The Cooperative Northern Scandinavian Enalapril 
Survival Study [CONSENSUS -1 1987] demonstrated a 40% reduction in mortality at 
6 months in patients with severe heart failure who were randomised to enalapril rather 
than placebo. Subsequent trials have examined the effects of ACE inhibitors in mild or 
moderate heart failure.. The treatment arm of the Studies on Left Ventricular 
Dysfunction trial [SOLVD 1991] that randomised patients with symptomatic mild -to- 
moderate heart failure with left ventricular ejection fraction (LVEF) less than 35% to 
either enalapril or placebo reported a statistically significant 16% reduction in overall 
mortality in the enalapril treated group. 
The second Veterans Administration Cooperative Vasodilator Heart Failure 
Trial (V- HeFT -II) showed a small but clear survival benefit in patients with mild -to- 
moderate heart failure who had been randomised to receive enalapril rather than the 
combination of hydralazine and isosorbide dinitrate [Cohn et al 1991]. The Survival 
and Ventricular Enlargement (SAVE) trial studied patients with recent myocardial 
infarction and LVEF of 40% or less, but without overt heart failure, and showed a 
20% reduction in mortality and a 36% reduction in the rate of progression to severe 
heart failure in the captopril- treated group after 48 months of follow up [Pfeffer et al 
1992, Rutherford et al 1994]. Both the SOLVD [1991] and the SAVE [Pfeffer et al 
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1992, Rutherford et al 1994] trials demonstrated that enalapril and captopril, 
respectively, markedly reduced or prevented the increases in left ventricular end - 
diastolic and end - systolic volumes and decline in EF observed in patients randomised 
to receive placebo. The Acute Infarction Ramipril Efficacy trial was similar to the 
SAVE trial, except that it randomised only patients who manifested clinical evidence 
of heart failure to either ramipril or placebo [AIRE 1993]. There was a significant 
27% reduction in mortality in the ACE inhibitor treated group that was apparent 
within 30 days of treatment (unlike SAVE, in which the survival curves did not 
diverge until 1 year). The Trandolapril Cardiac Evaluation (TRACE) trial studied 
patients with severe left ventricular dysfunction 3 to 7 days following myocardial 
infarction and reported a.20% reduction in mortality [Kober et al 1995]. 
Taken together these trials indicate that ACE inhibitors prolong survival in a 
broad spectrum of patients with myocardial infarction and heart failure, ranging from 
those who are asymptomatic with LV dysfunction to those with symptomatic heart 
failure. However, despite these major advances, a considerable degree of mortality 
still remains eg. 36% in CONSENSUS- 1(severe CHF) after 1 year, and 35% in 
SOLVD (mild to moderate CHF) after 4 years. Similarly whereas hospitalisation in 
SOLVD decreased by 15 %, a considerable number of hospitalisations for heart failure 
remained. The reasons for these high morbidity and mortality rates are unclear. The 
beneficial effects of ACE inhibitors have been attributed to its ability to cause 
neurohormonal suppression. For example, in the V -HeFT II Study [Cohn et al 1991], 
enalapril had a better effect on survival than did the combination of hydralazine and 
isosorbide dinitrate. Whereas both treatments cause vasodilation, only enalapril causes 
neurohormonal suppression. Furthermore, in the CONSENSUS I Study, increased 
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levels of Ang II and Aldosterone correlated with mortality [Swedberg et al 1990]. 
However the long term suppressive effects of ACE inhibitors on aldosterone are 
weak, variable and unsustained [Struthers 1996]. Therefore, neurohormonal 
reactivation or "escape" of aldosterone (and to a lesser extent, Ang II) as mentioned 
earlier, may be one of the reasons why mortality rates remain high in conditions such 
as CHF despite ACE inhibitor therapy. 
The effects of concomitant administration of the aldosterone antagonist, 
spironolactone, with ACE inhibitors were recently evaluated in the multicentre 
Randomised Aldactone Evaluation Study (RALES) [Pitt et al 1999]. In this 
randomised double -blind study, 1663 CHF patients with an LV ejection fraction 
<35% and who were already established on ACE inhibitors were assigned to either 
spironolactone 25mg daily or placebo. Over a mean follow up period of 24 months, 
both total mortality (including sudden deaths) and hospitalisations were substantially 
reduced by 30% and 35% respectively, in the spironolactone group compared to 
placebo. These results suggest that neurohormonal suppression by ACE inhibitors 
alone may not be adequate and further therapeutic mileage may be obtained through 
the addition of an aldosterone antagonist. 
1.2 Mechanisms for neurohormonal reactivation (escape) during chronic ACE 
inhibition 
The introduction of ACE inhibitor therapy reduces plasma Ang II and 
aldosterone levels in CHF. It is however uncertain whether the initial reduction in 
plasma aldosterone levels promoted by ACE inhibition can be sustained. A resurgence 
in aldosterone (and to a lesser extent, Ang H) levels has been observed after as little 
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as 3 months of ACE inhibitor therapy in hypertension [Staesson et al 1981, Biollaz et 
al 1982]. A similar pattern can also be seen with the use of ACE inhibitors following 
myocardial infarction [Barghi et al 1993]. In CHF, Cleland et al [1984] found that a 
wide and variable range of plasma aldosterone levels remained after 6 weeks of 
treatment with captopril. 
There are several possible underlying mechanisms for this aldosterone escape 
phenomenon. Firstly, aldosterone escape may be secondary to angiotensin II 
reactivation during chronic ACE inhibition. Secondly, even when Ang II production is 
completely suppressed, there is evidence to suggest that aldosterone escape may 
occur independently. Staessen et al [1981] found an increase in plasma aldosterone 
levels after 3 months of -ACE inhibition that was not associated with an increase in 
plasma levels of Ang II. This suggests that aldosterone and Ang II levels may become 
dissociated over time and raises the possibility that there are alternative pathways for 
aldosterone production. 
I will now discuss some of these mechanisms. 
Angiotensin II reactivation: 
Ang II reactivation may be the result of any, or all, of the following: 
i) Poor compliance with ACE inhibitor therapy. Non -compliance is more likely 
in patients with CHF as they are elderly and often on multiple drug therapy [Monane 
et al 1994]. 
ii) Counteracting effects of concomitant treatment with diuretics and 
vasodilators [Doig et al 1993]. Vasodilators such as nitrate -hydralazine [Cohn et al 
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1991], calcium channel blockers [Packer 1989] and diuretic -induced salt and water 
loss [Bayliss et al 1987, Kubo et al 1987, Cleland et al 1988] have all been shown to 
cause neurohormonal activation. 
iii) Generation of Ang II by a non -ACE dependent pathway. The first 
physiological descriptions of alternative Ang II formation were reported by Cornish et 
al [ 1979] in the hamster cheek pouch, and by Trachte and Lefer [ 1979] in the cat 
cardiac papillary muscle. Cornish et al [1979] also found ACE -independent Ang II 
formation in the hamster coronary artery. Since then numerous investigators have 
reported ACE inhibitor -insensitive Ang II formation in the heart, blood vessels or 
systemic circulation in different species including man [Urata et al 1990, Okunishi et 
al 1984, Chen et al 1991]. Urata et al [1990] reported a dual pathway for Ang II 
formation in the human heart in vitro where the chymase enzyme is the main enzyme 
involved in Ang II formation, in addition to the ACE enzyme system. Chymase or 
other endopeptidases can covert Ang I to II without being inhibited by ACE 
inhibitors. Whether they are present in sufficient quantity to generate significant 
amounts of Ang II either systemically or at a local (tissue) level is uncertain. Studies 
suggest that mRNA for chymase is expressed at much lower levels than mRNA for 
ACE in human cardiac tissues [Morgan et al 1994]. Several other enzymes such as 
chymotrypsin angiotensin generating enzyme (CAGE) and cathepsin D can also 
produce Ang II from Ang I in vitro, but again their physiological roles in the 
cardiovascular system in vivo have not been clarified [Morgan 1993]. 
In summary, ACE inhibition appears to be a relatively non -specific approach 
to blockade of the RAAS system. It is likely that a more complete blockade can be 
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achieved by blocking the Ang II receptor directly with an angiotensin II type 1 (AT1) 
receptor antagonist. Specific blockade of the Ang II receptor has other theoretical 
advantages over nonspecific ACE inhibition. Unlike ACE inhibitors, which inhibit 
bradykinin degradation, AT1 receptor antagonists such as losartan do not increase 
bradykinin levels. Hence AT1 receptor antagonists lack the bradykinin- related adverse 
effects profile of ACE inhibitors such as cough and angio- oedema. However the 
decrease in breakdown of bradykinin may also be partly responsible for some of the 
beneficial effects seen with ACE inhibitors. Not much is known about bradykinin; it is 
associated with the release of nitric oxide and prostacyclin, which may contribute to 
the haemodynamic effects of ACE inhibitors [Gavras 1992]. Therefore although AT1 
receptor antagonists may provide a more complete blockade of Ang II along with a 
better side -effect profile, it may potentially lose out in terms of the benefits resulting 
from the increased bradykinin levels found with ACE inhibitors. To fuel the 
controversy even further, it is now also thought that AT2 receptors stimulation may 
increase local bradykinin levels (although not as much as ACE inhibitors). 
The Evaluation of Losartan in the Elderly (ELITE) trial [Pitt et al 1997] was 
the first long term trial (48 weeks) to compare an ACE inhibitor, captopril, with an 
AT1 receptor antagonist, losartan in CHF patients with EF <40 %. In this study, those 
randomised to losartan had a 46% reduction in all -cause mortality in comparison to 
captopril- treated patients, which was primarily due to a decrease in sudden cardiac 
deaths. However the study was only designed to assess safety and efficacy of the 
treatments; mortality was not the primary endpoint and the absolute number of deaths 
was small. The intriguing results of ELITE were however not replicated in a 
subsequent larger scale randomised trial in which total mortality was the primary 
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endpoint (ELITE II). In the latter study, , although losartan was significantly better 
tolerated, it did not appear to be superior to captopril in improving survival in CHF 
patients. At present, there are clearly, many unresolved issues regarding the use of 
AT1 receptor antagonists in CHF. Increased sympathetic tone and impaired 
baroreceptor function are key processes, which predispose the myocardium to sudden 
cardiac death in CHF. At present, no one knows if AT1 receptor antagonists attenuate 
the cardiac autonomic tone more efficaciously than ACE inhibitors. This is one of the 
issues that will be addressed in further detail in this thesis. 
Aldosterone reactivation: 
Aldosterone escape during chronic ACE inhibition may occur through several 
mechanisms. It may be: 
i) secondary to Ang II reactivation. 
ii) it may be produced by non -Ang II dependent mechanisms regulated by 
corticotropins, atrial natriuretic peptide and serum potassium [Weber et al 1993]. 
Certainly when Ang II production is completely suppressed, aldosterone escape may 
still occur [Staesson et al 1981]. 
iii) a result of impaired aldosterone clearance. Aldosterone is extracted almost 
exclusively from the splanchnic circulation and metabolised in the liver. In patients 
with CHF, in whom hepatic and splanchnic blood flows are impaired, splanchnic 
extraction and clearance of aldosterone are reduced [Tait et al 1965]. 
This aldosterone escape may affect the myocardium adversely in a number of 
ways. In CONSENSUS [ 1987], baseline levels of aldosterone were predictive of long- 
term survival in placebo recipients, and patients with more complete aldosterone 
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suppression among ACE inhibitor recipients had better survival outcome than those 
with less effective suppression. In addition to its well known renal effects (sodium and 
water retention, hypokalemia and hypertension) aldosterone is now thought to have 
adverse autonomic effects not unlike those of Ang II. Furthermore, aldosterone may 
promote myocardial fibrosis, electrolyte disturbances and predispose the myocardium 
to ventricular arrhythmias. 
The evidence for these effects of aldosterone are reviewed in the following 
sections. 
1.3 Aldosterone and autonomic regulation in CHF 
In CHF, the RAAS and. the autonomic nervous system are inextricably linked. It is 
well established that Ang II attenuates the baroreflex control of heart rate and 
sympathetic activity [Guo and Abboud 1984, Mace et al 1985]. Activation of the 
sympathetic nervous system, RAAS and parasympathetic withdrawal occur in 
response to the inadequate "filling" of the arterial tree which is characteristic of 
systolic heart failure. In the early stages of acute systolic failure, these changes are 
compensatory and act to maintain perfusion to vital organs and to expand the 
inadequate arterial blood volume. However, as heart failure becomes chronic, these 
compensatory mechanisms can cause undesirable effects such as excessive 
vasoconstriction, increased aflerload, excessive salt and water retention, electrolyte 
abnormalities and arrhythmias. Patients with CHF have depleted myocardial 
catecholamine stores [Chidsey et al 1965] and down regulated beta -receptors 
[Bristow et al 1982], and these abnormalities may further contribute to the 
demonstrated inability of the cardiovascular system to respond to stress in heart 
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failure. 
Mechanisms for sympathetic activation and parasympathetic withdrawal in heart 
failure 
Sympathetic activation and parasympathetic withdrawal in heart failure have 
been attributed to alterations in inhibitory and excitatory influences on brainstem 
vasomotor neurons. 
Excitatory inputs on brainstem vasomotor neurons are derived from arterial 
chemoreceptors and muscle "metaboreceptors ". Baroreceptor afferents from the 
carotid and aortic arch (arterial high pressure mechanoreceptors) and the 
cardiopulmonary regions; (low pressure mechanoreceptors) on the other hand, are the 
principal inhibitory influences on vagal and sympathetic outflow to the heart and 
circulation. Sensory information from the mechanosensitive endings in the carotid 
sinus and aortic arch travels to the central nervous system by means of the 
glossopharyngeal and vagal nerves, respectively. The primary afferent neurons 
synapse in the nucleus tractus solitarius, from which there are projections to the 
medulla and other regions of the brain stem. Increases in arterial pressure activate 
these primary afferent neurons and result in increased vagal efferent outflow and 
reduced sympathetic outflow to the heart and circulation. Vagal efferent outflow 
originates from neurons in the nucleus ambiguus, whereas sympathetic neural 
influences are controlled from the rostral and caudal ventrolateral medulla and project 
to the intermediolateral cell column, which is the site of origin of the preganglionic 
cell bodies of the sympathetic nerves. These preganglionic cell bodies project to the 
sympathetic ganglia, including the stellates, which are the sites of origin of the 
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postganglionic sympathetic fibers. Similarly, sensory information from the receptors in 
the cardiopulmonary region (located throughout the heart and lungs) travels over the 
vagal nerves to the nucleus tractus solitarius and exerts influences on the vagal and 
sympathetic outflow. 
Under normal conditions, the inhibitory inputs dominate, and the integrated 
response to these competing influences results in low efferent sympathetic traffic and 
arterial catecholamines, and high heart rate variability. 
As heart failure progresses, the principal stimuli to arterial baroreceptor 
afferent discharge (eg. systolic blood pressure, rate of rise of blood pressure etc) 
become blunted, and the sensitivity of the mechanoreceptors to stretch diminishes, 
resulting in decreased inhibitory input from the arterial and cardiopulmonary receptors 
[Hirsch et al 1987, Ferguson 1990, Wang et al 1990, Hainsworth 1991] and increased 
excitatory inputs [Ferguson 1990]. The net response to this shift in balance between 
the inhibitory and excitatory afferent inputs includes a generalised increase in basal 
sympathetic outflow, parasympathetic withdrawal, blunted reflex parasympathetic (ie. 
impaired baroreceptor sensitivity) and sympathetic control of heart rate (reduced heart 
rate variability), and impairment of the reflex sympathetic regulation of vascular 
resistance [Hirsch et al 1987, Ferguson et al 1991, Saul et al 1988, Casolo et al 
1991]. 
Circadian variation of autonomic regulation in CHF 
The integrated response to these neural influences is a dynamic process 
undergoing continuous but predictable changes throughout day and night in normal 
man. These circadian fluctuations of the cardiac autonomic tone are best reflected by 
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analysis of heart rate variability (HRV) [Saul et al 1988, Casolo et al 1991]. 
HRV can be analysed as a function of time using parametric indices of 
measurement (time domain analysis) or by exploration of the periodic oscillations of 
heart rate at different frequencies using spectral frequency domain analysis (see 
Chapter 2: Methods). In power spectral analysis, there are three main spectral 
components: very low frequency (VLF), low frequency (LF) and high frequency (HF) 
components. Vagal activity is the major contributor to the HF component. However 
controversy exists with regards to the LF component - whereas some studies suggest 
that LF, when expressed in normalised units, is a quantitative marker of sympathetic 
modulation, other view LF as reflecting both sympathetic and vagal activity. 
Consequently, the LF/HF ratio is considered by some to mirror sympathovagal 
balance or to reflect the sympathetic modulation [Task Force of the ESC 1996]. The 
physiological explanation for the VLF component is much less defined. 
Spectral analysis of 24hr recordings have shown consistently that in normal 
subjects, LF and HF exhibit a circadian pattern and reciprocal fluctuations with higher 
values of LF in the daytime and of HF at night, corresponding with a sympathetic 
predominance during the day and vagal predominance during the night [Furlan et al 
1990]. A major change in the autonomic profile occurs at approximately 6am, 
coinciding with the time of awakening, when a surge of sympathetic activity occurs 
rapidly and concomitantly with vagal withdrawal [Furlan et al 1990]. 
In CHF, this normal circadian variation of the autonomic tone is disrupted. 
Both time -domain and frequency- domain parameters of HRV are reduced [Casolo et 
al 1991, Casolo et al 1989, Panina et al 1995, Adamopoulos et al 1995, Tani et al 
1991]. Data on the circadian variations of the spectral components are however 
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limited and conflicting in CHF. Casolo et al [1991] and Panina et al [1995] both 
reported reduced HRV in CHF patients but no significant changes in any of the 
spectral components were observed over a 24hr period. Adamopoulos et al [1995] on 
the other hand observed a reduced but still preserved circadian pattern in the spectral 
components. Whilst Tani et al [1991] found that LF and HF components were 
significantly reduced at any time compared to HRV in normal subjects, they observed 
a loss of the circadian variation of the LF component but the 24hr variation of the HF 
component was preserved. 
It must be borne in mind that these spectral HRV indices are not direct 
measures of autonomic tone, since by their nature they reflect the power of an 
oscillation, but not the ;absolute level of the signal [Malik and Camm 1993]. For 
instance, the LF component which reflects sympathetic activity, is diminished with 
worsening heart failure, and this is thought to be due to extreme adrenergic 
hyperactivity, leading to saturation of the beta -receptors, limited oscillations and an 
incapacity to respond to modulating mechanisms [Malik and Camm 1993]. This 
abnormal circadian regulation of the autonomic tone in CHF may be an important 
factor contributing to the high incidence of adverse cardiac events such as lethal 
ventricular arrhythmias. Certainly, acute ischaemic events [Muller et al 1985, 
Goldberg et al 1990, Hansen et al 1992], arrhythmic events [Raeder et al 1988, 
Mallavarapu et al 1995, Davila et al 1995] and sudden cardiac deaths [Willich et al 
1987, Levine et al 1992, Marron et al 1994, Moser et al 1994] are all known to 
exhibit a circadian pattern with an increased incidence during the morning hours 
compared to the evening period (See Section 1.7). 
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Potential autonomic modulating properties of aldosterone: 
Recent experimental work suggest that aldosterone possess autonomic 
modulating effects independent of Ang II. Firstly, aldosterone may potentiate the 
effects of catecholamines. Aldosterone has been shown to block myocardial uptake of 
norepinephrine in vivo in an animal model [Barr et al 1995]. In support of this 
experimental finding, in a clinical study with CHF patients, the addition of 
spironolactone, an aldosterone antagonist, was found to increase myocardial 
norepinephrine uptake by metaiodobenzylguanidine (1VIIBG) scanning [Barr et al 
1995]. 
Secondly, aldosterone may also possess direct constrictor effects on the 
vascular smooth muscle This may be the biologic consequence of aldosterone's 
potentiation of catecholamines [Weber and Purdy 1982]. Furthermore, aldosterone 
receptors and mRNA encoding the key enzyme for aldosterone biosynthesis have also 
been detected in both endothelial and smooth muscle cells from the human pulmonary 
artery [Hatakeyama et al 1994]. Endothelium- dependent vasodilation by acetylcholine 
is reduced in patients with essential and renovascular hypertension as well as in 
patients with primary aldosteronism compared to control subjects; surgical correction 
of the aldosteronism, on the other hand, restored endothelial function [Taddei et al 
1993]. These data suggest that endothelium- dependent vasodilatation by acetylcholine 
is attenuated by high aldosterone levels. Schohn et al [1993] observed that 
spironolactone attenuated the haemodynamic effects of intravenously infused Mg II 
and noradrenaline in anuric terminal renal failure patients, suggesting that the effects 
of aldsoterone antagonism was extra- renal, and probably through a direct vascular 
reflect. 
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In addition to sympathetic potentiation, current evidence also suggest that 
aldosterone may reduce parasympathetic activity. Wang et al [1992] showed 
conclusively that aldosterone not only directly reduces baroreceptor discharge from 
the carotid sinus in an animal model, but also that aldosterone reduces the heart rate 
response to changes in blood pressure. These effects were seen with both acute and 
chronic administration of aldosterone [Wang 1994]. In man, aldosterone infusion had 
been shown to halve the bradycardic response to infused noradrenaline, a vasopressor 
agent [Barr and Struthers 1994]. Furthermore, MacFadyen et al [1997] had recently 
found that spironolactone improved heart rate variability (an index of parasympathetic 
activity) in CHF patients. An interesting observation from this study is the fact that 
spironolactone reduced ; the 6 -9am increase in heart rate in these patients. As 
aldosterone under the influence of ACTH secretion, is known to peak at this time of 
the day, as does cortisol [Armbruster et al 1975], it is perhaps not surprising that the 
autonomic effects of spironolactone are most prominent at 6 -9 am. 
These studies suggest that the ACTH induced dawn increase in aldosterone 
may alter the autonomic balance in such a way as to increase ischaemia, arrhythmias 
and sudden death. 
1.4 The arrythmogenic role of Aldosterone: 
There are a number of reasons why aldosterone is potentially arrhythmogenic. 
This may be the result of: 
i) augmentation of the autonomic nervous system: As mentioned in the 
previous section, aldosterone may potentiate the action of catecholamines and reduce 
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parasympathetic activity. Whereas catecholamines are arrhythmogenic, the 
parasympathetic system has cardioprotective effects. For example, in animal models of 
myocardial ischaemia, vagal stimulation reduced the frequency of reperfusion induced 
VF from 60% to 7% while abolishing ventricular tachycardia altogether in ishaemic 
cats [Zuanetti et al 1987], whereas in ischaemic dogs, vagal stimulation had been 
shown to increase survival from 12% to 57% [Myers et al 1974]. Hence by reducing 
heart rate variability and baroreflex sensitivity - both surrogate markers for sudden 
cardiac death [Barron and Lesh 1996]- aldosterone may play a pivotal role in the 
generation of malignant arrhythmias and sudden death in cardiovascular diseases. 
ii) magnesium and potassium depletion: Aldosterone independently increases 
urinary magnesium and potassium loss [Rahman et al 1992]. Both hypokalemic and 
hypomagnesaemic states increase cell excitability [Whang and Welt 1963] and are 
potentially arrhythmogenic [Fisch 1973, Gettes 1976]. A low serum magnesium 
concentration is associated with an increase in ventricular ectopy in CHF [ Eichhorn et 
al 1993]. Conversely, magnesium replacement causes a decline in the number of 
ventricular arrhythmias in CHF [Gottlieb et al 1990, Bashir et al 1993]. In addition to 
direct electrophysiological effects [Kaseda et al 1989], magnesium depletion may also 
increase the arrhythmogenic response to catecholamines [Bean and Varghese 1994]. 
Although a clear link is established between magnesium depletion and arrhythmias, 
the effect of magnesium on mortality is uncertain. Although intravenous magnesium 
had no effect on mortality in acute myocardial infarction (where a large proportion of 
the patients are not on diuretic therapy) [ISIS -4 Group 1995], the situation may be 
different in CHF, where the patients are on chronic therapy with magnesium and 
potassium losing diuretics . 
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iii) myocardial fibrosis: Chronic administration of aldosterone induced 
biventricular fibrosis in the rat [Brilla and Weber 1992]. This myocardial fibrosis 
could be prevented by spironolactone at a dosage too low to alter blood pressure 
[Brilla and Weber 1992], suggesting that the mechanisms in which aldosterone 
produce fibrosis are independent of its effect on blood pressure and left ventricular 
hypertrophy. Aldosterone has been shown to induce mRNA for collagen formation in 
both left and right ventricles [Robert et al 1994]. MacFadyen et al [1997] recently 
provided further evidence by showing that aldosterone blockade with spironolactone 
reduced serum procollagen type III amino terminal peptide (PIIINP), a marker of 
collagen turnover, in CHF patients. Patchy myocardial fibrosis may cause electrical 
inhomogeneity and reduce threshold for ventricular fibrillation [Pye and Cobbe 1992]. 
iv) direct arrhythmogenic effect: In an animal model by Arora and Somani 
[1962], the direct administration of aldosterone infusion into coronary artery ligated 
dogs was associated with the generation of ventricular arrhythmias. This pro - 
arrhythmic effect of aldosterone was not only dose -dependent, but it was more 
striking and prolonged compared to the arrhythmogenic agent, epinephrine. As the 
arrhythmogenic effect of the aldosterone infusion was of rapid onset, electrolyte 
depletion was an unlikely mechanism for this phenomenon. 
In conclusion, aldosterone may produce arrhythmias through a combination of 
any or all, of the above mechanisms. High levels of aldosterone in conditions such as 
CHF may therefore contribute to the development of malignant ventricular 
arrhythmias and the high incidence of sudden death. 
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1.5 Aldosterone and QT dispersion: 
Recently, QT dispersion (QTd), which is the difference between the longest 
and shortest QT interval measured on the 12 -lead electrocardiogram (ECG), has been 
identified as a simple and easily measured predictor of sudden cardiac death [Barr et 
al 1994, Molnar et al 1997]. Although not fully understood, QTd is thought to be a 
measure of electrical inhomogeneity in the heart which decreases an individual 
threshold for ventricular arrhythmias [Pye and Cobbe 1992]. Han and Moe [1964] 
showed that differences in refractory periods in adjacent areas could be responsible 
for the occurrence of arrhythmias especially fibrillation. This spatial inhomogeneity of 
the repolarisation phase; of the action potentials may be caused by either different 
durations of the action potentials, or by action potentials arriving late due to slow 
conduction at different sites of the myocardium (eg, ischaemic or fibrotic areas). 
At present there are still many gaps in our understanding as to what causes 
these differences in action potential durations in ventricles Although the effect of 
aldosterone on QTd has not been documented, there are however, several potential 
mechanisms by which hyperaldosteronism may contribute to increased QTd in 
conditions such as CHF. In fact, most of the adverse effects of aldosterone described 
in the previous sections could potentially increase QTd. 
Firstly, current evidence suggests that aldosterone has particularly malignant 
autonomic effects (potentiating sympathetic activity and reducing parasympathetic 
tone) and that these may contribute to increased QTd [Bonnar et al 1997]. The 
significance of these neural influences is further supported by the observations that the 
only drugs so far to have reduced QTd are those that modulate the autonomic tone, 
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such as beta -blockers [Priori et al 1994, Day et al 1991] and ACE inhibitors [Barr et 
al 1997], which are well recognised to have vagomimetic effects [Flapan et al 1992, 
Osterziel et al 1996]. 
Secondly, QTd could also be due to patchy myocardial fibrosis, promoted by 
hyperaldosteronism [MacFadyen et al 1997, Brilla and Weber 1992], which leads to 
electrical inhomogeneity and anisotropic re -entry arrhythmias [Pye and Cobbe 1992, 
Han and Moe 1964]. Thirdly, QTd is linked to ventricular dilatation [Pye et al 1994]. 
Aldosterone may cause dilatation of the ventricles through a variety of mechanisms: 
by increasing afterload (through increased vascular tone, salt and water retention and 
autonomic modulation), and promoting myocardial fibrosis. Fourthly, there is some 
evidence to suggest that aldosterone may also have ischaemic enhancing properties 
(see Section 1.6). Janse et al [1985] found that myocardial ischaemia and infarction 
increase the local dispersion in animal models mainly by a decrease in conduction 
velocity and to a lesser extent, by action potential differences. Furthermore, repeated 
ischaemic episodes and infarctions predispose the myocardium to scarring and patchy 
fibrosis. In agreement with this, recent studies have confirmed that ischaemia 
increases QT dispersion [Sporton et al 1997]. 
Finally, electrolyte depletion, in particular that of potassium and magnesium, 
may also contribute to dispersion of the QT intervals. Both hypokalemic and 
hypomagnesaemic states are arrhythmogenic, associated with prolongation of the QT 
intervals and increased likelihood of developing ventricular arrhythmias such as 
torsade de pointes [Whang and Welt 1963, Fisch 1973, Gettes 1976]. Conversely, 
magnesium replacement therapy shortens the QT interval and has been shown to be a 
very effective anti -arrhythmic agent in terminating episodes of torsade de pointes 
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[Tzivoni et al 1984]. The effects of magnesium on QT dispersion is at present 
unknown. Potassium, on the other hand, is one of the main determinants of the QT 
interval, as it is responsible for the outward repolarisation currents. Reduction of 
serum potassium, results in slower repolarisation and prolonged QT intervals 
[Nabauer et al 1993]. Recently, Choy et al [1997] observed that intravenous 
potassium infusion not only normalised QT prolongation but also reduces dispersion 
in CHF and in normal subjects pre- treated with quinidine. The relationship between 
potassium and QT dispersion may have important clinical implications particularly in 
CHF, where QT dispersion is increased and potassium levels are chronically deficient 
as a result of hyperaldosteronism and diuretic therapy. In addition to CHF, these 
observations may also be of relevance in other clinical settings. For instance, recent 
observations suggest that hyperinsulinaemic states are associated with increased QT 
dispersion [Watanabe et al 1997]. The underlying mechanisms are unclear but once 
again, potassium may play a significant role contributing to QT dispersion as 
hyperinsulinaemia causes hypokalemia by pushing potassium into cells. 
In summary, aldosterone can cause QT dispersion through a number of ways. 
Some of these mechanisms are explored further in this thesis. They have important 
clinical and therapeutic implications as QT dispersion is a predictor of sudden death in 
a variety of clinical settings [Barr et al 1994, Molnar et al 1997, Buja et al 1993, 
Potratz et al 1993, Perkiomaki et al 1995, Darbar et al 1996]. 
1.6 Aldosterone and myocardial ischaemia 
Although there is no direct evidence that aldosterone causes myocardial 
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ischaemia, there are a number of interesting observations. Aldosterone blockade has 
been shown to reduce the dawn (6 -9am) increase in heart rate in CHF patients 
[MacFadyen et al 1997]. Spironolactone may therefore have anti -ischaemic effects by 
way of reducing heart rate at this time. The importance of this observation is that this 
is the same time of day when ischaemic, arrhythmic and sudden death events are 
commonest (see Section 1. 7). 
Aldo sterone may cause an increase in myocardial oxygen demand through a 
number of ways, including potentiation of sympathetic activity and withdrawal of 
vagal cardioprotection (Section 1.3). The increase in sympathetic activity may also 
increase coronary artery tone [Weber and Purdy 1982, Hatakeyama et al 1994, 
Taddei et al 1993]. Aldosterone- induced magnesium depletion could also cause 
coronary vasoconstriction [Turlapaty and Altuna 1989]. Aldosterone blockade has 
also recently been shown to improve endothelial dysfunction and increase vascular 
nitric oxide bioactivity in CHF patients [Farquharson and Struthers 2000]. Finally, 
aldosterone itself may be implicated in the pathogenesis of atherosclerosis. Patients 
with primary hyperaldosteronism have endothelial dysfunction, which is reversed 
when the tumour is removed [Taddei et al 1993]. Furthermore monocytes which are 
implicated in the development of atherosclerosis, appear to have functionally active 
aldosterone receptors [Wehling et al 1987]. 
1.7 The circadian variation of aldosterone and cardiovascular events: 
Like cortisol, aldosterone secretion follows a diurnal variation, with peak 
secretion during the morning hours [Armbruster et al 1975]. In CHF, this ACTH- 
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induced dawn surge in aldosterone still occurs despite ACE inhibitors therapy 
[Davidson et al 1996]. This diurnal profile mirrors that of cardiovascular events. 
Numerous epidemiologic studies have shown that the frequency of acute 
cardiovascular events is not evenly distributed throughout the day, with a peak 
incidence occurring during the morning hours (ham - 12 noon), after a nadir in these 
events at nights. Muller et al [ 1985] who were the first to establish the circadian 
pattern of acute myocardial infarction, found that AMC was at least 3 times more 
likely to occur in the morning than in the late evening. Since then, a number of studies 
[Goldberg et al 1990, Hansen et al 1992] have confirmed these observations by 
analysing detailed records of patient symptoms and the time- activity patterns of 
cardiac enzymes. Studies evaluating 24hr to 48hr Holter ambulatory ECG in patients 
with stable angina have shown that transient myocardial ischaemic events too exhibit a 
circadian pattern [Rocco et al 1987]. 
The distribution of ventricular arrhythmias over 24hrs has also been observed 
to conform to a similar diurnal pattern. Raeder et al [1988] observed a striking diurnal 
distribution of ventricular ectopic activity with a trough at 5 am and a peak between 
10 am and noon, in patients with a history of malignant sustained ventricular 
tachyarrhythmias. This finding is supported by recent studies of patients with 
implantable cardioverter -defibrillator where ventricular arrhythmias recorded by the 
device have been shown to exhibit a circadian pattern with occurrence rate lowest 
between tam and 3 am and highest between 10am and 11 am [Mallavarapu et al 
1995]. Implantable defibrillator shocks were delivered mostly during the morning 
hours [Davila et al 1995]. 
Similarly, the circadian pattern of sudden deaths have been documented in 
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patients with previous myocardial infarction [Willich et al 1987, Levine et al 1992], 
hypertrophie cardiomyopathy [Maron et al 1994] and CHF [Moser et al 1994]. 
Moser et al [ 1994] found that in patients with advanced CHF (NYHA III/IV) 46% of 
deaths occurred between 6 am and noon, accounting for a 2.5 fold increase in the risk 
of sudden death in the morning hours compared with the other times of the day. 
The mechanisms underlying the circadian pattern of adverse cardiac events are 
not known. Further characterisation of this circadian pattern has identified the hours 
of awakening, rather than the hour of the day as being most closely related to the 
occurrence of adverse events [Willich et al 1992, Muller et al 1989]. Willich et al 
[1992] found that after- adjusting for individual waking times, the relative risk of 
sudden cardiac death was 2.6 during the first 3 hours after awaking when compared 
to the rest of the 24hr period. Furthermore this morning peak of cardiovascular events 
is known to coincide with the surge of sympathetic activity and vagal withdrawal, as 
reflected by changes in various autonomic and physiological parameters such as 
increased heart rate and blood pressure, raised plasma catecholamines, increased 
vascular tone and enhanced platelet aggregability. As discussed in Section 1.3, the 
sympathetic tone is known to exhibit a circadian rhythm characterised by diminished 
activity during the night and a peak in the morning hours associated with assumption 
of the upright position. Diabetic patients with autonomic dysfunction [Zarich et al 
1994] and patients on beta -blockers [Peters 1990] who do not demonstrate this 
morning peak of events provide indirect evidence that alterations in the 
sympathovagal balance may be partly responsible for the circadian pattern of 
cardiovascular events. 
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Aldosterone secretion may play a contributory role to the development of the 
diurnal pattern of these adverse events, especially in view of the growing body of 
evidence that aldosterone has detrimental autonomic modulating properties that may 
contribute to ischaemia, arrhythmia and sudden deaths. The significance of some of 
these observations has yet to be fully explored. 
1.8 Review of current drug therapy in chronic heart failure: The effects on 
potential surrogate markers for mortality 
A significant proportion of the studies carried out in this thesis is focussed on 
the interaction between the components of the RAAS pathway and the autonomic 
nervous system such as the assessment of aldosterone blockade on heart rate 
variability (HRV) and baroreflex sensitivity (BRS). The effects on these autonomic 
markers have important clinical implications. Recent compelling evidence linking the 
autonomic nervous system and cardiac mortality including sudden death [Barron and 
Lesh 1996], suggests that these autonomic markers such as HRV, BRS and 
ventricular repolarisation characteristics eg. QT dispersion, are of prognostic value 
and may serve as potential "surrogate" markers for mortality in CHF. 
Therefore to place into perspective the clinical relevance of the studies carried 
out in this thesis, I have in this section, reviewed the literature on the prognostic value 
of these surrogate markers and the impact of current drug therapy in CHF on them. 
The impact of the different drugs on mortality and these surrogate markers are 
summarised in Table 1.3. The markers looked at include heart rate and its variability 
(HRV), baroreflex sensitivity, QT dispersion, arrhythmias, late potentials and 
neurohormones. 
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1.8.1 Surrogate Markers In Chronic Heart Failure: 
HRV 
HRV is a strong and independent predictor of mortality following acute 
myocardial infarction [Odemuyiwa et al 1994, Hartikainen et al 1996, Kleiger et al 
1987, La Rovere et al 1998]. Although there is clear evidence that patients with 
chronic heart failure also exhibit a reduced HRV, the prognostic implications of the 
different spectral components and disease severity is more complex in heart failure, 
and there have been conflicting reports (see Table 1.2). With regards to its predictive 
value for mortality, preliminary results from the UK HEART study which followed 
433 NYHA II -III patients over a mean of 458 days, have revealed that HRV is a 
powerful independent predictor of mortality [Nolan et al 1998]. 
BRS 
Like HRV, baroreflex sensitivity (BRS) is an established parameter used to 
assess cardiac autonomic tone. Whereas HRV reflects tonic vagal activity at rest, 
BRS is predominantly a marker of activated vagal activity [Schwartz et al 1992, 
Hohnloser et al 1994]. The prognostic value of BRS was first demonstrated by La 
Rovere et al [1988] in post MI patients and has been confirmed by the recent 
ATRANII study [La Rovere et al 1998]. Subsequent studies not only confirmed the 
predictive value of BRS but have shown that it is superior to HRV [La Rovere et al 
1998, Farrell et al 1991, Farrell et al 1992]. The prognostic value of a depressed BRS 
in heart failure has been demonstrated by Osterziel et al [1995]. 
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OT Dispersion 
Since the pioneering work by Day et al [1990], numerous studies have 
evaluated the usefulness of QT dispersion as a marker of arrhythmic risk and sudden 
death in different clinical settings [Barr et al 1994, Priori et al 1994, Buja et al 1993, 
Potratz et al 1993, Perkiomaki et al 1995, Darbar et al 1996]. Barr et al [1994] and 
Brooksby et al [ 1996] recently found QT dispersion to be associated with sudden 
death and total cardiac mortality respectively, in patients with chronic heart failure. In 
contrast, Fei et al [1996] did not find any association. QT dispersion is very much at 
its infancy stage and there are still unresolved issues particularly relating to 
standardisation of the methodology used. As such, the predictive value of QT 
dispersion has been questioned by several investigators [Zareba et al 1994, Surawicz 
1996]. 
Signal- averaged ECGs and Ambulatory Holter (24 hr ECGs) 
In recent years the signal- averaged ECGs and ambulatory Holter have been used 
extensively to predict the risk of sustained ventricular tachyarrhythmias and sudden 
death. The prognostic value of signal- averaged ECGs for arrhythmic events including 
sudden death in post myocardial infarction patients is well established [McClements 
and Adgey 1993, Breithardt et al 1983]. However in heart failure the prognostic value 
of late potentials is uncertain. Whereas some studies described a high incidence of 
arrhythmias and sudden death in patients with an abnormal signal- averaged ECGs 
[Mancini et al 1993, Ohnischi et al 1990], others did not find any correlation 
[Middlekauff et al 1990, Silverman et al 1995]. Similarly the ambulatory 
electrocardiogram has been used with variable success in risk stratifying for sudden 
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death in patients with CHF [Szabo et al 1994, Olshausen et al 1988, Huang et al 
1983, Wilson et al 1983, Holmes et al 1985]. 
Neurohormones 
Several plasma neurohormones have also been found to be associated with increased 
mortality in CHF. Natriuretic peptides is of prognostic value in both congestive heart 
failure [Gottlieb et al 1989, Hall et al 1994, Swedberg et al 1990] and myocardial 
infarction [Hall et al 1994, Darbar et al 1996]. Plasma norepinephrine has also been 
shown to be an independent prognostic predictor for mortality in patients with 
symptomatic [Cohn et al 1984] and asymptomatic LV dysfunction [Benedict et al 
1996]. The CONSENSUS I study found that in addition to catecholamines, increased 
levels of AngII, aldosterone and ANP were significantly correlated with mortality 
[Swedberg et al 1990]. Similarly the SAVE group had shown that other 
neurohormonal markers such as plasma renin activity and ANP provided significant 
predictive information about 1 year cardiovascular mortality [Rouleau et al 1994]. 
Endothelin 1 has also recently been shown to correlate negatively with 1 year survival 
[Pacher et al 1996]. 
General considerations with regard to surrogate markers: 
Despite their predictive value for mortality, the above parameters cannot be 
accepted as surrogates to assess efficacy of drug therapy unless it can be shown that 
drug therapy which alters mortality can cause a corresponding change in the markers. 
Drug therapies that improve cardiac markers without any evidence of mortality 
benefits are useless and could in some cases be potentially dangerous. For example, 
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attempts to suppress arrhythmias in post MI patients with flecainide and d- sotalol in 
the CAST [Akiyama et al 1991] and SWORD [Waldo et al 1996] trials respectively 
have been associated with an increased mortality. 
The potential of all the above markers as surrogates to assess efficacy of drug 
therapy will be evaluated in the next section. 
1.8.2 Drug therapy in Chronic Heart Failure 
Drugs That Have A Favourable Effect On Mortality 
ACE Inhibitors 
The mortality benefits of ACE inhibitors have been attributed to both 
neurohormonal suppression and vasodilatation [Cohn et al 1991]. Furthermore, it has 
been shown that the effect of ACE inhibitors on mortality reduction was greater in 
those with a high baseline circulating norepinephrine levels or an activated renin 
angiotensin system [Benedict et al 1995]. This reduction in mortality is paralleled by 
changes in various markers of the autonomic tone including a decreased heart rate 
[CONSENSUS -1 1987], increased heart rate variability [Flapan et al 1992, Binkley et 
al 1993, Kontopoulos et al 1996], increased baroreceptor sensitivity [Osterziel and 
Dietz 1996, DibnerDunlap et al 1996, Marakas et al 1995], decreased QT dispersion 
[Barr et al 1997] and a reduction in malignant ventricular arrhythmias [Cleland et al 
1984, Webster et al 1985, Fletcher et al 1993]. In summary therefore, all potential 
surrogates are favourably altered by ACE inhibitors, which correspond with their 
favourable effect on mortality. 
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Hydralazine -Isosorbide Dinitrate 
The vasodilator combination of hydralazine and isosorbide dinitrate has been 
shown to reduce mortality in the V -HeFT I study [Cohn et al 1986]. It has no impact 
on arrhythmic events in patients with left ventricular dysfunction and a history of 
inducible ventricular tachycardia [Bashir et al 1992]. However unlike ACE inhibitors, 
the hydralazine plus isosorbide dinitrate combination is associated with a small but 
significant rise in heart rate and an increased plasma norepinephrine concentration 
during the first year of follow -up [Cohn et al 1991]. However the impact on 
autonomic markers such as heart rate variability and baroreceptor sensitivity is not 
known. In summary, unlike the situation with ACE inhibitors, there is a discrepancy 
here between their favourable effects on mortality and their unfavourable effects on 
heart rate and neurohormones. 
Beta -Blockers 
The beneficial effects of beta -blockers on mortality reduction in CHI' are now 
well established. Over the years there have been a number of small studies which 
demonstrated favourable but not statistically significant benefits with beta -blockers 
[Waagstein et al 1993, CIBIS Investigators 1994]. However recently Carvedilol 
[Packer et al 1996] a second generation beta -adrenergic antagonist with alphal- 
blocking effects has been shown to reduce mortality by 65% when compared to 
placebo in CHF. Since then there has been two further large randomised trials 
published which also demonstrated mortality reduction with the beta -1 selective 
agents, metoprolol and bisoprolol [MERIT-HI Study Group 1999, CIBIS -II 
Investigators 1999]. 
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In addition to heart rate reduction [Waagstein et al 1993, CIBIS Investigators 
1994], beta -blockers have consistently improved heart rate variability [Kontopoulos et 
al 1996, Coumel et al 1991, Pousset et al 1996] and plasma neurohormones 
(eg.ANP, catecholamines) [Nemaniach et al 1990, Eichhorn et al 1991]. Beta 
blockers have also been reported to reduce ventricular tachyarrhythmias [Steinbeck et 
al 1992, Antz et al 1995]. The reports on the effects of beta -blockers on baroreceptor 
sensitivity are however conflicting [Parati et al 1983, Sanderson et al 1997, Lucini et 
al 1993]. With regard to QT dispersion beta -blockers have also been shown to reduce 
QT dispersion in the long QT syndrome [Priori et al 1994, Napolitano et al 1996]. 
Napolitano et al [1996] found that beta -blockers caused a greater reduction in those 
with higher baseline values. Sotalol also reduced QT dispersion in post -myocardial 
infarction patients [Day et al 1991]. Therefore as far as beta -blockers are concerned, 
there is good consensus between their effects on mortality and their effects on all 
surrogates. 
Drugs That Have No Overall Impact On Mortality 
Digoxin 
Until recently the use of digoxin therapy in CHF and sinus rhythm has been 
controversial. Digoxin has been shown to reduce heart rate significantly in some 
studies [Brouwer et al 1995, Krum et al 1995] but not in others [Newton et al 1996]. 
Furthermore, it has also been shown to have favourable autonomic modulating 
properties; it restores HRV [Brouwer et al 1995, Krum et al 1995], improves 
baroreceptor sensitivity [Ferrarri et al 1981] and reduces circulating catecholamines 
[Brouwer et al 1995, Ferguson 1992, van Veldhuisen et al 1993]. However despite 
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these promising signs digoxin had no impact on mortality in the DIG trial [ 1997] or 
on arrhythmic events in the DIMT study [van Veldhuisen et al 1993]. 
Calcium Channel Antagonists 
The use of Ca- channel blockers in heart failure has been controversial because 
of their potentially negative inotropic activity and their ability to activate the 
neurohormonal system [Packer 1989]. However recent evidence have shown that the 
second generation dihydropyridines (eg.amlodipine or felodipine) possess more 
favourable neurohormonal effects [Devries and Dunselman 1995, Goldsmith 1995, 
Devries et al 1995]. They appear to have no adverse effects on plasma norepinephrine 
levels in both normal subjects [Goldsmith 1995] and heart failure patients [Devries 
and Dunselman 1995, Devries et al 1995]. The long term impact of these drugs on 
heart rate has not been reported from large trials. Although some dihydropyridines are 
known to cause an acute reflexogenic rise in heart rate, there are several small studies 
which show that the heart rate may subside in the long term [Lindqvist et al 1994]. 
The effects of calcium antagonists on HRV in CHF is not known but felodipine has 
been shown to have no significant effect on HRV in post -myocardial infarction(MI) 
patients [Bonaduce et al 1997]. Similarly, Cook et al [1991] could not show any 
effect with diltiazem in normal subjects. Only verapamil, which is not used in heart 
failure, has been shown to improve HRV in post MI patients [Ferrick et al 1990]. 
There is some data suggesting that calcium antagonists improve baroreflex sensitivity 
[Timmis et al 1984, Kassie and Armtorp 1987, Hirsch et al 1992] in heart failure. In 
mortality trials, amlodipine and felodipine appear overall to have a neutral effect 
[O'Connor et al 1995, Cohn et al 1995]. 
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Amiodarone 
Low dose amiodarone has been shown to reduce total mortality (including 
sudden death) by 28% over a 2 year period in the GESICA trial [Doval et al 1994]. 
However controversy has arisen as another trial CHF -STAT [Singh et al 1995] did 
not show any improvement in survival with amiodarone despite an improvement in 
LV ejection fraction. The discrepancy has not been fully explained but may be 
partially accounted for by differences in doses and characteristics of the patients used 
in the two studies. Results from the recent EMIAT and CAMIAT trials of post -MI 
patients (including those with LV dysfunction) have revealed a reduction in 
arrhythmic events although total mortality was not reduced. Nonetheless, amiodarone 
appears to have a favourable effect on potential surrogate markers; it has been shown 
to reduce heart rate significantly in both the GESICA and CHF -STAT studies. 
Furthermore it also improves heart rate variability [Zuanetti et al 1991, Woo et al 
1994] and reduces QT dispersion [Cui et al 1994, Dritsas et al 1992]. 
Drugs With Adverse Effects On Mortality 
Dopamine Receptor Agonists ( Ibopamine) 
Ibopamine is an active dopaminergic prodrug which works primarily as a 
vasodilator with some inotropic activity. It has no significant effects on heart rate 
[Brouwer et al 1995]. Furthermore it does not appear to have any significant 
proarrhythmic effects as documented by Holter monitoring and signal- averaged ECGs 
[van Veldhuisen et al 1991, van Veldhuisen et al 1993]. It has also been shown to 
modulate the autonomic tone favourably and to reduce circulating plasma 
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neurohormones [van Veldhuisen et al 1993, Metra et al 1995]. An improvement in 
HRV (although not statistically significant) has also been documented in a substudy of 
the DIMT study [Brouwer et al 1995]. Published long term survival data are 
unavailable at present but the multicentre trial PRIME II(second Prospective 
Randomised study of Ibopamine on Mortality and Efficacy) has been terminated due 
to adverse effects on mortality. Ibopamine would appear to be the most worrying 
example of disagreement between survival data and the results with potential 
surrogate markers, with the latter suggesting favourable effects which were far from 
reproduced in the mortality trial. 
Flosequinan 
Flosequinan is a novel vasodilator with inotropic properties, no longer in use 
because of its adverse effects on mortality [Packer et al 1993, Moe et al 1994]. It 
caused an increase in heart rate [ Binkley et al 1994] and is associated with increased 
norepinephrine levels [Moe et al 1994]. However the worsened mortality is 
inconsistent with its effects on heart rate variability, where it appears to increase 
parasympathetic and decrease sympathetic tone respectively [Binkley et al 1994]. 
Positive Inotropic Agents (Milrinone) 
Despite their beneficial effects on the haemodynamics of heart failure, 
phosphodiesterase inhibitors such as Milrinone have been shown to have adverse 
effects on mortality [Packer et al 1991]. They are known to activate the 
neuroendocrine systems especially the renin -angiotensin system [Smyth et al 1986] 
and predispose the myocardium to arrhythmias [Ferrick et al 1990]. The effects of 
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these inotropic agents on autonomic markers such as heart rate variability are 
unknown. 
Anti Arrhythmic Therapy 
The use of antiarrhythmic therapy in chronic heart failure is limited. Apart 
from amiodarone, most antiarrhythmic drugs (especially Class I) have no significant 
effects on baseline heart rate but are associated with proarrhythmic effects, increased 
mortality and a deterioration in heart rate variability [Zuanetti et al 1991]. 
1.9 Scope of thesis and conclusions 
Neurohormonal suppression in heart failure patients has a major impact on 
morbidity and mortality rates. In general, as one can clearly see from the previous 
section, drugs that have a favourable impact on mortality are those that cause 
neurohormonal suppression. In particular, the introduction of ACE inhibitors has 
revolutionised our management of heart failure patients in the 1980s. However, 
despite these benefits, CHF remains a lethal disease. It is now becoming clear that 
ACE inhibitors do not completely suppress the RAAS, and neurohormonal re- 
activation occurs with chronic ACE inhibition. The aldosterone "escape" may play a 
pivotal role in the regulation of the cardiac autonomic tone, the generation of 
malignant arrhythmias and ischaemia. 
New therapeutic strategies to improve on the efficacy of ACE inhibitors on 
neurohormonal suppression of the RAAS include the introduction of specific Ang II 
antagonists, such as losartan, and the concomitant administration of aldosterone 
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antagonists, such as spironolactone, with ACE inhibitors. The impact of these new 
treatment strategies on mortality has recently been evaluated in large, randomised 
trials such as the ELITE II trial for losartan and the RALES trial (Randomised 
Aldactone Evaluation Study) [Pitt et al 1999] for spironolactone. 
In this thesis, I have attempted to address some of the unresolved issues in this 
area of research. The thesis is divided into two main sections. The first are large 
clinical studies examining the consequences of aldosterone blockade in patients and 
the second are smaller mechanistic studies in normal man. Firstly, in two large clinical 
studies carried out in Chapters 3 and 4, the clinical significance of aldosterone escape 
was examined in further depth in both CHF and IHD patients respectively. In 
particular, the effects of aldosterone blockade on the diurnal profile of the cardiac 
autonomic tone, arrhythmic events and QT dispersion are described in order to try to 
understand the mechanisms underlying the mortality benefit seen in RALES. 
Furthermore, in Chapter 4, the intriguing possibility that aldosterone blockade has 
similar beneficial autonomic effects was explored in a cohort of patients with chronic 
stable angina. 
The subsequent chapters consist of a series of mechanistic studies designed to 
explore some of the possible mechanisms in which aldosterone may contribute to 
autonomic dysfunction and increased dispersion of the QT intervals, a sensitive 
predictor of sudden death. In Chapters 5 and 6, the effects of the different 
components of the renin -angiotensin -aldosterone system on baroreceptor function 
were explored. Baroreceptor dysfunction occurs with worsening heart failure and is 
thought to predispose the myocardium to ventricular arrhythmias and sudden death. 
Although animal studies suggest that hyperaldosteronism may impair baroreceptor 
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function, this has not been previously documented in man. The paper in Chapter 5 
describes for the first time, the effects of aldosterone on the baroreflex in man. The 
study in Chapter 6 on the other hand, describes the haemodynamic and baroreceptor 
responses of the Ang II antagonist, losartan, in comparison with an ACE inhibitor. 
The study was designed and carried out following the publication of the results of the 
ELITE I study [Pitt et al 1997] which suggested that losartan may well have an 
overall survival benefit (as a result of a reduction in sudden deaths), compared to 
ACE inhibitors. However the mortality benefits of losartan were not confirmed in the 
more recent ELITE II study. The study in chapter 6 may therefore provide us with 
valuable mechanistic insights as to why this may be the case. 
Some of the potential mechanisms in which aldosterone may contribute to 
increased QT dispersion were explored in Chapter 7 where two separate studies were 
carried out. The direct effects of an intravenous infusion of aldosterone on QT 
dispersion were examined in one while the effects of increasing cardiac afterload (eg. 
vasoconstriction) and reflex vagal withdrawal on QT dispersion were described in the 
other. 
In conclusion, CHF remains a complex clinical syndrome and the management 
of these patients continue to pose a difficult and challenging problem for clinicians. 
The therapeutic benefits of neurohormonal modulation in heart failure are now 
without doubt, as evident by the effects of ACE inhibitors, and more recently, of 
spironolactone and beta -blockers, on mortality. It is however disappointing as we 
enter the new millennium that despite all these advances, mortality rates remain high. 
The clinical significance of neurohormonal escape of aldosterone and Ang II despite 
ACE inhibitors is now being realised and opens up a whole new avenue for research 
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and drug development. The concept of aldosterone blockade given in addition to ACE 
inhibitors is an exciting yet simple therapeutic strategy. The studies carried out in this 
thesis provide a mechanistic insight and further enhance our understanding of the 
interaction between the RAAS, the cardiac autonomic tone and electrophysiology of 
the heart. 
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Table 1.1: Actions of Angiotensin II 








- decreases glomerular filtration rate 
- biphasic actions on tubular transport 
- redistribution of blood flow 
- antidiuretic 
- direct vascular smooth muscle constriction, 
hypertrophy and hyperplasia 
- potentiates neurogenic vasoconstriction 
- increases platelet adhesion 
- secretion of PAI -1 
- increases intimai lipid permeability 
? Atherogenic 
- increases Aldosterone secretion 
- increases medullary catecholamine release 
- sympathomimetic 
- parasympatholytic 
- increases thirst, salt intake 
- increases secretion of ADH, ACTH and 
oxytocin. 
- direct positve inotropic effect 
- cardiac myocyte hypertrophy 
- myocardial fibrosis 
- stimulates fluid reabsorption 
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SDNN<100ms was strongly 
predictive of death but rMSSD and 
sNN50 were similar among survivors 
Szabo et al 173 22+12 sNN50, SDNN 
1996 NYHA lII -IV months 
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Poincare Plots 
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Brouwer 95 4 years Both time and 





Binder et 61 17 months Time and 
al 1992 LVEF<20% frequency 
domains 
Woo et al 
1993 
108 I year SDANN, 
PLOTS 
Fei et al 40 1 year Frequency 




and those who died. 
Both parameters significantly 
predictive of total cardiac death but 
not for arrhythmogenic / sudden 
death. 
Both parameters predictive of 1 year 
mortality (p <0.05). 
None of the time and frequency 
domain measures correlated 
significantly with survival. However 
abnormal PLOTS had independent 
prognostic value for sudden death and 
total cardiac mortality. 
SDANN, total and low frequency 
bands correlated with total mortality. 
PLOT but not SDANN, predictive of 
sudden death. 
Frequency domain parameters not 
predictive of arrhythmic events or 
sudden death. 
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SUMMARY TABLE 1.3 The effects of drug therapy on mortality and potential 
surrogate markers in heart failure 










ACE G G G G G G G 
Inhibitors 
13- Blockers G G G J.T G -n G G 
Digoxin 0 G 0/G G ? 0 G 
Diuretics ? ? 0/G ? ? J.T B 
Ibopamine B G 0 ? ? 0 G 
Ca- 
antagonists 
0 0 -n 0/B G ? ? 0 
Hydralazine- G ? B ? ? 0 B 
Nitrate 
Flosequinan B ?G B ? ? ? B 
Milrinone B ? ? ? ? B B 
Class I: B B 0 ? ? T.1. ? 
Flecainide 
Class III: 0/G G G ? G G ? 
Amiodarone 
Symbols: G - good effect 
B - bad effect 
0 - neutral effect 
? - not known 
- conflicting data 
n - effect documented in non -CHF patient 
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CHAPTER TWO 
SUBJECTS AND METHODOLOGY 
2.1 SUBJECTS 
Patient Subjects 
All of the patient subjects entered into the studies described in this thesis were 
recruited from within Ninewells Hospital and Medical School in Dundee. The studies 
involving patients were conducted in accordance with the declaration of Helsinki as 
amended in Tokyo 1975, Venice 1983 and Hong Kong 1989. Details of patient 
selection are given in the appropriate chapters. The patients with chronic heart failure 
and chronic stable angina pectoris were recruited from the Heart Failure and 
Cardiology outpatient clinics respectively. 
Healthy Volunteers 
All volunteers were healthy normal subjects recruited by advertisements in the 
local hospital notice -boards at Ninewells Hospital. All had a normal medical 
assessment including physical examination, biochemical and haematological profile, 
urinalysis and electrocardiogram. Subjects who had a history of an adverse drug 
reaction, allergy or who required routine drug therapy were excluded. Subjects were 
also required to abstain from any self medication prior to and during the course of the 
studies. Sodium intake was not strictly controlled but each subject was asked to 
adhere to their usual diet throughout the study period and where possible, to maintain 
the same pattern of meals in the 48hrs preceding each study day. Subjects were also 
required to refrain from alcohol, caffeine and cigarettes for 24 hrs and to fast for 2hrs 
before each study session. 
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Consent 
All subjects were provided with a study information sheet. Following a 
detailed explanation, subjects gave written informed consent and were advised of their 
right to withdraw from participation at any time. 
Ethical approval 
All studies were performed after approval by the local Tayside Committee on 
Medical Research Ethics. 
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2.2 METHODS 
All the following procedures and analyses were performed by myself 
All intravenous infusions were administered through 18G intravenous 
cannulae placed in the antecubital veins. All infusions were given at the indicated rate 
by means of a constant infusion pump (IMED, San Diego, CA). Throughout each 
experiment, the electrocardiogram and heart rate were continuously monitored by an 
ECG oscilloscope (Hewlett Packard, USA) and blood pressure was recorded semi- 
automatically (Dinamap Vital signs monitor 1846, Critikon, Tampa, Florida, USA). 
All electrocardiograms [ECGs] (with simultaneous 12 lead acquisition for QT 
Dispersion analysis) were recorded using a Hewlett- Packard 4700A 
electrocardiograph. 
The following sections describe the specific methodology and practical 
procedures performed in the studies constituting this thesis. 
2.2.1. Arrhythmia / Ambulatory 24hr (Holter) Analysis 
Twenty -four hour ambulatory electrocardiogram recordings were obtained for 
analysis in all subjects using a standard two -channel (four leads) Tracker 2 analogue 
tape recorder (Reynolds Medical Limited, Hertford, UK), recording standard leads 
CM1 and CM5. The recorder provided continuous 24 hr recording of ECG at a tape 
speed of 1.47mm/sec, using a standard battery and low noise, magnetic tape Normal 
Bias Ferric Oxide cassette (TDK D90). It had a crystal generated timing track; the 
time of day was displayed on the Tracker and a time code recorded the real time 
accurately onto the tape. This also allowed for correction for recording and replay 
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speed errors (a feature essential for accurate measurement of heart rate variability). 
Subjects were also instructed to note their times of retiring to bed and rising to 
facilitate analysis. 
Semiautomatic analysis of arrhythmias was performed using the Pathfinder 
500 Series analyser system (Version 4.63 software, Reynolds Medical Limited, 
Hertford, UK). The trigger section of the analyser detected individual QRS complexes 
in the electrocardiogram, distinguishing them from P and T waves, muscle noise and 
artifacts using a continuously adaptive threshold derived from the noise components 
by independent filtering. The accuracy with which each QRS can be detected 
depended upon the quality of the recorded electrocardiograms, but it had been 
demonstrated that in routine ambulatory electrocardiograms, QRS detection errors 
occur at a rate of only twelve per 24 hrs [Neilson 1985]. Excessive noise sufficient to 
obscure QRS complexes automatically inhibited analysis until the noise subsides. The 
overall accuracy of QRS detection with this system was high, and the speed surveyor 
in the replay unit minimised inaccuracy due to speed variation [Neilson 1985, 
Bjerregaard 1980]. This is the only commercially available system whose performance 
had been evaluated by independent investigators [Stein et al 1994]. 
In addition, the recordings were also visually checked, and RR intervals and 
QRS configuration manually edited, to ensure correct arrhythmia recognition and 
classification. The classification criteria for arrhythmia analysis used by the Pathfinder 
500 Series are shown in Table 2.1. 
2.2.2. Heart rate variability (HRV) assessment 
The measure of heart rate variability (HRV) describes variation of both 
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instantaneous heart rate and beat to beat RR interval changes. These oscillations in 
the interval between consecutive heart beats are mediated by fluctuations in the 
autonomic nervous system. Analysis of the ambulatory ECG recordings for HRV in 
the studies constituting this thesis was standardised and carried out according to the 
guidelines set by the joint Task Force of the European Society of Cardiology and The 
North American Society of Pacing and Electrophysiology [1996]. HRV was assessed 
in both time and frequency domains. As above, the recordings were analysed using the 
Pathfinder 500 Series analyser. Segments of tape in which changes in RR interval 
duration arise due to occurrence of supraventricular or ventricular ectopic beats were 
excluded from analysis by the Pathfinder, which can identify non -sinus beats by their 
difference in timing and morphology when compared with sinus beats [Zuanetti et al 
1991, Neilson 1975]. The Pathfinder analyser maintained a continuously updated 
example of each subject's normal QRS complex in its memory. Each detected QRS 
complex was compared with this and those with different morphology were labeled as 
ectopics and excluded from subsequent analysis [Neilson 1985]. The program also 
continuously maintained time thresholds corresponding to 63% and 175% of the 
prevailing normal RR interval, and rejected beats with intervals outside these limits. 
Interval calculations were recommenced from the third normal QRS complex down 
the line. Since the Pathfinder took no account of P wave morphology, and was thus 
unable to determine whether complexes showing minor degrees of prematurity were 
of sinus origin, the signal was closely monitored and edited by myself For each QRS 
complex classified as sinus in origin, the Pathfinder generated an external pulse to 
signify the detection of a complex. The RR interval variability was then automatically 
analysed statistically as a function of time using parametric indices of measurement 
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(time domain analysis) by the Pathfinder with a validated software program (Reynolds 
Medical software version 4.63). 
Frequency domain (power spectral) analysis of the RR interval variability on 
the other hand, was undertaken by Fast Fourier Transformation (FFT). Power 
spectral analysis provided the basic information of how power (or variance of the RR 
intervals) distributes as a function of frequency. The FFT is a complex mathematical 
device that allows this exploration of the periodic oscillations of heart rate at different 
frequencies by decomposing the signal into a series of sine waves of different 
amplitudes and spectral frequencies (see below). This process operated on 5 minute 
segments of data. The spectral measures were computed by FFT using a software 
programme (RR- Tools, Version 3.5, Reynolds Medical, Hertford, UK). 
Recordings shorter than 18 hrs, or with less than 40% of the tape suitable for 
analysis were discarded. Separate analyses were undertaken for daytime (1000hrs - 
2330hrs), nightime (2330hr - 0630hrs) and dawn (0630hrs - 1000hrs). These times 
were prespecified before the studies began. The intra- observer variability for HRV 
analysis, as assessed by a second count on 10 tapes, was 5 -6 %. 
Time domain measures of HRV 
A variety of time -domain measures are available. A selection of the commonly 
used parameters in this thesis and their descriptions are listed in Table 2.2. The 
SDNN and HRV Triangular Index both provide estimates of the overall HRV [Task 
Force of the ESC 1996]. SDANN gives an estimate of the long -term components of 
HRV (ie. changes in heart rate due to cycles longer than 5 min) whereas both 
RMSSD and pNN50 estimate the short term components of HRV [Task Force of the 
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ESC 1996]. 
Frequency domain measures of HRV 
In power spectral analysis, there are three main spectral components: very low 
frequency (VLF), low frequency (LF) and high frequency (HF) components (Fig 2.1). 
Measurements of VLF,LF and HF power components are made in absolute values of 
power (ms2). LF and HF are also expressed in normalised units (n.u.), which represent 
the relative value of each power component in proportion to the total power minus 
the VLF component (see Table 2.3). 
The physiological significance of the VLF component is uncertain and has not 
been clearly defined. The representation of the LF and HF in n.u. emphasises the 
controlled and balanced behaviour of the two branches of the autonomic nervous 
system. Vagal activity is the major contributor to the HF component. Some 
controversy exists with regards to the LF component - whereas some studies suggest 
that LF when expressed in n.u., is a quantitative marker of sympathetic modulation, 
other view LF as reflecting both sympathetic and vagal activity [Task Force 1996]. 
Consequently, the LF/HF ratio is considered by some to mirror sympathovagal 
balance [Task Force 1996]. In this thesis, both absolute power and normalised units 
are quoted to give a complete picture of the distribution of the spectral components. 
2.2.3. ST segment analysis for cardiac ischaemia 
ST segment analysis was carried out on the ambulatory electrocardiogram 
recordings using the Pathfinder 500 Series analyser. Standardised criteria for 
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ischaemia were used [Pepine et al 1987]. Significant ST depression for cardiac 
ischaemia was defined as > 0.1 mV (or 1 mm) planar or downsloping ST segment 
depression from baseline at 80ms after the J point lasting for more than 60sec. ST 
elevation was defined as the development of > 0.1mV upward ST segment deviation 
at the J point. Each episode had to be separated by a return of the ST segment to 
baseline for at least lminute to be counted as a discrete episode. The maximal depth 
of the ST segment depression during each episode was noted to allow the calculation 
of an index of ST segment depression (mm) X duration (min) as the "total ischaemic 
burden ". 
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Table 2.1: Criteria for arrhythmia classification used by the Pathfinder 
arrhythmia analyser 
Arrhythmia classification Criteria 
Pause 
Dropped beat 
Ventricular tachycardia (VT) 
> 2.50 sec 
> 180% of RR Interval 
Minimum of 5 consecutive ventricular premature 
beats with a frequency of more than 100bt /min. 
Defined as non -sustained (NSVT) if last for < 30 
sec and terminating spontaneously. 






Minimum of 4 consecutive beats at < 45 bt /min 
Minimum of 5 consecutive beats at > 130 bt /min 
< 66% of RR Interval 
< 66% of RR Interval 
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Table 2.2 Selected time- domain measures of HRV 





HRV triangular index 
msec Standard deviation of all NN intervals. 
msec Standard deviation of the averages of NN intervals in 
all 5 min segments of the entire recording. 
msec The square root of the mean of the sum of the squares 
of differences between adjacent NN intervals. 
Number of pairs of adjacent NN intervals differing by 
more than 50 msec in the 24 hr recording. 
The pNN50 is a derivative of this that expresses the 
sNN50 as a percentage of the total number of all NN 
intervals. 
Baseline width of a triangle superimposed on the 
histogram of all RR intervals obtained in a 24 hr ECG. 
The position and configuration of the triangle is 
determined by the modal value and distribution of RR 
intervals in the frequency histogram, and excludes 
outliers. 
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(low frequency) and HF (High frequency) 




Table 2.3 Selected frequency domain measures of HRV 
Measure Units Description Frequency range 
Total power ms2 Variance of all NN intervals Approx. <0.4 Hz 
VLF ms Power in the very low frequency range < 0.04 Hz 
LF ms- Power in the low frequency range 0.04-0.15Hz 
HF ms` Power in the high frequency range 0.15 - 0.4 Hz 
LF (norm.) n.u. LE power in normalised units ie: 
LF/ (Total power -VLF) X 100 
HF (norm.) n.u. HE power in normalised units ie: 
HF/ (Total power -VLF) X 100 
LF/i-1F Ratio LF/ HF 
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2.2.4 ECG and QT Dispersion analysis 
QT interval analysis was performed on electrocardiograms (with simultaneous 
1 2-lead acquisition) recorded with a Hewlett -Packard 4700A electrocardiogram 
machine (Palo Alto, California). ECGs from the following subjects were excluded 
from analysis: those in atrial fibrillation or whose predominant rhythm was of 
nonsinus in origin, bundle branch block, paced complexes on the ECG or those on 
anti -arrhythmic medication. All QT intervals and dispersion (QTd) were analysed 
blindly by myself on a Calcomp digitizing tablet (Twyford, Berkshire, United 
Kingdom) using customised software (Medical Computing Unit, Ninewells Hospital). 
QT intervals were measured in all leads, if possible, on a surface 12 -lead 
ECG(25mm/s speed). QT interval was taken from the onset of the QRS to the end of 
the wave (ie. return to the T/P baseline). If U waves were present, the QT interval 
was measured to the nadir of the curve between the T and U waves. Three 
consecutive cycles were usually measured for each lead. In all of the studies, QT 
intervals were corrected with Bazett's formula (QTc= QT/RRI/Z ). In addition to 
Bazett's formula, the QT intervals in the study described in Chapter 8 were also 
corrected using Morrison and Hodges linear correction formula [Hodges et al 1983]. 
QTd was calculated in ECGs in which > 9 leads were measurable. QTd is 
defined as the difference between maximum and minimum QT intervals (QTd = 
QTmax - QTmin). Corrected QT dispersion (QTcd) is defined as the difference 
between maximum and minimum QTc (QTcd = QTmmax -QTcmin). The intra- 
observer variability (obtained from 20 set of ECGs that were repeatedly measured on 
2 separate occasions) was 3% and 6 -7% for measurements of QT intervals and QT 
dispersion, respectively. 
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2.2.5 Assessment of baroreflex sensitivity 
The method most widely used for assessment of baroreflex responsiveness 
was devised by the Oxford group [Smyth et al 1969]. Traditionally, with this method, 
small bolus injections of the a- adrenoreceptor agonist phenylephrine are given 
intravenously. Phenylephrine, a vasopressor agent, increases blood pressure and 
causes a reflex bradycardia. Increases in arterial BP activate mechanosensitive nerve 
endings in the carotid sinus and aortic arch, which then send sensory information to 
the central nervous system via the glossopharyngeal and vagus nerves. This in turn, 
results in increased reflex vagal efferent outflow to the heart. A linear relationship 
exists between the systolic blood pressure and the change in cardiac cycle length; the 
slope of this relationship_ has been taken as a measure of baroreflex sensitivity (BRS) 
[Smyth et al 1969, La Rovere et al 1998, Sullebarger et al 1990]. 
However, there are practical limitations with this method. The Oxford bolus 
method requires beat to beat arterial pressure measurement. This would either involve 
an invasive approach or more usually, the use of a device called the FINAPRES 
(F[Nger ARterial PRESure), designed specifically for non -invasive recording of beat- 
to-beat blood pressure. Unfortunately, this form of non -invasive beat -to -beat analysis 
was not possible to do in our studies as the FINAPRES machines are no longer 
produced or sold in the United Kingdom. 
Hence in the studies described in Chapters 5 and 6, we have opted instead, to 
administer phenylephrine by a graded infusion technique to measure baroreflex 
sensitivity. In addition our technique described below, has several other advantages. 
Firstly, infusions allowed us to monitor HR and BP changes at steady state non - 
invasively at each incremental dose, and hence avoiding the need for invasive beat -to- 
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beat intrarterial measurements as required by the bolus method (and hence, lessening 
risk and discomfort to the subjects). 
Secondly, our readings were taken at steady state and more importantly still 
each of our readings were taken in triplicate, which should minimise random 
measurement error. Furthermore in our studies, we were more interested in changes 
or differences in baroreceptor sensitivities between different treatments rather than in 
using absolute levels of BRS to compare one population with another. BRS 
measurements by infusion method are not equivalent to the bolus method. Unlike the 
bolus method, infusions allow for baroreceptor "resetting" to occur to some degree, 
(and therefore reduce or dampen the change in baroreflex response). Although BRS 
measurements by infusion method are not equivalent to the bolus method, it has been 
shown to be reproducible in several studies [Sullebarger et al 1990, Ferguson et al 
1985]. 
Infusion method of baroreflex sensitivity assessment: 
The haemodynamic study was carried out after 30mins of supine bed rest. 
Intravenous PE was given by infusion into the right forearm. It was administered in 
stepwise 10 min infusions (0.2 -3.6 ug/kg/min) by use of an infusion pump (IMED, 
San Diego, CA). The infusion was stopped when a 35 -40 mmHg rise in systolic 
arterial pressure had been achieved. The average systolic BP and HR readings were 
obtained in triplicate using a semi -automatic sphygmomanometer (Dinamap Vital 
signs monitor 1846, Critikon, Tampa, Florida, USA), and R -R interval obtained from 
continuous ECG recordings between 8 and 10 mins after each infusion dose. 
The R -R intervals were plotted against the systolic blood pressure in a graph, 
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and a computerised curve fit was then carried out to establish a linear portion of the 
line of best fit. As described in other studies [La Rovere et al 1998, Sullebarger et al 
1990, Marakas et al 1995], only regression lines that had a correlation coefficient of 
>0.8 were used; the slope of the linear portion of this relationship was taken as an 
index of baroreflex sensitivity (BRS). An example of BRS assessment in a normal 
volunteer is shown in Fig 2.2. 
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y = 10.2x + 17.44 
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BRS, measured as the slope of the linear regression line (dRR Int/ dsBP), in this individual is 10.2 
msec/ mmHg. 
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2.2.6 Noradenaline Kinetics Studies 
The plasma concentration of noradrenaline is a composite of two concurrent 
processes: spillover of noradrenaline into plasma after release from sympathetic 
nerves, and subsequent removal of noradrenaline from the circulation. Thus a 
comprehensive assessment of sympathetic activity must take into account both 
processes. In this thesis, noradrenaline kinetics were determined by the well 
established technique of Esler et al [ 1979]. 
This radiotracer kinetic technique using infusions of [3H]noradrenaline, can 
simultaneously assess noradrenaline spillover to the plasma and noradrenaline 
clearance. It requires the radiotracer to be infused until steady- state, and assumes that 
the infused [3H]noradrenaline is not re- released to an appreciable degree, and that 
alumina extractable [3H]metabolites do not accumulate during infusion. 
I-(2,5,6-3H) noradrenaline infusion protocol: 
All studies were performed in subjects in the supine position at rest. The 
tritiated noradrenaline infusion (NEN- DuPont, UK) was administered via an 
intravenous cannula inserted in the antecubital fossa. An initial loading dose was given 
as a bolus (12.5 uCi given iv over 2 minutes) followed by a constant infusion 
(0.7uCi /min/m2) for 60 minutes. This infusion regimen has been shown to reach 
steady -state and achieve constant plasma concentration of tritiated noradrenaline 
within 30 minutes [Esler et al 1979]. 20mis venous blood samples were taken for 
determination of resting plasma noradrenaline and tritiated noradrenaline levels after 
40 and 50 minutes of the infusion (two samples were taken to ensure that steady state 
had been achieved). 
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Blood samples were taken in chilled lithium- heparin tubes, centrifuged at 
3000rpm at 4 °C and the plasma separated and stored at -70 °C until assayed as a 
batch. Two 5mis samples of the infusate were also collected (one at the start prior to 
and the other after completion of infusion), stored and assayed as described for the 
blood samples, to allow determination of the actual rate of tritiated noradrenaline 
infusion. 
Determination of noradrenaline kinetics: 
Noradrenaline (NA) concentrations were measured by High Performance 
Liquid Chromatography (HPLC). All plasma samples were run on the same day in 
duplicate. After the addition of dihydroxybenzylamine used as an internal standard, 
catechols were extracted through adsorption on alumina. After elution from the 
alumina through the addition of 0.2 mol/L HCIO4, the catechols (NA and DHPG) 
were then separated and measured by HPLC. The HPLC effluent coinciding with the 
NA peak was collected and [3H]NA radioactivity levels determined by liquid 
scintillation spectroscopy. This allowed determination of the plasma [3H] NA 
concentration without interference from tritiated metabolites. The intrassay coefficient 
of variability was 6.1%. 
From this data, NA spillover and clearance can be calculated using the 
following formulae: 
Whole body NA clearance = [3HJNA infusion rate (dpm/min) 
Plasma [3HJ NA concentration (dpm/ml) 
Whole body NA spillover - PHI NA infusion rate (dpm/min) 
Specific radioactivity of plasma NA (dpm /pg) 
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2.3 MATERIALS AND ASSAYS 
2.3.1 Handling of blood samples prior to analysis 
Intravenous cannulae (18G) were placed into antecubital veins. Intermittent 
blood samples were taken from the indwelling cannula to cause the least disturbance 
to the resting subject. 
Aliquots (5m1) were taken into chilled lithium heparin tubes for measurements 
of catecholamines (NA and DHPG) and aldosterone. 
Aliquots (10m1) were taken into chilled glass tubes containing a solution of 
0.05 M 0- phenanthroline, 2 g/1 neomycin, 0.125 M EDTA disodium salt and 2% 
ethanol, for measurement of Ang II. 
Aliquots (20m1) were taken into chilled lithium heparin tubes for 
measurements of plasma [3H] noradrenaline. 
Aliquots (5m1) were taken into plain glass tubes for measurement of urea and 
electrolytes. The blood was allowed to clot at room temperature and serum separated 
and stored at -20 °C until assayed. 
The samples taken for measurement of NA, DHPG, Ang 11, aldosterone and 
plasma [3H] noradrenaline were immediately centrifuged at 4 °C, separated and stored 
at -70 °C (NA, DHPG, Ang II and plasma [3H] noradrenaline) or -20 °C ( aldosterone) 
until assayed. All assays were done simultaneously in a batch. 
2.3.2 Analytical methods and biochemical assays 
Serum electrolytes 
Plasma sodium, potassium, urea and creatinine were measured using a Chem Trak 
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system (Medical Analysis Systems, Camarillo, Carlifornia) while plasma magnesium 
was measured by atomic absorption spectrophotometry (Pye Unicam atomic 
absorption spectrophotometer, Pye Unicam Ltd, Cambridge, UK). The intrassay 
coefficients of variability were 0.7 %, 1.1 %, 2.2 %, 1.9% and 2.4% respectively. 
Plasma catecholamines (Noradrenaline & Dihydroxyphenylglycol) 
Plasma noradrenaline (NA) and plasma dihydroxyphenylglycol (DHPG) were 
measured by HPLC as described in the previous section on Noradrenaline Kinetics. 
Specific radioactivity of plasma NA 
See previous section on Noradrenaline Kinetics. 
Plasma aldosterone 
Plasma aldosterone was measured after plasma extraction, by a commercially available 
radioimmunoassay kit (Sorin Biomedica, Sallugia, Italy). The intra -assay coefficient 
of variation for this method in our laboratory was 7.8% and the inter -assay coefficient 
of variability was 9.6 %. 
Plasma Ang II 
Plasma Ang II was measured after plasma extraction, by a commercially available 
radioimmunoassay kit (Nichols Institute Diagnostic BF, Nieuweweg, The 
Netherlands). The intra -assay coefficient of variation for this method in our laboratory 
was 4.0% and the inter -assay coefficient of variability was 9.3 %. 
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2.3.3 List of Pharmacological Agents 
d- Aldosterone: d- Aldosterone (Sigma Chemical Co Ltd, UK) was prepared as 
a solution (0.5mg/m1) for human administration to be diluted in 500m1 Dextrose 5% 
for intravenous infusion by Tayside Pharmaceuticals, Dundee. 
Phenylephrine: Phenylephrine hydrochloride 1% (Knoll Pharma,UK) was 
prepared as a solution (10 mg/ml) for human administration to be diluted in Dextrose 
5% for intravenous infusion by Tayside Pharmaceuticals, Dundee. 
Sodium nitroprusside: Sodium nitroprusside (non -proprietary) was prepared 
as a solution (10 mg/ml) for human administration to be diluted in Dextrose 5% for 
intravenous infusion. 
142,5,6- 3H) Noradrenaline: 1- (2,5,6- 3H) Noradrenaline (NEN- DuPont, 
UK) was prepared as a solution (100 uCi) diluted in 50m1 N Saline containing 
Ascorbic Acid for human intravenous administration. The solution was prepared by 
the Medical Physics Department, Ninewells Hospital. 
Spironolactone: Aldactone 50mg Tablets (Searle Ltd, UK). 
Enalapril maleate: Innovace 20mg Tablets (Merck Sharp & Dohme Ltd, UK) 
Frusemide: Lasix 40mg Tablets (Hoechst UK Ltd, UK) 
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Losartan potassium: Cozaar 50mg Tablets (Merck Sharp & Dohme Ltd, UK) 
Note: All intravenous infusions were made up and/or diluted as indicated immediately 
prior to infusion. 
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2.4 STATISTICAL ANALYSIS 
Unless otherwise indicated, all the data in this thesis were analysed using 
Statgraphics software package (STSC Software Publishing Group, MD, USA). 
Repeated measures analysis of variance was used to analyse the effect of treatments 
on the various HRV and QT dispersion indices measured. Subjects, treatment and 
dose were used as within factors for analysis. The effects of different treatment and 
placebo groups on other parameters were analysed using the paired Student t -test. 
Correlations between parameters were performed using standardised linear 
regression. A probability of p< 0.05 was considered as being of significance. Data and 
variables are expressed as arithmetic Mean -f- Standard Deviation (SD) unless 
otherwise stated. The specific statistical techniques in each study are detailed in the 
relevant chapters. Assistance on statistics was obtained from Mr. S Ogston from the 
Medical Statistics Department at Ninewells Hospital, Dundee. 
80 
CHAPTER THREE 
ALDOSTERONE BLOCKADE AND AUTONOMIC REGULATION 
IN CHRONIC HEART FAILURE 
3.1 INTRODUCTION 
In the RALES mortality trial, spironolactone therapy given in addition to 
ACE inhibitors, improved survival in chronic heart failure (CHF) but the mechanism 
of its benefit is not fully understood. Experimental evidence (as discussed in Chapter 
1) suggests that aldosterone may have detrimental effects on the autonomic nervous 
system, especially during the morning hours when ACTH -induced aldosterone 
secretion is maximal. 
Intriguingly, aldosterone secretion [Armbruster et al 1975, Davidson et al 
1996] and the autonomic nervous system [Furlan et al 1990, Adamopoulos et al 
1995] exhibit a diurnal variation, with both increasing in the early morning. Even 
more intriguingly, this early morning peak in aldosterone and sympathetic activity 
occurs at the same time of day as cardiac events peak [Muller et al 1985, Moser et al 
1994, Raeder et al 1988]. Hence, the hypothesis arises that the dawn surge in 
aldosterone may unfavourably modulate the sympathovagal balance which then 
contributes to the high incidence of cardiac arrhythmias [Raeder et al 1988], 
ischaemia [Muller et al 1985] and sudden deaths [Moser et al 1994] seen particularly 
during the early hours of the day. In this study, I have sought to explore whether the 
dawn peak in aldosterone unfavourably alters the autonomic nervous system in CHF. 
A full diurnal assessment of the influence of aldosterone blockade on sympathovagal 
balance was carried out in CHF patients already established on ACE inhibitors. The 
circadian variation of autonomic function was assessed by heart rate variability 
analyses and norepinephrine kinetics studies. In addition the effects of aldosterone 
blockade on cardiac arrhythmias and on the diurnal variation of QT dispersion 




Twenty -eight patients with CHF (NYHA Class II to IV) and left ventricular 
ejection fraction (LVEF) < 40% were recruited from the heart failure clinic of our 
institute. All patients gave informed written consent and the protocol was approved 
by the local Tayside Ethics Committee on Medical Research. The baseline 
demographic characteristics of the patient population are listed in Table 3.1. All 
patients were on optimal therapy and had been treated with a diuretic and ACE 
inhibitor for at least 6 weeks before the study. LVEF was measured by either 
echocardiography or radionuclide ventriculography. Coronary artery disease was 
documented either by coronary angiography, positive exercise test or based on 
history of previous myocardial infarction. We excluded subjects whose predominant 
rhythm was of nonsinus origin (eg. atrial fibrillation), who had a bundle branch block 
or paced complexes on the ECG. Similarly, no patient recruited was taking anti - 
arrhythmic medication which might have altered the QT interval. All cardioactive 
drugs and their dosages were unchanged throughout the entire study (except for 
spironolactone or placebo). 
Six patients had non -insulin dependent diabetes mellitus and three had 
hypertension. No patient had significant haematological abnormality, serum 
creatinine >200Umol/L, or abnormal liver function tests. 
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Protocol 
All patients were recruited into a double -blind, randomised cross -over study. 
Each patient had been clinically stable for at least 3 months prior to recruitment. 
Baseline haemodynamic, biochemical and ECG measurements were made at the start 
of the study before each patient was randomised to receive spironolactone 50mg 
daily or placebo for a 1 month period for each treatment. Between each treatment 
phase, there was a washout period of 30 days. During each treatment, patients were 
reviewed weekly for clinical evaluation of tolerability and biochemical 
measurements of plasma urea and electrolytes. 
At the end of each treatment phase, the patients were admitted to and studied 
at our research unit over a 24hr period. On arrival at 11 am on each study day, all 
patients had two intravenous 18G indwelling cannulae inserted (one in each 
forearm), and a 24hr ambulatory Holter (Reynolds Tracker 2) monitor attached to 
their chest. After 30 mins of bedrest, baseline values of blood pressure and heart rate 
were determined in triplicate using a semi- automatic sphygmomanometer (Dinamap 
Vital Signs Monitor 1846, Critikon, Tampa, Florida). 
A series of measurements were carried out during the 24hr spell. Repeated 
12 -ECGs and venous blood samples (10m1s) for plasma norepinephrine were 
obtained at the following time points: 1500hr, 1700hr, 2300hr, 0300hr, 0600hr, 
0700hr, 0800hr and 1100hr. Venous samples for plasma aldosterone (5m1s) were also 
obtained at the 0600hrs and 1100hrs time points. The patients were asked to lie 
supine for 30 minutes prior to each sampling time -point. In addition, at 1600hr and 
0700hr, the patients were administered an intravenous infusion of 1- (2,5,6 -H) 
norepinephrine for assessment of norepinephrine kinetics (see Chapter2). 
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In between the study time -points, the patients were allowed to sit or move 
about the bedside. Excessive movements were kept to a minimum and they were 
instructed to record all their movements. Regular meals were provided for the 24hr 
period. Bedtime and mealtimes were standardised as follows: breakfast 0930hr, 
lunch 1300hr, dinner 1830hr and bedtime 2300 - 0700hr. 
Ambulatory ECG monitoring 
Twenty -four hour ambulatory electrocardiogram recordings were obtained for 
analysis in all subjects using a standard two -channel (four leads) Tracker 2 analogue 
tape recorder (Reynolds Medical Limited, Hertford, UK), recording standard leads 
CM1 and CM5 as described in Chapter 2. 
To facilitate analysis, subjects were instructed to note their times of retiring to 
bed and rising. Semiautomatic analysis of arrhythmias was performed using the 
Pathfinder 500 Series analyser system (Version 4.63 software, Reynolds Medical 
Limited, Hertford, UK). In addition, the recordings were also visually checked, and 
RR intervals and QRS configuration manually edited, to ensure correct arrhythmia 
recognition and classification. 
Heart rate variability analysis 
HRV was assessed in both time and frequency domains according to the 
guidelines set by the joint Task Force of the European Society of Cardiology and The 
North American Society of Pacing and Electrophysiology [ 1996] and described in 
detail in Chapter 2. The following time -domain indices were evaluated from each 24 
hr ECG recording: standard deviation of all RR intervals (SDNN), 24hr triangle 
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index, standard deviation of 5 min mean RR intervals (SDANN) and the root mean 
square of differences of successive RR intervals (rMSSD). 
Frequency domain (power spectral) analysis of the RR interval variability on 
the other hand, was undertaken by Fast Fourier Transformation (FFT). This process 
operated on data of 5 min segments of each hour over the 24hr recording whilst the 
subjects were at rest. Time -periods where there were excessive movements (eg. 
subjects getting up to go to the toilet) were excluded from the analysis. Spectral plots 
were used to identify the low frequency (LF) component (0.03 -0.14 Hz) and the high 
frequency (HF) component (0.18- 0.40 Hz). Indices are expressed in normalised 
units (n.u.) ie. the relative percentage compared to the total oscillatory power. 
Recordings shorter than 18 hrs, or with less than 40% of the tape suitable for 
analysis were discarded. Separate analyses were undertaken for daytime (1000hrs - 
2330hrs), nightime (2330hr - 0630hrs) and dawn (0630hrs - 1000hrs). These times 
were prespecified before the study began, as the hypothesis was that the dawn period 
may be different from the rest. 
QT interval and dispersion analysis 
QT interval analysis was performed on electrocardiograms (with 
simultaneous 12 -lead acquisition and all QT intervals and dispersion (QTd) were 
analysed blindly by myself on a Calcomp digitizing tablet (Twyford, Berkshire, 
United Kingdom) using customised software (Medical Computing Unit, Ninewells 
Hospital) as detailed in Chapter 2. The intra- observer variability (obtained from 20 
set of ECGs that were repeatedly measured on 2 separate occasions) were 3% and 8- 
9% for measurements of QT intervals and QT dispersion, respectively. 
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Norepinephrine kinetics 
All studies were performed in subjects in the supine position at rest according 
to the well established technique of Esler et al [1979] as described in Chapter 2. The 
tritiated norepinephrine infusion protocol was used twice per patient on each study 
day; the first infusion was commenced at 1600hr and the second repeated at 0700hr 
to allow us to assess norepinephrine spillover during the morning hours and evening 
hours. 20mis venous blood samples were taken in chilled lithium -heparin tubes for 
determination of resting plasma norepinephrine and tritiated norepinephrine levels 
after 40 and 50 minutes of the infusion (two samples were taken to ensure that steady 
state had been achieved). 
Analysis of the blood samples and determination of the noradrenaline 
kenetics are detailed in Chapter 2. 
Biochemical assays 
See Chapter 2. 
Statistical analysis 
All the data were analysed using Statgraphics software package (STSC 
Software Publishing Group, MD, USA) as described in Chapter 2. Repeated 
measures ANOVA was carried out on the HRV and QT outcome measures. The 
within subject factors were treatment and time, and the between subject factor was 
order of treatment. A full factorial model was fitted to test the significance of these 
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factors. The effects of treatment on the other measures were analysed using the 
paired Student t -test. 
3.3 RESULTS 
Both spironolactone and placebo given in addition to ACE inhibitors were 
clinically well tolerated by all patients. There were no significant changes in baseline 
haemodynamic parameters such as resting heart rate and blood pressure. Plasma 
potassium, magnesium and urea were significantly increased with spironolactone 
compared to placebo after four weeks of treatment (see Table 3.2). Three of the 
patients had significant hyperkalemia (potassium > 5.5mmol/L) and elevation of 
plasma creatinine ( >300umol/L) which necessitated the dose of spironolactone to be 
halved (25mg) in these individuals. Plasma aldosterone levels measured between 6 
and 11 am rose from 90 ± 39 pg/ml to 137 ± 60 pg/ml, and from 220 ± 80 pg/ml to 
316 ± 108pg/ml on the placebo and spironolactone study days, respectively. 
The effects of spironolactone compared to placebo on the various autonomic 
parameters measured are displayed in Tables 3 -5. Arrhythmic activity was unaffected 
by spironolactone therapy compared to placebo; there were no significant differences 
in the number of ventricular extrasystoles or non -sustained ventricular tachycardias 
(NSVT) between the two treatments. 
Circadian pattern of heart rate variability 
The indices of heart rate variability were significantly improved by 
spironolactone therapy compared to placebo. Although 24hr time domain measures 
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were not significantly affected by spironolactone therapy, there was a significant 
overall increase in the mean 24hr (averages of all the 5mins segments over the 24hr 
period) high frequency component (HF) and decrease in the low: high frequency 
ratio (LF/HF) throughout the 24hr period compared to placebo (Table 3.3). The 
effects of spironolactone on the HRV indices were greatest during the hours of 
awakening (0600- 1000hr) (Table 3.4, Fig 3.1 -3.2). During these hours, the standard 
deviation of RR intervals were significantly increased whereas both heart rate and 
the LF/HF ratio of the power spectral components were significantly reduced 
compared to placebo. The increase in the HF component by spironolactone was also 
highest during this time of day but the LF component was not significantly affected. 
Circadian pattern of QT dispersion 
QT interval dispersion indices were significantly higher during the day 
compared to the sleeping hours (Fig 3.3). All measured QT indices including 
QTcmax and QTd were significantly reduced by spironolactone compared to placebo 
(Table 3.3 and Fig 3.4). The reduction in QTcmax, QTd and QTcd were greatest at 
the 6am time -point (488 ± 30ms to 470 ± 33ms, p =0.04; 68.0 ms ± 12.8 ms to 55.0 ± 
9.5ms, p <0.001 and 74.4 ± 13.3 ms to 62.0 ± 9.5ms, p <0.001 respectively). 
Norepinephrine kinetics 
The diurnal profile of plasma norepinephrine levels is displayed in Fig 3.5. 
There were no significant differences between the two treatments. Whole body NA 
clearance and spillover did not appear to be significantly affected by spironolactone 
therapy compared to placebo (Table 3.5). 
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Subgroup analyses 
There were no significant differences in treatment effects between the NYHA 
Classes or between the NIDDM and the non -NIDDM subgroups (Table 3.6). 
Spironolactone improved both HRV and QT dispersion indices to the same degree in 
all subgroups. 
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Table 3.1: Baseline Demographic Characteristics of randomised patients. 
Mean SSD (% in brackets) 
Characteristics n =28 
Age (yrs) 63 ± 9 
M/F 24/4 
Weight (kg) 75 ± 12 
Aetiology of CHF: 
Ischaemic 23 (82 %) 
Idiopathic dilated cardiomyopathy 3 (11%) 
Unknown 2 (7 %) 
LVEF ( %) 29 ± 7 
NYHA 
Class II 15 (54 %) 
Class III 13 (46 %) 
Frusemide 25 (89 %) 
ACE Inhibitor 28 (100 %) 
Ca antagonist 6 (21 %) 
Aspirin 21 (75 %) 
Nitrates 15 (54 %) 
Beta -blockers 2 (7 %) 
Digoxin 8 (29 %) 
History of Diabetes Mellitus 6 (21 %) 
History of Hypertension 3 (11 %) 
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Table 3.2: Effect of Spironolactone and Placebo on resting haemodynamic 
and biochemical measures after four weeks of treatment . 
Mean + SD. P <0.05 if statistically significant. 
PARAMETER PLACEBO SPIRO P VALUE 
HR 72 +13 70 +12 NS 
SBP 125 ± 20 121 ± 18 NS 
Kr 3.9 ± 0.4 4.3 ± 0.4 0.01 
Urea 7.6 ± 3.5 8.8 ± 4.1 0.01 
Creatinine 120 + 31 137 + 37 NS 
Mg' ̀  0.82 ± 0.05 0.85 + 0.06 0.05 
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Table 3.3 Mean 24 hr Values: Effect of Spironolactone or Placebo on 
Arrhythmias, Heart Rate Variability and QT Dispersion. Mean ±SD. 
Parameter Placebo Spiro p -value 
Time -domain RR Int 771 ± 122 798 ± 143 NS 
measures HRV Index 27±10 27±8 NS 
SDNN 91 ± 32 92 ± 26 NS 
SDANN 81±30 82±23 NS 
RMSSD 20±11 21±8 NS 
Frequency LF (n.u) 69.5 ± 16.5 67.7 ± 17.1 NS 
(Power Spectral) HF (n.u) 21.8 ± 14.7 24.6 ± 16.8 0.004 
measures LF/IF 4.98 ± 3.54 4.40 ± 3.10 0.002 
24hr arrhythmia Ventricular 
extrasystoles /24hr 
2240 ± 2125 2425 ± 4555 NS 
analysis 
NSVT(no.pats) 3 1 NS 
QT Interval and QTd 66.6 ± 12.3 58.2 ± 73 0.003 
Dispersion QTcd 73.2 ± 13.4 65.3 ± 7.6 0.0001 
variables QTmax 468 ± 26 456 ± 24 0.017 
QTcmax 480 ± 34 467 ± 30 0.001 
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Table 3.4: Diurnal Effects of Spironolactone and Placebo on HRV 
parameters: Mean ±SD. 
Time (hr) HRV parameter Placebo Spiro p -value 
1000 -2300 hr RR (ms) 749 ± 130 780 ± 158 
SDRR (ms) 53 ± 25 56 ± 25 
LF(n.u) 71±14 70±16 
HF(n.u.) 21±12 23±15.5 
LF/11F 4.98±3.35 4.65±3.12 
2300-0600hr RR (ms) 828 ± 143 845 ± 146 
SDRR (ms) 53 ± 25 50.5 ± 23 
LF (n.u) 65 ± 18 64 ± 19 
HF(n.u.) 25±19 27±18 
LF/IIF 4.52±3.56 4.13 ±3.25 
0600-1000hr RR (ms) 785 ± 154 821 ± 161 
SDRR (ms) 61 ± 30 71 ± 31 
LF (n.u) 71 ± 18 67 ± 16 
HF (n.u.) 20 ± 14 27 ± 18 

















Table 3.5: Effect of Spironolactone and Placebo on whole body 
Norepinephrine (NA) spillover and clearance. ,Clean + SD. 
Placebo Spiro P -value 
AM (0700hrs) NA clearance (I/min) 3.41 + 1.0 3.35 + 0.8 NS 
NA spillover (ug /min) 1.50 + 0.65 1.71 + 0.35 NS 
PM (1600hrs) NA clearance 3.32 + 0.8 3.0 + 0.7 NS 

























































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.1: Diurnal variation of RR intervals (RR Int) [top] and ratio of low 
frequency to high frequency component (LF/HF) of heart rate 
variability [bottom]. Data expressed as Mean + SEM. 
Figure 3.2: Diurnal variation of normalised high frequency component (111') 
[top] and normalised low frequency component (LF) ]bottom] of 
heart rate variability. Data expressed as Mean + SEM. 
Figure 3.3: Diurnal variation of QT dispersion (QTd) [top] and Bazett's rate - 
corrected QT dispersion (QTc Disp) ]bottom]. Data expressed as 
Mean + SEM. 
Figure 3.4: Individual mean 24hr QTc Dispersion (QTc Disp) data: The effects 
of Spironolactone and Placebo on QTc Disp. 
Figure 3.5: Diurnal profile of plasma norepinephrine levels (NA conc). Data 
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In the RALES study, the addition of spironolactone in CHF patients had been 
shown to confer a survival benefit over and above that of ACE inhibitors alone [Pitt 
et al 1999]. The results of this study provide mechanistic insights as to why this may 
be so. 
In this study, the effects of spironolactone therapy in CHF patients already 
established on ACE inhibitors were examined. Consistent with previous findings 
[6,10,24,25], the addition of a small dose of spironolactone (50mg/daily) to 
maintenance treatment with a loop diuretic and ACE inhibitor in heart failure appear 
to be safe and well tolerated. After four weeks of treatment, spironolactone caused a 
small but significant rise in plasma potassium and magnesium levels, compared to 
placebo. 
The effects of aldosterone blockade on various arrhythmic and autonomic 
surrogate markers were assessed in this study. Although ectopic activity was not 
significantly affected, spironolactone therapy was found to improve not only heart 
rate itself but also HRV as well as QT dispersion parameters. Perhaps the most 
intriguing aspect of our findings is that these effects appear to be maximal during the 
morning hours (6- l0am), coinciding with the surge of aldosterone levels in man. 
Like cortisol, aldosterone secretion follows a diurnal variation with peak secretion 
during the morning hours [Armbruster et al 1975]. In CHF, it is well documented 
that this ACTH -induced dawn surge in aldosterone still occurs despite ACE inhibitor 
therapy [Davidson et al 1996]. 
As spironolactone was administered once daily, the question naturally arises 
whether the observed heightened early morning effects of spironolactone could also 
103 
be partly attributed to the pharmacokinetics of the drug itself This is not likely as 
spironolactone has a very gradual and prolonged action with its activity persisting for 
more than 24hrs after a single dose, and steady state conditions are established within 
a few days [Gardiner et al 1989]. Furthermore the observed beneficial effects were 
observed from 6am onwards, which was well before the patients took the study 
medications (8 -9am). 
In this study, the magnitude of beneficial autonomic effects was similar across 
all subgroups of CHF patients. We could find no significant differences in HRV or 
QT dispersion changes between the NYHA subgroups, or between the NIDDM and 
the non -NIDDM subjects. It must however be pointed out that the study was not 
designed (and therefore was not statistically "powered ") for subgroup analyses. 
Aldosterone and diurnal sympathovagal modulation: 
To date, there has been very limited data regarding the diurnal variation of 
the autonomic tone in CHF patients. Spectral analysis of 24hr HRV recordings have 
shown consistently that in normal subjects, LF and HF indices exhibit a circadian 
pattern and reciprocal fluctuations with higher values of LF in the daytime and of HF 
at night, corresponding with a sympathetic predominance during the day and vagal 
predominance during the night [Furlan et al 1990]. A major change in the autonomic 
profile occurs at approximately 6am, coinciding with the time of awakening, when a 
surge of sympathetic activity occurs rapidly and concomitantly with vagal 
withdrawal [Furlan et al 1990]. 
In CHF, this normal circadian variation of the autonomic tone is disrupted. 
Both time -domain and frequency- domain parameters of HRV are reduced 
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[Adamopoulos et al 1995, Casolo et al 1989, Casolo et al 1991, Panina et al 1995]. 
Reduced HRV has recently been shown to be a good predictor of cardiac death in 
CHF [Nolan et al 1998]. Data on the circadian variations of the spectral components 
are however limited and conflicting in CHF. In the present study, we observed a 
reduced but still preserved circadian pattern in the spectral components in CHF, a 
finding also reported by some [ Adamopoulos et al 1995] but not others [Casolo et al 
1989, Panina et al 1995]. 
This circadian pattern is further enhanced or preserved following 
spironolactone therapy. In particular, the HF spectral component was significantly 
increased whereas the L;F/HF ratio was significantly reduced during the hours of 
awakening (6- l 0am). Interestingly, heart rate was also significantly reduced during 
this crucial time -period, a finding that was previously observed in another study 
[MacFadyen et al 1997]. These findings suggest that aldosterone blockade may have 
a favourable impact on the sympathovagal balance during these hours when 
aldosterone secretion is high. On the other hand, we found that the overall 24hr time 
domain measures of heart rate variability did not significantly differ between the two 
treatment groups. Although time domain methods are ideal for long -term recordings, 
they are not as robust as frequency domain methods, which are preferred for shorter 
term recordings [Task Force 1996]. By analysing short time segments (5mins) of 
each hour, the latter method better allowed us to assess the diurnal impact of 
aldosterone blockade at different time periods of the day. As aldosterone secretion 
occurs in a diurnal fashion, it is thus not surprising to find that the overall 24hr time 
domain HRV indices were not significantly altered, whereas between the 6 -l0am 
time period, the standard deviation of the RR intervals were significantly increased, 
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an observation which is consistent with the changes seen with the frequency domain 
indices. 
How should one interpret these data? Vagal activity is thought to be 
the major contributor to the HF component [Task Force 1996]. Whereas some studies 
suggest that LF, when expressed as n.u., is a quantitative marker for sympathetic 
modulations, others view LF as reflecting both sympathetic and vagal activity [Task 
Force 1996]. Consequently, the LF/IF ratio is considered by some investigators to 
mirror sympathovagal balance [Task Force 1996]. Thus the favourable impact of 
spironolactone therapy on both the HF and LF/FfF (but not LF) indices suggest that it 
works predominantly on the vagal limb of the autonomic tone. This is also consistent 
with the observation that spironolactone had no effect on norepinephrine kinetics. 
There is certainly a growing body of experimental evidence that aldosterone has 
detrimental effects on vagal activity. It has been shown to reduce baroreceptor 
discharge from the carotid sinus in experimental dog models [Wang et al 1992]. 
The role of aldosterone in sympathetic modulation is however, more 
controversial. Although there is some evidence in the literature to suggest that 
aldosterone may potentiate sympathetic activity [Barr et al 1995, MacFadyen et al 
1997], we were unable to confirm this in our study. The diurnal plasma 
norepinephrine profiles were similar with both treatments; and neither whole body 
norepinephrine spillover nor clearance was significantly affected. These findings are 
not necessarily a contradiction to previous observations where cardiac 
norepinephrine uptake as assessed by MIBG scanning was increased by 
spironolactone therapy [Barr et al 1995]. The sympathetic nervous system is highly 
differentiated and the effects observed in the body as a whole may not be 
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representative of adrenergic drive specifically to the heart [Haskings et al 1986]. 
Newton et al [ 1996] made a similar observation with digoxin therapy in CHF 
patients where they found that digoxin administration reduced cardiac 
norepinephrine spillover but did not affect total body norepinephrine kinetics. 
Aldosterone and QT Dispersion: 
Another interesting observation in this study is the finding that spironolactone 
also reduced QT dispersion compared to placebo. The diurnal pattern of the QTc 
interval and dispersion in normal man is well established [Molnar et al 1997, Ishida 
et al 1997] but we believe that ours is the first study to show that QT dispersion 
occurs in a diurnal fashion in CHF patients, with daytime values being significantly 
higher than night time values. 
Following spironolactone treatment, QTcmax and all indices of QT 
dispersion (QTd and QTcd) were significantly reduced at nearly all time -points 
compared to placebo (Table 3.3, Fig 3.4). This effect was greatest in the morning 
hours where there was a 19% reduction in QTd compared to placebo. Even more 
important is the fact that of the six patients who had a QTd >80msec on placebo, none 
of them had a QTd >80msec on spironolactone. 
These observations may have important clinical implications. QTc interval 
prolongation has repeatedly been shown to be an independent risk factor for sudden 
cardiac death (SCD) [Schwartz and Wolf 1978, Algra et al 1991, Naas et al 1998]. 
Similarly, QTd has recently also been identified as a simple and easily measured 
predictor of SCD [Buja et al 1993, Barr et al 1994, Darbar et al 1996]. A QTd >80 - 
85msec has been identified as a crucial threshold in predicting SCD [Naas et al 
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1998]. Although not fully understood, QTd is thought to be a measure of electrical 
inhomogeneity in the heart which decreases an individual threshold for malignant 
ventricular arrhythmias [Pye and Cobbe 1992]. There are a number of possible 
mechanisms in which aldosterone may contribute towards dispersion of the QT 
interval. As our heart rate variability data suggests, aldosterone may have detrimental 
autonomic modulating properties. Certainly decreased vagal activity and enhanced 
sympathetic activity has been linked with increased QT dispersion [Bonnar et al 
1997]. The significance of these neural influences is further supported by the 
observations that the only drugs so far to have reduced QTd are those that modulate 
the autonomic tone, such as beta -blockers [Priori et al 1994, Day et al 1991] and 
ACE inhibitors [Barr et al 1997], which are well recognised to have vagomimetic 
effects [Flapan et al 1992, Osterziel and Dietz 1996]. 
Apart from its direct autonomic modulating effects, part of the beneficial 
effects of spironolactone may also be due to its diuretic effect (which may potentially 
reduce right atrial stretch and improve heart rate variability by mechanoelectric 
feedback [Horner et al 1996]). Certainly, in experimental models, an increase in 
cardiac afterload has been shown to be arrhythmogenic [Han et al 1990, Sideris et al 
1995]. Therefore part of the reduction in QT dispersion seen with ACE inhibitors and 
spironolactone may be attributed to their ability to reduce cardiac afterload. These 
concepts are studied and discussed further in Chapter 7. 
Furthermore, aldosterone- induced electrolyte depletion, in particular that of 
potassium and magnesium, may also contribute to dispersion of the QT intervals. 
Both hypokalemic and hypomagnesaemic states are arrhythmogenic, associated with 
prolongation of the QT intervals and increased likelihood of developing ventricular 
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arrhythmias such as torsade de pointes [Genes 1976, Fisch 1973, Whang and Welt 
1963]. Conversely, magnesium replacement therapy shortens the QT interval and has 
been shown to be a very effective anti -arrhythmic agent in terminating episodes of 
torsade de pointes [Tzivoni et al 1984]. The effects of magnesium on QT dispersion 
are at present unknown. Potassium, on the other hand, is one of the main 
determinants of the QT interval, as it is responsible for the outward repolarisation 
currents. Reduction of serum potassium, results in slower repolarisation and 
prolonged QT intervals [Nabauer et al 1993]. Recently, Choy et al [1997] observed 
that intravenous potassium infusion not only normalised QT prolongation but also 
reduces QT dispersion in CHF and in normal subjects pre- treated with quinidine. The 
relationship between potassium and QT dispersion may partly account for why 
spironolactone reduces QT dispersion. 
There are therefore clearly a number of possible mechanisms by which 
spironolactone may reduce QTd, especially autonomic and potassium effects. As 
QTd has been shown to be a sensitive predictor of cardiac deaths, it would suggest 
that spironolactone may have properties which reduce malignant arrhythmias. 
Although arrhythmic events were not significantly influenced by the treatments in 
this study, it must be borne in mind that the sample size and therefore, the number of 
potentially lethal arrhythmic events such as non -sustained VTs recorded were very 
small. 
Study limitations: 
Firstly, the technical difficulty of obtaining a precise and reproducible 
determination of the QT interval, in particular the end of the T wave, is well 
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recognised. Care has been taken to use consistent criteria to define the end of the T 
wave and to exclude U waves. Although these methodological concerns are well 
appreciated, they were not a major issue for this study as we were looking at 
treatment induced intraindividual changes in QTd (rather than interindividual 
changes, which is the usual situation in previous case control studies). 
Secondly, it must be pointed out that this study was carried out at a time 
when it was not routine practice to prescribe beta -blockers for CHF in the United 
Kingdom ie. before the beneficial effects of beta -blockers were established. Hence 
the majority of subjects were not taking beta -blockers at the time of the study. 
Although beta -blockers could alter the autonomic tone, many CHF patients cannot 
tolerate them. In any case, the main effect of beta -blocker therapy is on the 
sympathetic system whereas the main effect of spironolactone appears to be on the 
parasympathetic tone and QTd. Hence, the use of both treatments may actually be 
synergistic in reducing mortality, as suggested by the RALES subgroup analysis [Pitt 
et al 1999]. 
Conclusions: 
Aldosterone blockade has a number of beneficial effects on the 
cardiovascular system in CHF. It reduces heart rate and improves both HRV and QT 
dispersion. The results of this study strongly suggest that its beneficial effects on the 
autonomic nervous system appear to be primarily parasympathomimetic in nature 
with minimal or little influence on sympathetic activity. The clinical significance of 
vagal tone modulation has been highlighted recently in a large prospective study 
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where reduced baroreflex sensitivity was found to correlate strongly with increased 
cardiac mortality [La Rovere et al 1998]. 
Hence the finding that spironolactone alters vagal tone favourably could 
potentially have important clinical implications. The effects of aldosterone on the 
parasympathetic tone are therefore, examined in further depths elsewhere in this 
thesis. In particular, the influence of aldosterone on the baroreflex is explored in a 
separate study in Chapter 5. 
How spironolactone reduces QT dispersion is not fully understood. Again, 
this may also be another clinically important finding. As discussed above, there are a 
number of potential mechanisms, which may account for the reduction in QT 
dispersion by aldosterone blockade. It is unfortunately beyond the scope of the 
present study to tease out the different mechanisms. Some of these potential 
mechanisms are explored further in Chapter 7. 
In summary, it would appear that the beneficial effects of aldosterone 
blockade are greatest during the morning hours, coinciding with the circadian pattern 
of cardiovascular events such as sudden death and myocardial infarctions. 
Aldosterone secretion under the influence of ACTH is known to peak at this time of 
the day, and therefore it is not surprising that the autonomic effects of spironolactone 
are most prominent then. By exerting its maximal effects during the morning hours 
(coinciding with the peak of cardiovascular events), it may particularly reduce the 
number of such events in the dawn period of the day. Unfortunately, the RALES 
study has not recorded accurate timings of death within the day to see if 
spironolactone reduces deaths more at dawn than at other times, which means that 
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the postulated effect of spironolactone on early morning deaths must remain for now 
an intriguing hypothesis. 
The intriguing findings - the reduction in heart rate and favourable 
sympathovagal modulation at dawn - also raise the possibility that spironolactone 
may have anti -ischaemic properties during these crucial hours. In the following 
chapter, I have attempted to address the issue of whether the spironolactone- induced 
reduction in heart rate at dawn would translate into a meaningful reduction in 
ischaemic events in a study of patients with angina pectoris, a cohort who is 
particularly at risk of dawn ischaemic events. 
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CHAPTER FOUR 
ALDOSTERONE BLOCKADE AND AUTONOMIC REGULATION 
IN CHRONIC STABLE ANGINA PECTORIS 
4.1 INTRODUCTION 
It was intriguingly observed in the previous study of CHF patients that 
aldosterone blockade improved heart rate variability and reduced the dawn (6 -10am) 
increase in heart rate. This may be a clinically important observation as a dawn 
increase in heart rate could be pro -ischaemic and contribute to the well known dawn 
increase in sudden deaths. Spironolactone may therefore have early morning anti - 
ischaemic effects by way of reducing heart rate during these crucial hours. 
In addition to an increase in early morning heart rate, the detrimental effect of 
aldosterone on the sympathovagal tone has also been linked with an increase in 
coronary artery tone [Weber and Purdy 1982, Hatakeyama et al 1994]. 
In addition to these autonomic modulating properties, aldosterone is also 
known to increase urinary potassium and magnesium electrolytes loss [Rahman et al 
1992], and magnesium depletion could cause coronary vasoconstriction [Turlapaty 
and Altuna 1989]. It was also recently observed that aldosterone blockade 
dramatically improved endothelial dysfunction and increased vascular nitric oxide 
bioactivity in CHF patients [Farquharson and Struthers 2000]. Finally, aldosterone 
itself may be implicated in the pathogenesis of atherosclerosis. Furthermore 
monocytes which are implicated in the development of atherosclerosis, appear to have 
functionally active aldosterone receptors [Wehling et al 1987]. 
Hence there is a growing body of evidence to suggest that circulating 
aldosterone could have detrimental autonomic, pro -ischaemic and arrhythmogenic 
effects. However the data above all refer to CHF patients who tend to have neuro- 
endocrine activation. The question naturally arises whether spironolactone would 
demonstrate similar effects in patients with stable angina pectoris, especially since 
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these patients are at risk of dawn ischaemic events. Therefore like the previous study, 
we conducted a full diurnal assessment of the influence of aldosterone blockade on 
sympathovagal balance to see if spironolactone altered autonomic tone in the 
vulnerable early morning period in patients with stable angina pectoris. The circadian 
variation of autonomic function was assessed comprehensively by both time and 
frequency- domain (power spectral) heart rate variability analyses and norepinephrine 
kinetics studies. The study was also carried out to see if the previously observed 
spironolactone- induced bradycardia at dawn would lead to a reduction in ischaemic 
events. 
Like the previous study, the effects of aldosterone blockade on cardiac 
arrhythmias and the diurnal variation of QT dispersion parameters on the 12 lead ECG 
were also examined. 
4.2 METHODS 
Subjects 
Twenty -seven patients with chronic stable angina [Mean age (SD) 64 (9)] 
were recruited from the Cardiology out -patient clinic of our institute. All patients 
gave informed written consent and the protocol was approved by the local Tayside 
Ethics Committee on Medical Research. The baseline demographic characteristics of 
the patient population are listed in Table 4.1. All patients were clinically stable and 
had been established on standard anti -anginal therapy for least 6 weeks before the 
study. Coronary artery disease was documented either by coronary angiography (17 
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subjects), positive exercise test (7 subjects) or radionuclide thallium scanning (3 
subjects). All subjects recruited had normal or near normal left ventricular ejection 
fraction. Subjects with ejection fraction <35% or who were in NYHA Class >II were 
excluded. Similarly we excluded subjects whose predominant rhythm was of nonsinus 
origin (eg. atrial fibrillation), who had a bundle branch block or paced complexes on 
the ECG. Similarly, no patient recruited was taking anti- arrhythmic medication which 
might have altered the QT interval. All cardioactive drugs and their dosages were 
unchanged throughout the entire study (except for spironolactone or placebo). The 
subjects were on regular anti - anginal therapy including beta -blockers (48 %). Sixteen 
subjects (59 %) were taking ACE inhibitors regularly. 
Two patients had non -insulin dependent diabetes mellitus and three had 
hypertension. No patient had significant haematological abnormality, serum creatinine 
>200Umol/L, or abnormal liver function tests. 
Protocol 
All patients were recruited into a double -blind, randomised cross -over study. 
Each patient had been clinically stable for at least 3 months prior to recruitment. 
Baseline haemodynamic, biochemical and ECG measurements were made at the start 
of the study before each patient was randomised to receive spironolactone 50mg daily 
or placebo for a 1 month period for each treatment. Between each treatment phase, 
there was a washout period of 30 days. During each treatment, patients were 
reviewed weekly for clinical evaluation of tolerability and biochemical measurements 
of plasma urea and electrolytes. 
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At the end of each treatment phase, the patients were admitted to and studied 
at our research unit over a 24hr period. The protocol is similar to the CHF study 
described in the previous chapter. On arrival at 11 am on each study day, all patients 
had two intravenous 18G indwelling cannulae inserted (one in each forearm), and a 
24hr ambulatory Holter (Reynolds Tracker 2) monitor attached to their chest. After 
30 mins of bedrest, baseline values of blood pressure and heart rate were determined 
in triplicate using a semi- automatic sphygmomanometer (Dinamap Vital Signs 
Monitor 1846, Critikon, Tampa, Florida). 
A series of measurements were carried out during the 24hr spell. Repeated 12- 
ECGs and venous blood samples (lOmis) for plasma norepinephrine were obtained at 
the following time points: 1500hr, 1700hr, 2300hr, 0300hr, 0600hr, 0700hr, 0800hr 
and 1100hr. Venous samples for plasma aldosterone (5m1s) were also obtained at the 
0600hrs and 1100hrs time points. The patients were asked to lie supine for 30 minutes 
prior to each sampling time -point. In addition, at 1600hr and 0700hr, the patients 
were administered an intravenous infusion of 1- (2,5,6 -H) norepinephrine for 
assessment of norepinephrine kinetics (see below). 
In between the study time -points, the patients were allowed to sit or move 
about the bedside. Excessive movements were kept to a minimum and they were 
instructed to record all their movements. Regular meals were provided for the 24hr 
period. Bedtime and mealtimes were standardised as follows: breakfast 0930hr, lunch 
1300hr, dinner 1830hr and bedtime 2300 - 0700hr. 
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Ambulatory ECG monitoring 
Twenty -four hour ambulatory electrocardiogram recordings were obtained for 
analysis in all subjects using a standard two -channel (four leads) Tracker 2 analogue 
tape recorder (Reynolds Medical Limited, Hertford, UK), recording standard leads 
CM1 and CM5 as described in Chapter 2. 
To facilitate analysis, as in the previous study, subjects were instructed to note 
their times of retiring to bed and rising. Semiautomatic analysis of arrhythmias was 
performed using the Pathfinder 500 Series analyser system (Version 4.63 software, 
Reynolds Medical Limited, Hertford, UK). In addition, the recordings were also 
visually checked, and RR intervals and QRS configuration manually edited, to ensure 
correct arrhythmia recognition and classification. 
Heart Rate Variability analysis 
HRV was assessed in both time and frequency domains according to 
standardised guidelines as described in Chapter 2. The following time -domain indices 
were evaluated from each 24 hr ECG recording: standard deviation of all RR intervals 
(SDNN), 24hr triangle index, standard deviation of 5 min mean RR intervals 
(SDANN) and the root mean square of differences of successive RR intervals 
(rMSSD). 
Frequency domain (power spectral) analysis of the RR interval was 
undertaken by Fast Fourier Transformation (FFT). This process operated on data of 5 
min segments of each hour over the 24hr recording whilst the subjects were at rest. 
Time -periods where there were excessive movements (eg. subjects getting up to go to 
the toilet) were excluded from the analysis. Spectral plots were used to identify the 
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low frequency (LF) component (0.03 -0.14 Hz) and the high frequency (HT) 
component (0.18- 0.40 Hz). 
Recordings shorter than 18 hrs, or with less than 40% of the tape suitable for 
analysis were discarded. Separate analyses were undertaken for daytime (1000hrs - 
2330hrs), nightime (2330hr - 0630hrs) and dawn (0630hrs - 1000hrs). These times 
were prespecified before the study began, as the hypothesis was that the dawn period 
might be different from the rest. All analyses were carried out blindly by myself The 
intra- observer variability for HRV analysis, as assessed by a second count on 10 
tapes, was 6 -7 %. 
ST Segment analysis 
ST segment analysis was carried out on the ambulatory electrocardiogram 
recordings using the Pathfinder 500 Series analyser, and standardised criteria for 
ischaemia were used, as detailed in Chapter 2. 
QT interval and dispersion analysis 
QT interval analysis was performed on electrocardiograms (with simultaneous 
12 -lead acquisition and all QT intervals and dispersion (QTd) were analysed blindly by 
myself on a Calcomp digitizing tablet (Twyford, Berkshire, United Kingdom) using 
customised software (Medical Computing Unit, Ninewells Hospital) as detailed in 
Chapter 2. The intra- observer variability (obtained from 20 set of ECGs that were 
repeatedly measured on 2 separate occasions) were 3% and 8 -9% for measurements 
of QT intervals and QT dispersion, respectively. 
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Norepinephrine kinetics 
All studies were performed in subjects in the supine position at rest according 
to the well -established technique of Esler et al [1979] as described in Chapter 2. The 
tritiated norepinephrine infusion protocol was used twice per patient on each study 
day; the first infusion was commenced at 1600hr and the second repeated at 0700hr to 
allow us to assess norepinephrine spillover during the morning hours and evening 
hours. 20m1s venous blood samples were taken in chilled lithium -heparin tubes for 
determination of resting plasma norepinephrine and tritiated norepinephrine levels 
after 40 and 50 minutes of the infusion (two samples were taken to ensure that steady 
state had been achieved). 
Analysis of the blood samples and determination of the noradrenaline kinetics 
are detailed in Chapter 2. 
Biochemical assays 
See Chapter 2. 
Statistical analysis 
All the data were analysed using Statgraphics software package (STSC 
Software Publishing Group, MD, USA) as described in Chapter 2. Repeated 
measures ANOVA was carried out on the HRV and QT outcome measures. The 
within subject factors were treatment and time, and the between subject factor was 
order of treatment. A full factorial model was fitted to test the significance of these 
factors. The effects of treatment on the other measures were analysed using the paired 
Student t -test. 
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Using variability data from Adamopoulos et al [1992], the study should have 
90% power to detect a 10% change in high frequency (HF) heart rate variability and 
SD of RR intervals (SDNN) at p <0.05, and have 80% power to detect a 15% change 
in plasma noradrenaline at p <0.05. Similarly, based on previous data [Schuang and 
Pepine 1977, Deanfield el al 1983] the study should also have 90% power at p <0.05 
to detect an 18% reduction in duration of each ST depression episode and a 25% 
reduction in the number of episodes of ST depression per 24hr. 
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4.3 RESULTS 
Both placebo and spironolactone therapy appear to be clinically well tolerated 
by all patients in this study. There were no significant changes in baseline 
haemodynamic parameters such as resting heart rate and blood pressure. Plasma 
potassium and urea were significantly increased with spironolactone compared to 
placebo after four weeks of treatment (see Table 4.2). Only one patient, who was also 
taking an ACE inhibitor, had significant hyperkalemia (potassium > 5.5mmol /L) and 
elevation of plasma creatinine ( >300umol/L) which necessitated the dose of 
spironolactone to be halved (25mg). There was a non - significant increase in plasma 
magnesium levels. Plasma aldosterone levels measured between 6 and 11 am rose from 
64 ± 35 pg/ml to 88 ± 29 pg/ml, and from 203 ± 122 pg/ml to 273 ± 160 pg/ml on the 
placebo and spironolactone study days, respectively. 
The effects of spironolactone compared to placebo on the various autonomic 
parameters measured are displayed in Tables 4.3-4.5. Arrhythmic activity was 
unaffected by spironolactone therapy compared to placebo; there were no significant 
differences in the number of ventricular extrasystoles or non -sustained ventricular 
tachycardias (NSVT) between the two treatments. 
Circadian pattern of heart rate variability 
None of the 24 hr average HRV indices (Table 4.3) differed significantly 
between the two treatments although there was a trend toward higher values in the 
spironolactone group. 
The circadian rhythm of the power spectral components normally seen in 
healthy subjects, appears to be preserved but blunted in our cohort of angina patients 
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(Fig 4.1 -4.2). The daytime values of the LF spectral component were significantly 
higher than the nightime values (Fig 4.2). However there did not appear to be any 
significant differences between night and day time values for the HF and LF/HF 
components. Spironolactone did not appear to have any significant effect on the 
circadian pattern of the power spectral indices compared to placebo. The early 
morning rise in HR was preserved and unaffected by both treatments (Fig 4.1). 
Norepinephrine kinetics 
The diurnal profile of plasma norepinephrine levels is displayed in Fig 4.3. 
There were no significant differences between the two treatments. Whole body NA 
clearance and spillover did not appear to be significantly affected by spironolactone 
therapy compared to placebo (Table 4.4). 
Circadian pattern of QT dispersion 
QT interval dispersion indices were significantly higher during the daytime 
compared to the sleeping hours (Figs 4.4). Spironolactone did not appear to have any 
significant effect on QT dispersion compared to placebo (Table 4.3, Fig 4.4). 
Circadian variation of ischaemic events 
Of the 27 patients in the study, 11 patients (41 %) while on placebo and 9 
patients (33 %) during spironolactone therapy had holter- documented ischaemic 
events There were no significant differences in the total number of ischaemic events 
between the two treatments (Fig 4.5). In particular, the increased incidence of 
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ischaemic events during the morning hours did not appear to be affected by 
spironolactone therapy. 
Subgroup analysis 
As beta -blocker and ACE inhibitor therapies may influence the autonomic 
tone, separate subgroup analyses were carried out to see if these drug therapies would 
influence outcomes. A summary of the results is displayed in Table 4.5. Neither 
subgroups taking beta -blocker nor ACE inhibitor demonstrated any significant 
differences in any of the measured outcomes compared to those that were not. 
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Table 4.1: Baseline Demographic Characteristics of randomised patients. 
Mean ±SD (% in brackets) 
Characteristics n =27 
Age (yrs) 64 ± 9 
M/F 23/4 
Weight (kg) 82 ± 16 
Frusemide 14 (52 %) 
ACE Inhibitor 16 (59 %) 
Ca antagonist 13 (48 %) 
Aspirin 21 (78 %) 
Nitrates 18 (67 %) 
Beta -blockers 13 (48 %) 
History of Diabetes Mellitus 2 (7 %) 
History of Hypertension 3 (11%) 
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Table 4.2: Effect of Spironolactone and Placebo on resting haemodynamic 
and biochemical measures after four weeks of treatment. 
Mean + SD. P <0.05 if statistically significant. 
PARAMETER PLACEBO SPIRO P VALUE 
HR 63 ±11 61 ±10 NS 
SBP 121 ± 23 120 ± 27 NS 
K+ 4.0 ± 0.6 4.5 ± 0.6 0.01 
Urea 6.8 ± 4.6 7.9 ± 4.4 0.03 
Creatinine 117 ± 28 128 ± 33 0.04 
Mgt, 0.80 ± 0.09 0.84 ± 0.04 NS 
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Table 4.3 Mean 24 hr Values: Effect of Spironolactone or Placebo on 
Arrhythmias, Heart Rate Variability and QT Dispersion. Mean ±SD. 
Parameter Placebo Spiro p -value 
Time- domain RR hit 959 ± 121 952 ± 155 NS 
measures HRV Index 32 ± 9 35 ± 10 NS 
SDNN 113 ± 28 125 ± 23 NS 
SDANN 96 ± 21 105 ± 28 NS 
RMSSD 23 ± 8 23 + 9 NS 
Frequency LF (n.u) 68.1 ± 12 66.3 ± 14 NS 
(Power Spectral) HF (n.u) 25.2± 10 25.0 ± 11 NS 
measures LF/HF 5.16 ± 3.35 4.69 ± 2.88 NS 
24hr arrhythmia Ventricular 2005 ± 2122 1895 ± 1586 NS 




No. ischaemic episodes /24hr 
Total duration of 
3.9 ± 0.5 3.8 ± 0.5 NS 
episodes /24hr (min/24hr) 68 ± 8 61 ± 11 NS 
Ischaemic burden (mm.min) 100 ± 31 91 ± 28 NS 
QT Interval and QTd 47.9 ± 12.5 50.4 ± 10 NS 
Dispersion QTcd 54.6 ± 11.5 53.5 ± 8.5 NS 
variables QTmax 485 ± 20 492 ± 21 NS 
QTcmax 515 ± 29 526 ± 35 NS 
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Table 4.4: Effect of Spironolactone and Placebo on whole body 
Norepinephrine (NA) spillover and clearance. Mean + SD. 
Placebo Spiro 
AM (0700hrs) NA clearance (1 /min) 3.88 + 0.8 
NA spillover (ug /min) 1.50 + 0.42 
PM (1600hrs) NA clearance 
NA spillover 
3.68 ± 0.54 
1.35 + 0.51 
4.01 + 0.7 
1.47 + 0.66 
3.49 ± 0.65 







Table 4.5 Summary tables of subgroup analyses: Effect of Spironolactone or 
Placebo on some of the main outcome measures in subgroups of 
patients taking concomitant beta -blockers and ACE inhibitors. Mean 
+ SD. 
Table 4.5a: Beta blocker subgroup analysis 
Parameter Placebo Spiro p -value 
SDNN 129±33 140±29 NS 
LF/HF 4.62 ± 2.71 4.74±2.22 NS 
On beta- No. ischaemic episodes /24hr 3.2 ± 0.4 3.3 ± 0.4 NS 
blockers (n =13) Ischaemic burden 71 ± 24 65 ± 20 NS 
QTd 51±8 48±11 NS 
NA cléarance (am) 
3.95 ± 0.5 4.01 ± 0.5 NS 
NA spillover (am) 
1.44 ± 0.5 1.42 ± 0.38 
NS 
SDNN 101 ±21 111 ±27 NS 
LF/HF 5.71 ± 2.49 4.65 ± 1.90 NS 
Without beta- No. ischaemic episodes /24hr 4.4 ± 0.7 4.3 ± 0.5 NS 
blockers (n=14) Ischaemic burden 120 ±30 115 ±26 NS 
QTd 45 ±14 51 ±7 NS 
NA clearance (am) 3.82 ±0.4 4.04 ±0.6 NS 
NA spillover (am) 
1.56 ± 0.4 1.51 ± 0.5 
NS 
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Table 4.5b: ACE inhibitor subgroup analysis 
Parameter Placebo Spiro p -value 
SDNN 122 ± 22 120 ± 20 NS 
LF/HF 4.88 ±2.11 4.90 ±2.60 NS 
On ACE No. ischaemic episodes /24hr 4.0 ± 0.3 4.1 ± 0.3 NS 
inhibitors Ischaemic burden 89 ± 20 100 ± 16 NS 
(n =16) QTd 50 ± 11 48.5 ±10 NS 
NA clearance (am) 3.92 ± 0.5 3.97 ± 0.5 NS 
NA spillover (am) 
1.38 ±0.4 1.52 ±0.6 
NS 
SDNN 107 ± 18 128± 24 NS 
LF/HF 5.25 ± 2.25 4.62 ± 2.05 NS 
Without ACE No. ischaemic episodes /24hr 3.7 ± 0.3 3.7±0.2 NS 
inhibitors Ischaemic burden 107 ± 20 84 ± 16 NS 
(n =11) QTd 45±8 52±8 NS 
NA clearance (am) 3.85 ± 0.6 4.06 ± 0.4 
NS 




Figure 4.1: Diurnal variation of RR intervals (RR lilt) (top] and ratio of low 
frequency to high frequency component (LF/HF) of heart rate 
variability [bottom]. Data expressed as Mean + SEM. 
Figure 4.2: Diurnal variation of normalised high frequency component (HF) 
[top] and normalised low frequency component (LF) [bottom] of 
heart rate variability. Data expressed as Mean + SEM. 
Figure 4.3: Diurnal variation of QT dispersion (QTd) [top] and Bazett's rate - 
corrected QT dispersion (QTc Disp) [bottom]. Data expressed as 
Mean + SEM. 
Figure 4.4: Diurnal profile of plasma norepinephrine levels (NA conc). Data 
expressed as Mean ± SEM. 
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The present study was designed to assess if the beneficial autonomic 
modulating properties of spironolactone seen in heart failure also occurred in a 
different cohort of patients - those with ischaemic heart disease and preserved LV 
function. In particular, the study was designed to assess if spironolactone- induced 
bradycardia during the morning hours would translate into a reduction of ischaemic 
events in patients with chronic stable angina. Spironolactone may have anti -ischaemic 
effects by way of reducing heart rate at this time. The importance of this observation 
is that this is the same time of day when ischaemic, arrhythmic and sudden death 
events are commonest. 
The circadian variation of myocardial ischaemia is well established [Muller et 
al 1985, Rocco et al 1987, Marchant et al 1994]. Studies evaluating 24hr to 48hr 
Holter ambulatory ECG in patients with stable angina have shown that transient 
myocardial ischaemic events exhibit a circadian pattern [Rocco et al 1987]. Ischaemic 
episodes peak during the daytime and are associated with a similar circadian rhythm of 
sympathovagal balance [Marchant et al 1994]. The morning peak of cardiovascular 
events is known to coincide with the surge of sympathetic activity and vagal 
withdrawal, as reflected by changes in various autonomic and physiological 
parameters such as increased heart rate and blood pressure, raised plasma 
catecholamines, increased vascular tone and enhanced platelet aggregability. The 
sympathetic tone is known to exhibit a circadian rhythm characterised by diminished 
activity during the night and a peak in the morning hours associated with assumption 
of the upright position [Furlan et al 1990]. ACTH -induced aldosterone secretion is 
also known to occur in a similar circadian fashion, with its peak secretion occurring 
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during the morning hours and before upright posture is assumed [Armbruster et al 
1975]. 
In this study, the effects of aldosterone blockade on various autonomic and 
ischaemic markers were assessed in patients with chronic stable angina pectoris. 
Unlike the RALES trial which focussed primarily on severe CHF patients (NYHA III - 
IV), the patients recruited here had a normal or near- normal LV function (LVEF 
>35% and were in NYHA I -H). The addition of a small dose of spironolactone in 
these patients with chronic stable angina appears to be safe and well tolerated despite 
the fact that half of them were on concomitant ACE inhibitors. After 4 weeks of 
treatment, spironolactone caused a small but significant rise in plasma potassium and 
urea, compared to placebo. These small but significant electrolyte disturbances 
provide indirect evidence that the subjects were compliant with their study 
medications. 
Spectral analysis of 24hr recordings have shown consistently that in normal 
subjects, a major change in the autonomic profile occurs at approximately 6am, 
coinciding with the time of awakening, when a surge of sympathetic activity occurs 
rapidly and concomitantly with vagal withdrawal [Furlan et al 1990]. This is reflected 
in our diurnal profile of plasma norepinephrine levels (Fig 4.3). Consistent with 
previous studies of patients with stable angina [Marchant et al 1994, Huikuri et al 
1994], a reduced but still preserved circadian pattern in the spectral components is 
observed. 
This is however, the first study to demonstrate that QT dispersion also occurs 
in a diurnal fashion in patients with ischaemic heart disease, with daytime values being 
significantly higher than night time values. Although the diurnal pattern of the QTc 
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interval and dispersion in normal man has been well documented [Molnar et al 1997, 
Ishida et al 1997], this has not been previously demonstrated in coronary artery 
disease. 
However, disappointingly in this study, spironolactone therapy did not appear 
to have any significant influence on the various HRV and QT dispersion measures 
compared to placebo. Neither norepinehrine spillover nor clearance was affected by 
aldosterone blockade. The early morning rise in heart rate was still observed in both 
treatment groups and there were no significant differences in terms of arrhythmic or 
ischaemic events over the entire 24hr study period. 
These findings are in contrast with the previous observations in CHF patients. 
Why is this so? There are a number of possible reasons. Firstly, the cohort of patients 
in this study was different from those recruited in the RALES trial. One possibility 
therefore, is the fact that patients with chronic stable angina and preserved left 
ventricular function are likely to be less neurohormonally -activated compared to 
severe CHF patients. This is certainly reflected in our measurements of plasma 
aldosterone levels during the morning hours. Compared to the cohort of CHF patients 
described in Chapter 3, the morning surge in plasma aldosterone between 6 and 11 
am is about a third less in these patients with chronic stable angina. This means that it 
is possible that we are not seeing the beneficial effects of aldosterone blockade as 
there is much less circulating aldosterone to antagonize in stable angina patients. Any 
potential beneficial effect of spironolactone therapy, if at all, may actually be much 
smaller in magnitude than we had anticipated. For instance, although the incidence of 
cardiac ischaemic events in our study was in accordance with what we had anticipated 
[Adamopoulos et al 1992, Schuang and Pepine 1977], our study only had a 90% 
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power at p <0.05 to detect a 25% reduction in the number of episodes of ST 
depression per day. The study would not have sufficient power to detect reliably an 
effect of a smaller magnitude (which would in any case, likely to be of doubtful 
clinical significance). 
A second possibility is the fact that unlike the previous studies with CHF 
patients where the majority of subjects were not on beta -blockers, about half of the 
patients in our study were. Although beta -blockers are generally accepted as first line 
anti -anginal therapy, they are not more widely perscribed in our study population 
(which reflects current practice in the UK) due to concomitant medical conditions (eg 
chronic obstructive airways disease, peripheral vascular disease etc) or intolerance to 
their side -effects. This class of drugs has been shown to improve heart rate variability 
and reduce myocardial ischaemia [Niemela et al 1994, Arnim et al 1995], and may 
therefore distort the outcome of the study. However this explanation is unlikely as 
subgroup analysis did not show any significant differences in outcomes between those 
taking beta- blockers and those who were not (Table 5a). 
A third possibility is that the diuretic effect of spironolactone itself may lead to 
reduced afterload and subsequent activation of neurohormones such as Angiotensin 
II. Unlike the CHF patients in our previous studies where spironolactone was given in 
addition to ACE inhibitor therapy, only about half the subjects in our study were on 
an ACE inhibitor. This means that it is possible that a large proportion of the subjects 
in this study will have activated Ang II that is unopposed, following the administration 
of spironolactone. The well -known detrimental autonomic effects of unopposed Ang 
II [Guo and Abboud 1984, Mace et al 1985] may theoretically neutralise any 
beneficial effects obtained from direct aldosterone antagonism. However, subgroup 
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analysis comparing those already taking ACE inhibitors with those who were not did 
not reveal any significant differences in outcomes (Table 5b). 
Study limitations: 
The technical limitations described in Chapter 3 also apply to this study. In 
particular, the technical difficulty of obtaining a precise and reproducible 
determination of the QT interval, especially the end of the T wave, is well recognised. 
Care has been taken to use consistent criteria to define the end of the T wave and to 
exclude U waves. Although these methodological concerns are well appreciated, they 
were not a major issue for this study as we were looking at treatment induced 
intraindividual changes ;in QTd (rather than interindividual changes, which is the 
usual situation in previous case control studies). 
Conclusions 
The clinical significance of the neuroendocrine activation of the renin- 
angiotensin- aldosterone system (RAAS) in the pathophysiology of heart failure is well 
established. However recent published data from the landmark HOPE trial suggest 
that inhibition of the RAAS may have far wider clinical implications than we had 
anticipated. The HOPE findings indicate that all patients with a history of 
cardiovascular disease, not just those with heart failure, may potentially benefit from 
ACE inhibitors. 
In this study, I had examined whether aldosterone blockade too would benefit 
those cardiac patients with normal LV function. However, the results of the study 
were disappointing - unlike patients with CHF, aldosterone blockade did not appear 
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to have any significant beneficial effect in patients with stable angina pectoris. The 
reasons remain unclear and may be multifactorial. The results of this study highlight, 
as often the case is with medicine, what we find in one disease state is not found in 
another. Had the study been positive, it would have provided a strong impetus for a 
mortality study with spironolactone in angina. As the case turns out, the findings in 
this study suggest that such a mortality trial would probably not be worth pursuing. 
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CHAPTER FIVE 
ALDOSTERONE AND THE BAROREFLEX 
RESPONSE IN MAN 
5.1 INTRODUCTION: 
The effects of aldosterone on the baroreflex response are explored in this 
chapter. Baroreflex dysfunction is thought to be a key process leading to ventricular 
arrhythmias and mortality in patients with chronic heart failure (CHF) and in post - 
myocardial infarction patients [La Rovere et al 1998, Osterziel et al 1995]. Indeed, it 
has even been highlighted that augmentation of the parasympathetic limb of the 
baroreflex may be an exciting new therapeutic possibility [Townend and Littler 1995]. 
In animal studies, vagal stimulation has been shown to dramatically improve survival 
and reduce arrhythmias after coronary artery ligation [Myers et al 1976, Zuanetti et al 
1987]. 
It is well established that Angiotensin II (Ang II) attenuates baroreflex control 
of heart rate and increases sympathetic activity [Guo and Abboud 1984, Mace et al 
1985] and that ACE inhibitors are able to improve baroreflex sensitivity (BRS) 
[Osterziel et al 1990, Marakas et al 1995]. Recent animal evidence suggest that 
aldosterone, like Ang II, may possess detrimental autonomic modulating properties. 
As discussed in Chapter 1, it is now being appreciated that aldosterone too may 
influence the baroreflex, irrespective of Ang II. Spironolactone improves heart rate 
variability (as a measure of parasympathetic activity) in CHF patients (Chapter 3). 
Although it remains inconclusive if this was a direct effect of autonomic modulation 
by aldosterone blockade or due to the diuretic effect of' spironolactone (which may 
potentially reduce right atrial stretch and improve heart rate variability by 
mechanoelectric feedback [Horner et al 1996]), there is experimental data to suggest 
that aldosterone has major direct effects on the autonomic nervous system and the 
baroreflex. In an animal model, Wang et al [1992] showed that aldosterone infusion 
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directly reduced baroreceptor discharge from the carotid sinus in dogs. 
However, no direct information has yet been reported on the effects of 
aldosterone on baroreflex responses in man. As with all animal studies, it is essential 
to determine if these observations also occur in man, especially since baroreceptor 
dysfunction is known to play a central regulatory role in the development of cardiac 
arrhythmias [La Rovere et al 1998, Osterziel et al 1995]. Thus, this study is designed 
to test the hypothesis that aldosterone attenuates the baroreflex control of heart rate 
in vivo in normal man. I have examined the effects of an acute intravenous 
aldosterone infusion on the vagal and sympathetic limbs of the autonomic nervous 
system, by assessment of blood pressure and reflex heart rate responses to 
phenylephrine (PE), a vasopressor agent, and to sodium nitroprusside (SN), a 
vasodilator. 
5.2 METHODS 
Subjects and Protocol 
14 normal male volunteers [mean age (SD) 25 (9)] were studied on 2 separate 
days, at least 72 hours apart, in a placebo -controlled, randomized, double -blind, 
cross -over fashion. Subjects were asked to refrain from alcohol, caffeine and 
cigarettes for 24 hrs and to fast for 2 hrs before each study day. 
Subjects rested quietly in the supine position throughout the study. Two 18G 
intravenous cannulae were inserted into forearm veins, one in the right arm for blood 
sampling and one in the left arm for infusion of either aldosterone or 5% dextrose as 
vehicle. After 45 minutes of bedrest, baseline values of blood pressure (BP) and heart 
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rate (HR) were measured non -invasively in triplicate using a semi- automatic 
sphygmomanometer (Dinamap Vital Signs Monitor 1846; Critikon, Tampa,FL, USA) 
with the cuff being placed around the subjects left arm. 12 lead electrocardiograms 
and venous blood (15m1s) for baseline aldosterone and angiotensin II assays were also 
obtained. 
Following this, a continuous infusion of either vehicle (5% Dextrose) or d- 
Aldosterone (Tayside Pharmaceuticals) in similar volumes was commenced in the left 
arm. The d- aldosterone was infused at a rate of 12pmol/kg/min. After 45 minutes into 
the infusion, further triplicate recordings of blood pressure, heart rate and continuous 
12 -lead ECGs were obtained along with blood samples for aldosterone and 
angiotensin II assays. 
The haemodynamic study was then started ie. after 90 mins of supine bed rest 
and after 45 mins after commencement of the infusion of aldosterone or vehicle. The 
reflex baroreflex response to a vasopressor agent, phenylephrine (PE), was assessed in 
the first half of the study. Intravenous PE was given by infusion into the right forearm. 
It was administered in stepwise 10 min infusions (0.2 -3.6 ug/kg/min) by use of an 
infusion pump (IMED, San Diego, CA). The infusion was stopped when a 35 -40 
mmHg rise in systolic arterial pressure had been achieved. The average systolic BP, 
HR and R -R interval obtained from continuous ECG recordings between 8 and 10 
mins after each infusion dose were recorded. 
After completion of these measurements with PE, HR and BP were allowed to 
return to baseline values for 30 minutes before the second phase of the study was 
commenced with intravenous sodium nitroprusside given in stepwise 5 minute 
infusions (0.2- 5.2ug/kg/min) until a maximum drop of systolic BP of 25mmHg was 
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achieved. HR, BP and ECG recordings were obtained after 4 -5 minutes of each 
infusion dose. 
Baroreflex Sensitivity (BRS) Assessment 
The R -R intervals were plotted against the systolic blood pressure in a graph, 
and a computerised curve fit was then carried out to establish a linear portion of the 
line of best fit. Separate linear regression lines were plotted for the responses to 
phenylephrine and sodium nitroprusside. Traditionally, the slope derived from the 
linear regression line (ARR/ASBP) obtained from the vasopressor (PE) half of the 
haemodynamic study has been used as an index of baroreflex sensitivity (BRS). As in 
previous studies [4,11], only regression lines that had a correlation coefficient of >0.8 
were used. Full description of the methodology is described in Chapter 2. 
Aldosterone And Angiotensin II Assays 
As described in Chapter 2. 
Statistical Analysis 
All data were analysed using the Statgraphics software package (STSC 
Software Publishing Group, Rockville, MD, USA) as described in Chapter 2. Analysis 
of variance at each dose increment, using subjects and treatment as within factors, and 
Bonferroni multiple range tests were performed to determine the significance of the 
effects of aldosterone on the haemodynamic response to phenylephrine and sodium 
nitroprusside. The relationships between R -R intervals and systolic BP were studied 
by correlation and linear regression analyses; BRS between treatment groups were 
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analysed using the paired Student's t test. 
5.3 RESULTS 
Baseline Measurements (See Table 5.1) 
No significant differences in baseline measurements were seen between vehicle 
and aldosterone infusion days. A significant rise in plasma aldosterone levels was 
noted after 45 mins of aldosterone infusion compared to placebo. There was a non- 
significant decrease in Ang II levels following aldosterone infusion compared to 
vehicle. 
Haemodynamic Measurements (See Fig.5.1 -5.5, Table 5.2) 
No significant changes in resting blood pressure and heart rate recordings 
were observed during aldosterone infusion compared to vehicle. Systolic blood 
pressure increased and decreased in a stepwise fashion in response to the 
phenylephrine and sodium nitroprusside infusions respectively in both groups; no 
significant differences in BP responses were observed in the aldosterone group 
compared to vehicle. Similarly, no significant differences in reflex heart rate responses 
to sodium nitroprusside were observed between the two groups. The slopes of the 
linear regression line in response to sodium nitroprusside (ARRJASBP) were not 
significantly affected by aldosterone compared to vehicle [8.62 ± 4.64 ms /mmHg 
(Mean ± SD) vs 9.07 ± 2.11 ms /mmHg; p =0.7] (See Fig 5.5). However, reflex heart 
rate responses to phenylephrine were significantly impaired in the aldosterone group 
compared to vehicle (p <0.05). BRS was significantly depressed in the aldosterone 
group [8.36 + 2.19 ms /mmHg vs 10.12 + 2.27 ms /mmHg ; p <0.04]. 
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TABLE 5.1: Baseline values. Results are expressed as means + SD. Statistical 
significance : *P <0.05 compared with vehicle. 
Vehicle Aldosterone 
Heart rate (beats /min) 





R -R Interval (msec) 999 (156) 1021 (181) 
Aldosterone- baseline levels (pg/ml) 115 (107.8) 106.1 (81.8) 
Aldosterone level- 45 mins after start of infusion 
(pl /mi) 
72.6 (62.6) 489.8 (83.3)* 
Angiotensin II levels - 45 mins after start of 
infusion (pg/ml) 







































































































































































































































































































































































































































































































Fig 5.1: Change in Heart Rate (AHR) and Blood Pressure (ABP) responses to 
incremental infusions of Phenylephrine. Values are mean±SEM. *p <0.05 
compared with placebo. 
Fig 5.2: Log Phenylephrine Dose -Response curve. Change in Heart Rate (AHR) 
and Blood Pressure (ABP) responses to incremental infusions of Phenylephrine. 
Values are mean + SEM. *p <0.05 compared with vehicle. 
Fig 5.3: Change in Heart Rate (AHR) and Blood Pressure (ABP) responses to 
incremental infusions of Sodium Nitroprusside. Values are mean ± SEM. 
Fig 5.4: Log Sodium Nitroprusside Dose -Response curve. Change in Heart Rate 
(AHR) and Blood Pressure (ABP) responses to incremental infusions of nitroprusside. 
Values are mean ± SEM. 
Fig 5.5: Relationship between changes in RR Interval (AR -R Int) and systolic 
Blood Pressure (ASBP). Values are mean ± SEM. Separate linear regression lines for 

















































































































































































































































































































































































































































































































This study confirms previous observations from animal models that 
aldosterone impairs the baroreflex response. The sensitivity of the arterial 
baroreceptors to a change in BP is an important determinant of the ability of the 
autonomic nervous system to maintain cardiovascular homeostasis. Increases in 
arterial BP in response to pressor stimuli such as PE, activate mechanosensitive nerve 
endings in the carotid sinus and aortic arch, which then send sensory information to 
the central nervous system via the glossopharyngeal and vagus nerves. This in turn, 
results in increased reflex vagal efferent outflow to the heart. The administration of a 
hypotensive agent such as Sodium Nitroprusside (SN), on the other hand results in 
vasodilatation and generalised unloading of arterial and cardiopulmonary 
baroreceptors leading to increased cardiac sympathetic activity [Newton and Parker 
1996, Shepherd et al 1981]. 
In this study, aldosterone has been shown to impair heart rate response to PE. 
This is in fact, in keeping with a previous observation that aldosterone halved the 
bradycardie response to infused noradrenaline, another vasopressor agent [Barr and 
Struthers 1994]. Furthermore, it is also interesting to note that aldosterone does not 
appear to have any significant effect on the reflex tachycardic (or cardiac sympathetic) 
response to SN. These data together suggest that aldosterone exerts major effects on 
the parasympathetic limb of the autonomic nervous system. 
With regards to its specific mechanism of action, there is evidence from animal 
studies to suggest that aldosterone may have a direct action on the arterial 
baroreceptors. Wang et al [ 1992] showed not only that aldosterone reduces the HR 
response to changes in BP, but they also showed conclusively that aldosterone 
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directly reduces baroreceptor discharge from the carotid sinus of dogs. These effects 
were seen with both acute and chronic administration of aldosterone [Wang 1994]. 
On a cellular level, the mechanism is less certain. Aldosterone may elicit part of its 
effect on the arterial baroreceptors by stimulation of the Na -K- ATPase activity [Wang 
1994] as aldosterone is known to be a potent Na -K- ATPase stimulant [Blot -Chabaud 
et al 1990, Verrey et al 1989]. Depressed baroreceptor function following chronic 
aldosterone infusion in animal models has been shown to be partially reversed with a 
bolus injection of the Na -K- ATPase inhibitor, ouabain [Wang 1994]. Similarly, 
digoxin, another cardiac glycoside / Na -K- ATPase inhibitor has also been shown to 
improve BRS in chronic hyperaldosteronemic states such as CIS [Ferrarri et al 
1981]. However, such an effect of ouabain was not seen following acute 
administration of aldosterone [Wang et al 1992] suggesting that other mechanisms 
may be responsible for the acute effects of the hormone. Interestingly, the impaired 
baroreceptor function due to acute administration of aldosterone could be prevented 
by denudation of the endothelial cells in the carotid sinus area, which has led to the 
suggestion that aldosterone may either stimulate endothelial cells to release an 
unknown substance that depresses BRS activity or inhibit endothelial cells from 
releasing a substance such as nitric oxide which may enhance BRS activity; the latter 
would be consistent with the recent observations of Farquharson and Struthers [2000] 
where aldosterone blockade was found to increase nitric oxide bioactivity and 
improve endothelial vasodilator dysfunction in CHF patients. 
Although this study was not designed to determine the specific mechanism by 
which aldosterone impairs the baroreflex, it has nonetheless, important clinical 
implications as it is the first study as such to extend these observations to man. This 
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study adds to the growing body of evidence that aldosterone, like Ang II, has 
autonomic modulating properties as discussed in previous chapters. Aldosterone has 
been shown to block norepinephrine uptake in the heart in vivo in an animal model 
[Barr et al 1995]. In accordance with this, spironolactone, an aldosterone antagonist, 
increased myocardial norepinephrine uptake [Barr et al 1995] and improved heart rate 
variability in patients with CHF (see Chapters 3 and 4). Although in this study, 
aldosterone did not appear to have any significant effect on the reflex sympathetic 
response to SN in healthy volunteers, this finding is not necessarily a contradiction to 
previous findings observed in heart failure patients since infusing nitroprusside into 
normal man clearly does not exactly reproduce the activated sympathetic system of 
CHF patients, even though nitroprusside is a traditional way of assessing 
sympathoactivation in man. One important difference between the two is that filling 
intracardiac pressures are high in CHF but are likely to be subnormal after 
nitroprusside unloading in normal man. 
Study limitations 
There are however, some limitations to the study worth discussing. Firstly, the 
study was performed in healthy subjects and not in patient groups. CHF patients for 
instance, have a markedly abnormal and complex haemodynamic and neurohormonal 
state. Although it would be of interest to assess the effects in these patient groups, 
they are not ideal for the purpose of this study which was to assess the effects of 
aldosterone on the baroreflex response in vivo in man. In this study of healthy subjects 
we were able to purely, isolate the effects of aldosterone on the baroreflex (and hence, 
confirming the data from animal models) while avoiding the many possible 
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confounding factors found in CHF patients who are characterised by the presence of 
other circulating neurohormones, impaired vascular tone and endothelial dysfunction. 
Secondly, infusions rather than boluses of pressor and vasodepressor stimuli 
were used in this study, allowing for baroreceptor "resetting" to occur and hence 
reducing or dampening any change in baroreceptor response. This may mean that 
small changes in baroreflex response to SN, for instance, may have gone undetected. 
On the other hand, one might expect, if anything, the blunting effect of aldosterone on 
the baroreflex response to PE to be amplified if the bolus method had been used 
instead. BRS measurements by infusion method may not be equivalent to the bolus 
method, but the infusion method has been shown to be reproducible [Sullebarger et al 
1990]. 
As mentioned in Chapter 2 (Methods), infusions were used in this study firstly, 
as it allowed us to monitor HR and BP changes at steady state non -invasively at each 
incremental dose which has the advantage that our readings were taken in triplicate, 
which should minimise random measurement error. Secondly, the bolus method 
requires either invasive intra- arterial measurements (more risk and discomfort to the 
subject using radial artery devices) or non -invasive beat -to -beat analysis to be 
performed using the FINAPRES but this is not possible at our institute as the 
FINAPRES devices are no longer available in the United Kingdom. Furthermore we 
were more interested in changes or differences in baroreceptor sensitivities between 




In summary, this study has established that in man in vivo aldosterone has a 
detrimental effect on the parasympathetic component of the baroreflex response. The 
effects of aldosterone on the autonomic nervous system have important clinical 
implications. It is noteworthy that in our study, the plasma concentration of 
aldosterone [mean (SD) 489.8 (83.3) pg/ml] achieved on the treatment days were 
similar to those observed in CHF patients [Struthers 1996]. A reduced BRS is a 
marker of high risk patients in both CHF [ Osterziel et al 1995] and IHD [La Rovere 
et al 1998]. Therefore, as baroreflex dysfunction predisposes the myocardium to 
arrhythmias, the findings of this study may explain some of the beneficial effects seen 
with spironolactone in the clinical studies described in the previous two chapters and 
also for the mortality reduction (particularly sudden deaths) seen in the multicentre 
RAZES study. [Pitt et al 1999]. 
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CHAPTER SIX 
ENDOGENOUS ANGIOTENSIN II AND BARORECEPTOR DYSFUNCTION: 
A COMPARATIVE STUDY OF LOSARTAN AND ENALAPRIL IN MAN 
6.1 INTRODUCTION 
It is well established that Angiotensin II (Ang II) attenuates baroreflex control 
of heart rate and sympathetic activity [Guo and Abboud 1984, Mace et al 1985]. 
Indeed, the effect of ACE inhibitors on BRS may well be instrumental in their ability 
to improve mortality in heart failure. Compared to ACE inhibitors, Ang II type I 
receptor (AT 1) antagonists offer a more selective and complete blockade of Ang II. 
The question naturally arises whether AT 1 receptor antagonists will also have 
favourable effects on BRS. 
Pharmacologically, they are an attractive class of drugs as they work at the 
receptor level, and should therefore avoid the neurohormonal "escape" phenomenon 
seen with ACE inhibitors resulting from Ang II production by non -ACE dependent 
pathways [Urata et al 1990]. Therefore they theoretically, may even be more effective 
at boosting BRS because Ang II levels are not completely suppressed by ACE 
inhibitors. However, although direct AT1 receptor antagonists have been shown to 
improve baroreceptor function in animal models [Moreira et al 1994, Oliveira et al 
1996], the only study to examine this question in man found no effect of losartan on 
baroreflex sensitivity [Rongen et al 1998]. This whole question has been given added 
impetus by the Evaluation of Losartan in the Elderly (ELITE I) trial results. Although 
designed primarily to assess safety and efficacy of the treatments and not mortality, it 
was intriguingly observed in the multicentre ELITE I trial [Pitt et al 1997] that those 
randomised to losartan had a 46% reduction in all -cause mortality in comparison to 
captopril- treated patients, which was primarily due to a decrease in sudden cardiac 
deaths *. 
The purpose of the present study, which was designed following the 
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publication of the intriguing ELITE I results, was two folds. Firstly, the main aim was 
to assess if AT 1 receptor antagonism really does improve baroreceptor function in 
man, as had been previously demonstrated in animal models although it did not appear 
to in the only human study of the matter [Rongen et al 1998]. The secondary aim was 
to perform a head to head comparison of direct Ang II blockade at the receptor level 
with that of non -specific ACE inhibition to see if there were any major differences 
between them which might be relevant to the ELITE* results. In this study, a 
comparison of a single oral dose of losartan potassium 50mg was made with a single 
dose of an ACE inhibitor, enalapril maleate 20mg. In particular, this study was 
performed in normal man in whom the endogenous renin angiotensin system (RAAS) 
had been activated as it would enable us to assess the activated RAAS of heart failure 
in isolation while avoiding the confounding influences of increased age, co- morbidity 
and polypharmacy which would be present in CHF. 
* [NB -The present study was designed, conducted and published prior to the publication of 
the ELITE II trial results. In the latter study, which was a much larger trial compared to 
ELITE I and had mortality as a primary end point, losartan did not appear to concur any 
survival benefit over that of captopril. The implications of the findings of the present study 
in the light of ELITE II, are discussed further in the Discussion section.] 
6.2 METHODS 
Subjects And Protocol 
10 normal male volunteers [mean age (SD) 23 (6.9)] were studied on 3 
separate days, 10 days apart, in a placebo -controlled, randomized, double -blind, 
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cross -over fashion. Three days prior to each study visit, subjects were pre- treated 
with oral frusemide 40mg/ day to activate their endogenous renin- angiotensin system. 
The subjects were instructed to take the daily Frusemide dose at 1800hr and they 
were asked to maintain their usual diet for the duration of the study and to adhere to 
the same pattern of meals in the 48hr preceding each visit day. Subjects were also 
required to refrain from alcohol, caffeine and cigarettes for 24 hrs and to fast for 2hrs 
before each study day. 
On the study day (ie. the day after they had completed each course of 
frusemide tablets), the subjects attended our department at 8am. Each subject was 
given randomly, a different tablet on each visit day, which comprised of either a 
placebo tablet, enalapril 20mg or losartan 50 mg. 
Subjects rested quietly in the supine position throughout the study period. An 
18G intravenous cannula was inserted into a right forearm vein for drug infusions and 
blood sampling. After 45 minutes of bedrest, baseline values of blood pressure (BP) 
and heart rate (HR) were measured non -invasively in triplicate using a semi -automatic 
sphygmomanometer (Dinamap Vital Signs Monitor 1846; Critikon, Tampa,FL, USA) 
with the cuff being placed around the subjects left arm. 12 lead electrocardiograms 
and venous blood (15m1s) for baseline aldosterone and Ang II assays were also 
obtained. 
The haemodynamic and baroreceptor assessments were carried out after 6 hrs 
following ingestion of the oral medication as the haemodynamic effects of both a 
single dose of oral losartan and enalapril are known to peak after 6 hrs [Brunner et al 
1981, Ohtawa et al 1993]. Further triplicate recordings of resting blood pressure, 
heart rate and continuous 12 -lead ECGs were obtained before the reflex baroreceptor 
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response to a vasopressor agent, phenylephrine (PE), was assessed. Intravenous PE 
was administered in stepwise 10 min infusions (0.2 -3.6 ug/kg/min) by use of an 
infusion pump according to the protocol as detailed in Chapter 2: Methods. The 
infusion was stopped when a 35 -40 mmHg rise in systolic arterial pressure had been 
achieved. The average systolic BP, HR and R -R interval obtained from continuous 
ECG recordings between 8 and 10 mins after each infusion dose were recorded. After 
completion of these measurements with PE, HR and BP were allowed to return to 
baseline values. 
Baroreflex Sensitivity (BRS) Assessment 
The R -R intervals were plotted against the systolic blood pressure in a graph, and a 
computerised curve fit was then carried out to establish a linear portion of the line of 
best fit. Full description of the methodology is described in Chapter 2. The slope of 
the linear portion of this relationship (ARR /AsBP) was taken as an index of 
baroreflex sensitivity (BRS). 
Aldosterone And Angiotensin II Assays 
As described in Chapter 2. 
Statistical Analysis 
All data were analysed using the Statgraphics software package (STSC 
Software Publishing Group, Rockville, MD, USA). Multiple analysis of variance, 
using subjects and treatment as within factors, and Bonferroni multiple range tests 
were performed to determine the significance of the effects of losartan and enalapril 
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on the haemodynamic response to phenylephrine. The relationships between R -R 
intervals and systolic BP were studied by correlation and linear regression analyses; 
BRS between the placebo and treatment groups were analysed using the paired 
Student t test. 
6.3 Results 
Baseline Measurements (See Table 1) 
Resting haemodynamic and biochemical measurements were similar at all 
study visits prior to administration of the study medications (Table 1). As expected, 
basal plasma Ang II and aldosterone levels were elevated as a result of frusemide- 
induced salt depletion. At 6hrs following ingestion of study medication, resting blood 
pressure was significantly reduced with both losartan and enalapril by 8.4 mmHg 
(95% CI 4.2, 12.6; p= 0.0038) and 9.6 mmHg (95% CI 4.6, 14.6; p= 0.004) 
respectively, compared to placebo. However there were no significant differences 
with resting heart rate either at the start or at 6 hrs after medication. 
Baroreflex Sensitivity Assessment (See Fig 6.1 -6.3, Table 6.2) 
Systolic blood pressure and reflex heart rate increased and decreased 
respectively, in a stepwise fashion in response to the phenylephrine infusion on all 
three study days. Whereas no significant differences in BP responses were observed 
with any of the study medications, reflex heart rate responses to phenylephrine were 
significantly increased with both enalapril and losartan compared to placebo (p <0.05). 
The ARR /AsBP ratio, taken as a measure of BRS was significantly increased with 
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enalapril [12.2 + 4.6 ms /mmHg (Mean + SD)] and losartan [11.9 + 3.6 ms/mmHg] 
compared to placebo [9.2 + 4.5 ms /mmHg]; ie. enalapril and losartan increased the 
ARR /AsBP ratio by 3.0 ms /mmHg (95 %CI 0.5, 5.6; p < 0.05) and 2.8 ms /mmHg 
(95 %CI 0.6, 5.0; p < 0.038) respectively. There were however no significant 
differences between losartan and enalapril [mean difference 0.25 (95 %CI -1.6, 2.1)]. 
The individual BRS indices are displayed in Fig 6.3. 
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Table 6.1: Baseline values. Results are expressed as Means + SD. Statistical 
significance: *p <0.004 compared to placebo. 
Heart rate (bt /min) pre -dose 
6 hr post -dose 
Systolic BP (mmHg) pre -dose 
6 hr post-dose 
R -R Int (cosec) pre -dose 
6 hr post -dose 
Placebo Enalapril Losartan 
67.6 (4.6) 66.6 (9.1) 69.1 (9.4) 
68.0 (7.4) 67.1 (8.4) 68.8 (7.1) 
117.6 (9.9) 117.1 (7.6) 118.5 (7.1) 
119.3 (8.5) 107.5 (9.8)* 110.1 (7.4)* 
892 (62) 916.5 (122) 883 (115) 
892 (96) 907 (108) 881 (89) 
Plasma Ang II (pg/ml) 42.6 (34.4) 40.7 (19.9) 44.9 (29.0) 
Plasma Aldo (pg /ml) 194 (189) 113 (63) 141 (79) 
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Table 6.2: Changes in haemodynamic parameters in response to phenylephrine 
infusion. Values are Mean + SD. Statistical significance: * p <0.01; t p <0.05 
compared to placebo. 
Dose PE(ug/kg/min) Placebo Enalapril Losartan 
dsBP (mmHg) 
0.6 5.3 ± 3.8 5.9 ± 5.1 5.0 ± 4.6 
1.2 20.6 ± 6.1 20.4 ± 8.3 19.5 ± 10.4 
2.4 38.1 ± 9.8 36.6 ± 4.5 34.6 ± 9.3 
3.6 45.6 ± 6.0 49.6 ± 2.6 43.6 ± 6.4 
dHR (bt/min) 
0.6 5.6 ± 3.9 6.6 ±3.6 7.0 ± 3.9 
1.2 14.0 ± 5.4 12.5 ± 4.2 13.0 ± 4.7 
2.4 15.4 ± 5.1 19.0±4.4* 21.4±3.6* 
3.6 23.9 ± 4.4 28.6±5.81 27.5±5.3* 
AR-R Int (msec) 
0.6 86±64.5 101.5±68 110±79 
1.2 250 ± 127 222 ± 113 224 ± 127 
2.4 280 ± 125 376 ± 142* 421 ± 149* 
3.6 517 ± 204 738 ± 309* 644 ± 269 
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LEGENDS TO FIGURES 
Fig 6.1: Change in Heart Rate (AHR) and Blood Pressure (AsBP) responses to 
incremental infusions of Phenylephrine. Values are mean±SD. *p <0.05 compared 
with placebo. 
Fig 6.2: Log Phenylephrine Dose -Response curve. Change in Heart Rate (AHR) and 
Blood Pressure (AsBP) responses to incremental infusions of Phenylephrine. Values 
are mean ± SD. *p <0.05 compared with placebo. 
Fig 6.3: Individual Baroreflex Sensitivity (BRS) data. The individual BRS 
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In this study, the haemodynamic effects of a single dose of oral losartan 
potassium and a single dose of oral enalapril maleate were examined in salt -depleted 
normotensive subjects pre- treated with diuretics. Assessments were made 6 hrs after 
oral administration of the respective medications ie. at the time when the 
haemodynamic effects of the drugs are maximal [Brunner et al 1981, Ohtawa et al 
1993]. The hypotensive effect of a single dose of 50mg losartan was comparable with 
that of 20 mg enalapril (systolic BP reduced by 8.4 mmHg [95% CI 4.2, 12.6] and 9.6 
mmHg [95% CI 4.6, 14.6] respectively). In accordance with data from other studies 
[Brunner et al 1981, Ohtawa et al 1993, Gradman et al 1995, Ibsen et al 1983] 
resting blood pressure was significantly reduced by both drugs but resting heart rate 
was unaffected. 
The absence of reflex tachycardia accompanying blood pressure reduction has 
been attributed to the parasympathetic activity of these drugs. The influence of Ang II 
on the cardiac vagal activity has certainly been well established in both animal studies 
[Potter 1982, Lumbers et al 1979] and human studies involving steady state infusions 
of Ang II [Mace et al 1985]. Although in disease states such as CHF, ACE inhibitors 
have been shown to enhance baroreceptor function [Osterziel et al 1990, Marakas et 
al 1995], the evidence for such a role for endogenous Ang II in healthy man has been 
conflicting. To date, a number of studies have been performed in both normotensive 
and hypertensive subjects. In sodium replete hypertensive subjects, captopril has been 
shown to cause displacement of the baroreceptor set -point but no modification of the 
BRS during activation by phenylephine [Mancia et al 1982, Warren et al 1983]. 
However, hypertensive patients are known to have a blunted baroreflex function 
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[Warren et al 1983, Bristow et al 1969] which might confuse the picture. Hence, only 
studies in normotensive subjects will allow a true assessment of the effect of Ang II 
blockade per se on baroreceptor function. Amongst normotensive subjects, Ibsen et al 
[1983] found that enalapril improved BRS function whereas Guidicelli et al [1985] 
did not. In the only human study involving ATI receptor antagonists, losartan had no 
effect on baroreflex sensitivity, although this was measured by the gain of the transfer 
function relating BP to pulse interval rather than by more standard techniques 
[Rongen et al 1998]. One of the possible reasons for the contradictory data in the 
literature may be related to the differences in the salt status and degree of endogenous 
Mg II activation in the different study populations. The latter two studies above 
[Rongen et al 1998, Guidicelli et al 1985] were carried out in normotensives with 
normal salt status whereas in the study by Ibsen et al [1983] which showed an 
improvement in baroreceptor function following ACE inhibitor therapy, the subjects 
were mildly sodium depleted. This observation may be important suggesting that the 
influence of endogenous Ang II on the autonomic and vascular tone may only become 
prominent during an activated RAAS state. For example, salt depletion may lead to 
activation of the RAAS and therefore allow for the influence of Ang II blockade on 
baroreceptor function to become detectable. It has been shown in a recent animal 
model that Ang II blockade improved the baroreflex response to a greater extent in 
rats fed with a sodium deficient diet compared with those on a high sodium diet [Xu 
and Brooks 1997]. The effects of raised endogenous Ang II is clinically relevant in a 
variety of cardiovascular diseases such as CHF and hypertension where the RAAS is 
activated and may even be further exacerbated by diuretic therapy. Recent data even 
suggest that the RAAS is activated in hypercholesterolaemic patients [Nickenig et al 
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1997] which may make the findings relevant to many disease groups. 
The effects of raised endogenous Ang II on reflex baroreceptor function were 
assessed in this study. The subjects in the study were pretreated with frusemide to 
activate the RAAS. The reflex bradycardic response to phenylephrine was 
significantly increased following treatment with enalapril and losartan. In addition, the 
slopes of the ARR/AsBP linear regression line were also significantly increased. These 
observations support our hypothesis that raised endogenous Ang II levels do 
contribute to baroreceptor dysfunction and that Ang II blockade, either by ACE 
inhibition or direct antagonism at the receptor level, would reverse it. These findings 
are also in agreement with observations from animal models where both losartan [Xu 
and Brooks 1997, Weinstock and Gorodetsky 1995] and enalapril [Weinstock and 
Gorodetsky 1995] have been shown to enhance baroreceptor sensitivity. 
It is also interesting to note in this study that the effects of losartan were 
comparable to that of enalapril. Although minor differences between the two clearly 
could not be excluded, we were able to exclude large or significant differences. Direct 
Ang II receptor antagonists such as losartan lack the bradykinin potentiation seen with 
ACE inhibition. Although there are beneficial effects associated with bradykinins, the 
lack of bradykinin- related adverse effects makes AT1 receptor antagonists an 
attractive alternative to ACE inhibitors. The ELITE I trial [Pitt et al 1997] results 
intriguingly suggest that losartan may be better than ACE inhibitors in terms of 
reducing mortality and in particular sudden deaths in heart failure. Although 
baroreflex dysfunction is thought to be a key process leading to ventricular 
arrhythmias and sudden deaths, the present study did not however show any large 
differences in baroreceptor modulation between the two strategies. There may be 
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several explanations for the discrepancy in these findings. Firstly, the mechanisms for 
sudden death are multifactorial. Secondly, and perhaps most importantly, the number 
of deaths in the ELITE I trial was small (49 deaths) as it was not designed primarily as 
a mortality trial and the results may have occurred by chance. The results of the more 
recent ELITE II Study [Pitt et al 2000] would certainly support this notion. Unlike 
ELITE I, the latter was a much larger trial (four times as many patients -3152 patients - 
and ten times more events) with all -cause mortality as its primary end -point. Over a 
mean follow -up period of 555 days, losartan did not appear to concur any survival 
advantage compared to captopril in NYHA II -IV heart failure patients The inability of 
ELITE II to confirm a survival advantage of losartan over captopril highlights the 
need for caution in the interpretation of trial results where the event numbers were 
small which may be influenced by the play of chance. 
Finally, there are inevitably, some limitations to the study, which are worth 
discussing. As in the study carried out in Chapter 5, infusions rather than boluses of 
pressor stimuli were used in this study, allowing for some baroreceptor "resetting" to 
occur and hence reducing or dampening any change in baroreceptor response. This 
may mean that potentially small differences in baroreceptor response between the two 
treatments for instance, may have gone undetected. The limitations associated with 
the infusion method has been previously described in Chapters 2 and 5. However as 
each of our readings were taken in triplicate, random measurement error should be 
minimised and any potential differences between the two treatments that may have 
gone undetected by the study is likely to be small. 
Despite these limitations, our data clearly indicates that blocking endogenous 
Ang II in man improves baroreceptor function. Both strategies, AT l receptor 
178 
antagonism and ACE inhibition appear to be equally effective in restoring 
baroreceptor function in salt -depleted normotensive subjects. This is clinically relevant 
and suggest that AT1 blockers may be an attractive alternative to ACE inhibitors in 
cardiovascular diseases such as CHF where the RAAS is activated. Clearly, the 
neurohormonal activation and haemodynamic responses are much more complicated 
in the CHF patient, and our observations need to be confirmed in this cohort of 
patients. The long term effects of these treatments have been evaluated in the ELITE 
II mortality trial. Although no mortality benefit was demonstrated, losartan did appear 
to be better tolerated than captopril in the ELITE II trial. This may be an equally 
important observation as an agent that is as effective as ACE inhibitors but better 
tolerated would make a;significant impact on the lives of CHF patients. However it 
must be noted that ELITE II was designed as a superiority trial; it was not designed 
to address equivalence and certainly the data was insufficient to claim that the two 
treatments were equally effective. 
For the moment ACE inhibitors remain the drug of choice although AT 1 
receptor antagonists, like aldosterone antagonists, may offer us an attractive 
therapeutic strategy to overcome the neurohormonal re- activation seen with chronic 
ACE inhibition. The principal results of the Val HeFT (Valsartan in Heart Failure 
Trial) were recently presented at the American Heart Association Scientific Sessions 
(New Orleans, Nov 2000). In this placebo -controlled trial where 5010 NYHA Class 
II -IV patients were randomised, the hypothesis that adding valsartan to conventional 
therapy (including ACE inhibitors and beta -blockers) would improve clinical 
outcomes was tested. Although Valsartan did not reduce all -cause mortality, CHF 
hospitalisations was significantly reduced (27% reduction, p= 0.000001). Important 
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issues regarding its efficacy have been highlighted in the subgroup analyses, which 
raises the possibility of drug interactions between valsartan and ACE inhibitors/beta - 
blockers. Therefore, clinicians should at least await the full publication of the Val 
HeFT results and seek confirmation from other ongoing randomised trials (such as 
CHARM for candersartan) before offering their CHF patients this class of drugs as a 
more tolerable and equally effective alternative to ACE inhibitors. 
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CHAPTER SEVEN 
DETERMINANTS OF OT DISPERSION IN MAN: 
THE EFFECTS OF ALDOSTERONE, 
AFTERLOAD AND VAGAL BLOCKADE 
7.1 INTRODUCTION: 
In Chapter 3, spironolactone was found to improve QT dispersion in heart 
failure patients. QT dispersion is however likely to be due to a multitude of different 
factors. In order to understand the mechanism by which spironolactone improves QT 
dispersion, we need to understand more about the various factors which determine an 
individual' s QT dispersion. In the present chapter, two studies examining some of 
these potential mechanisms are described. 
One factor which may be important is cardiac afterload. Many factors 
determine afterload but aldsoterone may be a contributor since it has receptors in 
vascular tissue and has been shown to increase vascular tone [Weber and Purdy 
1962], increase AT -1 receptor density [Ullian et al 1992]and potentiate Ang II- 
induced hypertrophy of vascular smooth muscle cells [Hatakeyama et al 1994]. The 
first study was therefore designed to assess if changes in cardiac afterload per se 
would affect QT interval dispersion. In experimental models, an acute increase in 
cardiac afterload has been shown to be arrhythmogenic [Han et al 1990, Sideris et al 
1995]. Therefore part of the beneficial effects on QT dispersion seen with ACE 
inhibitors and spironolactone may be attributed to their ability to reduce afterload. 
Alterations in cardiac loading may affect myocardial electrophysiology by the 
mechanism of mechano -electrical feedback, or contraction -excitation coupling [Lab 
1982]. In experimental studies, an increase in cardiac loading with subsequent 
stretching of the ventricular myocardium causes shortening of the action potential 
duration [Lab 1982, Taggart et al 1992], and this in turn, may result in an altered 
dispersion of action potential repolarisation in the ventricle [Dean and Lab 1990]. 
Until now, there has been little evidence for this occurring in man in vivo. 
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We therefore examined the effects of an acute phenylephrine- induced increase 
in afterload on QTd in man. As phenylephrine is known to alter heart rate significantly 
(via a reflex vagal- response), the study was carried out, with and without the presence 
of atropine, given to inhibit the reflex parasympathetic activity. We also examined 
whether atropine per se would alter the QTmax interval and QT dispersion in this 
study. 
The effects of an acute intravenous infusion of aldosterone itself on QT 
dispersion in man were explored in the second study. The detection of 
mineralocorticoid receptors in the heart [Agarval and Philippe 1979] suggest that 
aldosterone may have direct effects on the myocardium. Certainly in an animal model 
by Arora and Somani [1962], the direct administration of aldosterone infusion into 
coronary ligated dogs was associated with the generation of ventricular arrhythmias. 
7.2 METHODS: 
In both studies, subjects were asked to refrain from alcohol, caffeine and 
cigarettes for 24 hrs and to fast for 2 hrs before each study day. Subjects rested 
quietly in the supine position throughout the study. 
7.2.1 Study 1 
Subjects And Protocol 
10 normal male volunteers [mean age (SD) 25 (4.5)] were studied. One had to 
be withdrawn from the study as he was not able to tolerate the phenylephrine infusion 
(his arterial SBP increased by >50mmHg even at the lowest dose 
administered). 
Subjects were studied on 2 separate days, at least 72 hours apart, 
in a placebo- 
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controlled, randomized, single -blinded, cross -over fashion. A single 18G intravenous 
cannula was inserted into a right forearm vein of each subject. After 30 minutes of 
bedrest, baseline values of blood pressure (BP) and heart rate (HR) were measured 
non -invasively in triplicate using a semi- automatic sphygmomanometer (Dinamap 
Vital Signs Monitor 1846; Critikon, Tampa,FL, USA) with the cuff being placed 
around the subjects left arm. Baseline 12 -lead electrocardiograms (ECG) were also 
obtained. 
Following this, a continuous infusion of either phenylephrine (Knoll 
Pharma, UK) or placebo (5% Dextrose) in similar volumes, was commenced 
intravenously. Up to 6 incremental stepwise 10 minutes infusions (0.2 -3.6 ug/kg/min) 
were administered using an infusion pump (IMED, San Diego, CA). The infusion was 
stopped when a 35 -40 mmHg rise in systolic BP had been achieved with the active 
treatment. Infusions of the placebo were carried out in similar volumes and 
incremental steps as the active treatment. BP, HR and electrocardiogram recordings 
were obtained in triplicate between 8 and 10 minutes after each infusion dose. After 
completion of these measurements, the infusion was discontinued and resting BP and 
HR were allowed to return to baseline values for 30 minutes. 
Atropine 0.03mg/kg was then administered by slow iv injection over 1 minute. 
Once heart rate and blood pressure had restabilised following full vagal blockade, a 
repeat baseline 12 -lead ECG was obtained and the infusion of phenylephrine (or 
placebo) was restarted and the study repeated again as described above. Forty five 
minutes after the injection of atropine, a further 0.6mg atropine was given 
intravenously to ensure continued vagal blockade. At the end of the study resting 
blood pressure and heart rate were allowed to return to normal. 
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7.2.2 Study 2 
Subjects And Protocol 
10 normal male volunteers [mean age (SD) 23 (7)] were studied on 2 separate 
days, at least 72 hours apart, in a placebo -controlled, randomized, double -blind, 
cross -over fashion. Two 18G intravenous cannulae were inserted into forearm veins, 
one in the right arm for blood sampling and one in the left arm for infusion of either 
aldosterone or placebo. After 45 minutes of bedrest, baseline values of blood pressure 
(BP) and heart rate (HR) were measured non -invasively in triplicate using a semi- 
automatic sphygmomanometer with the cuff being placed around the subjects left arm. 
12 lead electrocardiograms and venous blood (15m1s) for baseline aldosterone and 
angiotensin II assays were also obtained. 
Following this, a continuous infusion of either placebo (5% Dextrose) or d- 
Aldosterone (Tayside Pharmaceuticals) in similar volumes was commenced in the left 
arm. The d- aldosterone was infused at a rate of 12pmol/kg/min. After 45 minutes into 
the infusion, further triplicate recordings of blood pressure, heart rate and continuous 
12 -lead ECGs were obtained along with blood samples for aldosterone and 
angiotensin II assays. 
QT Interval And Dispersion Analysis 
In both studies, QT interval analysis was carried out blindly on 
electrocardiograms (with simultaneous 12 -lead acquisition) as detailed in Chapter 
2: 
Methods. In addition to Bazett's formula (QTc= QT/RR' /2) for heart-rate 
correction, 
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the QT intervals were also corrected using the Morrison and Hodges [Hodges et al 
1983] linear correction formula [QTc = QT + 1.75 (HR - 60)] in Study 1. 
Aldosterone And Angiotensin H Assays 
As described in Chapter 2. 
Statistical Analysis 
All data were analyzed using the Statgraphics software package (STSC 
Software Publishing Group, Rockville, MD, USA) as detailed in Chapter 2: Methods. 
The relationships between variables in study were studied by Pearson correlation and 
linear regression analyses. Differences between treatment groups were analyzed using 
the paired Student t test. 
7.3 RESULTS: 
7.3.1 Study 1 
Baseline Measurements (See Table 7.1) 
Resting blood pressure, heart rate and ECG parameters were similar at the 
start of both study visits (Table 7.1). Following atropine, baseline HR increased 
significantly but resting blood pressure was unchanged. This was paralleled by a 
significant reduction in QTmax and an increase in the Bazett- corrected QTcmax. The 
linearly- corrected QTcmax was non -significantly increased. Atropine however did not 
appear to have any significant effect on either QTd or QTcd. 
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Correlation between alterations in blood pressure and QT dispersion 
Phenylephrine alone: Phenylephrine given in incremental doses caused a 
gradual rise in blood pressure paralleled by a significant fall in reflex heart rate. Both 
QTmax and the linearly -corrected OTcmax significantly increased but the Bazett- 
corrected QTcmax was not significantly affected by the changes in blood pressure 
induced by phenylephrine (see Table 7.2). The relationships between changes in blood 
pressure and QT interval and dispersion indices in response to phenylephrine are 
displayed in Fig 7.1 -7.5 and Table 7.3. It is clear that phenylephrine causes a 
significant increase in QTd and QTcd and that this occurs in the presence or absence 
of atropine. 
Changes in QTd (AQTd) and QTcd (AQTcd) appear to be significantly 
correlated with both changes in systolic and diastolic BP (ASBP and ADBP) in a 
linear fashion. The relationships between the variables, expressed as the slope of the 
linear regression line (eg AQTd/ ASBP), and their respective p- values and correlation 
coefficients for each individual are displayed in Table 7.3. 
Similar linear regression analysis made on the pooled data (pooled correlation 
coefficients and p values are displayed in Fig 7.2 -7.4 respectively) yielded comparable 
results confirming the above observations. 
Phenylephrine and Atropine: Following pre- treatment with atropine, 
phenylephrine had no significant effect on either heart rate, QTmax or QTcmax (Table 
7.2). The previously demonstrated relationship between the dispersion indices and 
blood pressure was still present and was unaffected by atropine pre- treatment. There 
were no significant differences in the slope, AQTd/ASBP before and after atropine 
[Mean difference -0.003 (95% CI -0.558 to 0.552) msec /mmHg; p =0.9]. Similarly, 
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atropine did not affect AQTd/ADBP [Mean diff -0.271 (95% CI -1.060 to 0.517) 
msec/mmHg; p = 0.45), AQTcd/ASBP [Mean diff -0.404 msec/mmHg (95% CI - 
1.066 to 0.258) msec/mmHg, p = 0.2] or AQTcd/ADBP [Mean diff -0.383 (95% CI 
-1.214 to 0.449) msec/mmHg; p = 0.32]. 
7.3.2 Study 2 (See Table 7.4-7.5) 
No significant differences in baseline measurements were seen between 
placebo and aldosterone infusion days. A significant rise in plasma aldosterone levels 
was noted after 45 mins of aldosterone infusion compared to placebo. There were no 
significant differences in Ang II levels following aldosterone infusion compared to 
placebo. All QT interval and dispersion indices were not significantly affected by the 
aldosterone infusion compared to placebo. 
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Table 7.1: Baseline haemodynamic and electrocardiographic measurements with: 
a) Placebo infusion. Expressed as Mean f SD. Statistical significance (p <0.05) refers to 
comparison with pre -infusion baseline values. 
Pre -infusion (Start) Post -atropine* P value 
SBP (mmHg) 114 ± 10 116 ± 11 NS 
DBP (mmHg) 64 ± 12 66 ± 9 NS 
HR (btdmin) 66 ± 12 109 ± 10 <0.001 
QTmax (msec) 401.5 ± 33 347 ± 19 <0.001 
QTcmax (linear corr.) 416 ± 19 421 ± 17 NS 
QTcmax (Bazett's corr.) 412 ± 14 448 ± 15 <0.001 
QTd (msec) 44.9 ± 14.7 45.8 ± 5.8 NS 
QTcd (linear corr.) 44.9 ± 14.7 45.8 ± 5.8 NS 
QTcd (Bazett's corr.) 47.3 ± 15.4 54.4 ± 9.7 NS 
b) Phenylephrine infusion 
Pre -infusion (Start) Post -atropine* P value 
SBP (mmHg) 116 ± 11 121 t 13.5 NS 
DBP (mmHg) 63 ± 12 68 ± 11.5 NS 
HR (bt/min) 58 ± 11 104 ± 13 <0.001 
QTmax (msec) 418 ± 27 345 ± 27 <0.001 
QTcmax (linear corr.) 415 ± 20 422 ± 18 NS 
QTcmax (Bazett's corr.) 410 ± 23 455 ± 24 0.002 
QTd (msec) 45.8 ± 10.7 46.1 ± 12.0 NS 
QTcd (linear corr.) 45.8 ± 10.7 46.1 ± 12.0 NS 
QTcd (Bazett's corr.) 46.3 ± 13.2 55.1 ± 11.9 NS 
* denotes resting values following atropinisation prior to re- commencement of phenylephrine 
(or placebo) infusion (see text). 
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Table 7.2: Effects of Phenylephrine (f Atropine) on Heart Rate and QT Intervals. 
Measurements taken at baseline and after phenylephrine infusion, with and without prior 
atropinisation (Phe Atr and Phe, respectively) 
Baseline (no atropine) Phe P value 
HR 58 ±11 42 f 4 0.0004 
QTmax 418 ± 27 460 ± 26.5 0.0003 
QTcmax (linear corr.) 415 ± 20 429 ± 25 0.017 
QTcmax (Bazett's corr.) 410 ± 22.5 400 ± 28 NS 
QTmin 373 ± 25 396 ± 24 0.001 
QTcmin (linear corr.) 369 ± 20 364 ± 20 NS 
QTcmin ( Bazett's corr.) 364 ±24 332 f 25 0.001 
Baseline (with atropine) Phe-Atr 
HR 104 ± 13 106 ± 13 NS 
QTmax 345 ± 27 348 ± 25 NS 
QTcmax (linear corr.) 422 ± 18 429 ± 13 NS 
QTcmax (Bazett's corr.) 455 ± 24 465 ± 14 NS 
QTmin 299 ± 24 285 ± 17 0.038 
QTcmin (linear corr.) 376 ± 16 365 ± 14 NS 
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TABLE 7.4: Baseline values (Study 2). Results are expressed as Mean + SD. Statistical 
significance : *P <0.05 compared with placebo. 
Placebo Aldosterone 
Heart rate (beats /min) 62 (7) 64 (8) 
Systolic blood pressure (mmHg) 117 (10) 113 (6) 
R -R Interval (msec) 1004 (167) 989 (175) 
Aldosterone- baseline levels (pg/ml) 104 (101) 113 (90) 
Aldosterone level- 45 mins after start of infusion 
(pg/ml) 
89 (78) 467 (90)* 
Angiotensin II levels - 45 .mins after start of infusion 17 (8) 13.5 (7) 
(Pg /ml) 
TABLE 7.5: ECG measurements after 45 mins infusion: Results are expressed as Mean ± 
SD. Statistical significance : *P <0.05 compared with placebo. 
Placebo Aldosterone 
QTmax 409+23 420+30 
QTcmax 414 + 18 417 + 24 
QTdisp 42.4 + 11.7 45.1 + 9.6 
QTcdisp 44.8 + 10.5 41.8 + 10.2 
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7.4 DISCUSSION: 
Mechanisms in which aldosterone may contribute towards dispersion of the 
QT interval are explored in this chapter. An acute aldosterone infusion did not appear 
to have any significant direct effects on QT dispersion in man. However in Study 1, 
which was designed to examine the effects of increasing cardiac afterload on QT 
dispersion, a significant positive correlation between changes in blood pressure and 
changes in all QT dispersion indices (QTd, Bazett- corrected QTcd and linear - 
corrected QTcd) was found. Importantly, the atropine data showed that this 
relationship between all QT dispersion indices and afterload was independent of heart 
rate changes or reflex vagal activity. These observations also suggest that reflex vagal 
activity does not influence QT dispersion. 
Phenylephrine is a vasopressor, acting principally on the arterial bed, causing 
vasoconstriction, an increase in peripheral resistance and a corresponding rise in blood 
pressure. This increase in afterload is accompanied by a fall in heart rate, resulting 
from reflex activation of the parasympathetic nervous system. Therefore, to exclude 
the potentially confounding effects of reflex vagal activity, the study was also carried 
out in the presence of atropine. Pre -treatment with atropine not only enabled us to 
assess the contributory role of vagal blockade on QT dispersion, but also allowed us 
to control for heart rate (which remained unchanged) during the combined infusion of 
phenylephrine and atropine. 
Due to the varying HRs, the effects of phenylephrine on Bazett's rate 
corrected QT intervals were significantly different from uncorrected values in our 
study (Tables 7.1 and 7.2). As one can clearly see, the QTmax values were not only 
significantly different between corrected and uncorrected values but they moved 
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numerically in opposite directions, as a result of over -correction with the Bazett's 
formula [Browne et al 1983, Ahnve and Vallin 1982]. 
However, despite this, the relationship between changes in QT dispersion and 
changes in BP was unaffected by HR (Fig 7.2 -7.3). Although it appears that acute 
cardiac afterload increases QT dispersion, there does not appear to be any significant 
correlation with QTcmax (Fig 7.4). The impact of these major haemodynamic 
perturbations appears to be mainly on the QTcmin (Table 7.2, Fig 7.5). The reduction 
in QTcmin with afterload is consistent with experimental data where stretching of the 
ventricular myocardium has been shown to shorten action potential duration [Lab 
1982, Taggart et al 1992, Dean and Lab 1990]. 
7.4.1 Afterload And QT Dispersion 
Our findings are consistent with the results of a recent study by Sun et al 
[ 1998] who found a 22% increase (although non - significant) in dispersion of the QT 
interval following phenylephrine infusion in normal subjects. It is well established from 
experimental models that alterations in cardiac afterload may affect the action 
potential duration through mechano -electrical feedback [Lab 1982]. From the law of 
Laplace, an increase in afterload should result in an increase in wall stress. Stretching 
of the ventricular myocardium has been shown to shorten the action potential duration 
in a number of studies [Lab 1982, Taggart et al 1992, Dean and Lab 1990]. 
Importantly however, these changes in effective refractory period may not be 
homogenous throughout the myocardium. Dean and Lab [ 1990] found that in an in 
situ pig heart model for instance, there was a greater change in refractory period 
occurring at the apex compared to the base in response to an increase in load by aortic 
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clamping. These animal observations of increased regional dispersion of repolarisation 
across the left ventricle agree with the results of our study in man. 
The dispersion of ventricular action potential provide a substrate for re- entrant 
circuits and the development of malignant arrhythmias [Han and Moe 1964, Kuo et al 
1983]. Hence, the effects of afterload on QT dispersion have important clinical 
implications. A number of previous studies have shown that an increase in afterload is 
arrhythmogenic [Hansen et al 1990, Sideris et al 1995]. Furthermore, patients with 
conditions associated with a raised afterload (eg. chronic heart failure, aortic stenosis, 
hypertrophic cardiomyopathy and hypertension) have an increased incidence of 
ventricular arrhythmias and sudden deaths [Von Olsahausen et al 1983, Franciosa et 
al 1983, McLenachan et al 1987]. Vasodilator drug therapy and afterload- reducing 
agents such as angiotensin converting enzyme (ACE) inhibitors, on the other hand, 
has been shown to reduce mortality, including sudden deaths [CONSENSUS -1 1987, 
Cohn et al 1991]. It is also intriguing to note that while QTd is increased in these 
cardiac diseases [Buja et al 1993, Barr et al 1994], the reduction in mortality by drug 
therapies such as ACE inhibitors is paralleled by a similar reduction in QTd [Barr et al 
1997]. It is generally thought the increased QT dispersion in these conditions occurs 
as a result of chronic changes in the myocardium such as left ventricular hypertrophy 
[Davey et al 1994]. Although this has been demonstrated in previous studies [Davey 
et al 1994], we believe that ours is the first to show QT dispersion may also be 
affected by acute changes in blood pressure. Our findings may therefore be relevant in 
a wide variety of other clinical settings where there are associated acute changes in 
blood pressure (eg stress, "white coat" hypertension etc). 
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7.4.2 Vagal Activity And QT Dispersion 
In our study, atropine reduced the resting QTmax (and QTmin) but increased 
the Bazett -corrected QTcmax (and QTcmin) significantly, an effect that has also been 
observed in other studies [Browne et al 1983, Annila et al 1993]. However, the QT 
intervals were not significantly changed when linearly corrected. Changes in QT 
intervals are highly dependent on heart rate changes with QT interval shortening 
occurring as heart rate increases with atropine. Although the primary aim of our study 
was to look at the effects on QT dispersion, our findings with the QT interval 
highlight the difficulty of rate -correction in studies such as this where pharmacological 
interventions change heart rate significantly. As discussed above, the increase in 
Bazett- corrected QTcmax for instance, is thought to be due to over- correction by the 
Bazett formula [Browne et al 1983, Ahnve and Vallin 1982]. This has led many 
investigators to question the appropriateness of heart rate correction formulae such as 
Bazett" s which can often be misleading. This inappropriateness is further emphasized 
by our results which showed that atropine prolongs the Bazett corrected QTcmax but 
not the linear corrected QTcmax;, on the other hand, phenylephrine prolongs the linear 
corrected QTcmax but not the Bazett corrected QTcmax. 
Because of these problems, it remains uncertain whether vagal activity does 
indeed modulate ventricular repolarisation, whereas some experimental data suggest 
that the cholinergic effects on ventricular repolarisation are minimal [Rosen et al 
1992], others have found that atropine shortens the ventricular effective refractory 
period and QTmax interval during fixed atrial pacing [Browne et al 1983, Ahnve and 
Vallin 1982]. Our data does not clarify this particular issue but 
purpose of the study . 
1111 s mvas not the main 
QT dispersion, unlike the QT interval, is not heart rate dependent (as reflected 
by the fact that we have found no discrepancy between our results with QTd, Bazett 
corrected QTcd or linear corrected QTcd). In our study, QT dispersion was 
unaffected by atropine. Although the effects of atropine on the QT interval have been 
extensively investigated, studies looking at its effects on QT dispersion are limited. 
Our results are consistent with the observations made by Uemura et al [ 1997] in the 
only study that we know of that had directly examined the effects of atropine on QT 
dispersion in man. 
The reflex vagal response to phenylephrine has also been previously 
investigated. Kautzner et al [1997] found that QT dispersion was unaffected by 
phenylephrine. Although this may initially appear to contradict our results, the 
findings are actually consistent with our study. Kautzner et al [1997] used boluses 
instead of infusions of phenylephrine in order to produce rapid vagal stimulation and 
to study whether vagal stimulation altered QT dispersion. Boluses of phenylephrine 
do not produce sustained increases in afterload and it is likely that afterload changes 
have to be maintained for more than a few seconds to affect QT dispersion. Hence it 
is not surprising that Kautzner et al [1997] did not find any change in QT dispersion 
because they were using phenylephrine boluses to study the effect of the vagus rather 
than using phenylephrine to study the effects of afterload as we were. The finding that 
reflex vagal activity did not influence QT dispersion is in fact, consistent with our 
observations. 
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7.4.3 Aldosterone And QT Dispersion 
In Chapter 3, aldosterone blockade reduced QT dispersion. As discussed in 
Chapter 1 (Section 1.5), there are a number of potential mechanisms in which 
aldosterone may cause QT dispersion. This may be the result of autonomic 
modulation [Bonnar et al 1997], electrolyte depletion [Choy et al 1997] or promotion 
of myocardial fibrosis [Brilla and Weber 1992]. Animal data even suggest that 
aldosterone may have direct arrhythmic effects on the heart. Aldosterone levels are 
higher in the heart than in plasma [Silvestre et al 1998]. The detection of 
mineralocorticoid receptors in the heart [Agarval and Philippe 1979] as well as 11- 
hydroxysteroid dehydrogenase activity [Walker et al 1991] and the recent discovery 
of local aldosterone synthesis by the myocardium in animal models [Silvestre et al 
1998], certainly suggest that aldosterone may possess paracrine or autocrine 
properties, with direct effects on the heart, in addition to its renal and autonomic 
modulating properties. 
The pro - arrhythmic effects of direct administration of aldosterone infusion was 
demonstrated by Arora and Somani [1962] who in an experimental animal model, 
found to be even more striking and prolonged compared to other arrhythmogenic 
agents such as epinephrine. As the arrhythmogenic effect of the infusion was of rapid 
onset, it was concluded by the authors that electrolyte depletion was an unlikely 
explanation for this observation. 
In this chapter the direct effects of intravenous aldosterone infusion on QT 
dispersion in man were examined. Despite achieving plasma levels comparable to 
those of CHF patients, the aldosterone infusion did not appear to have any significant 
effect on QT dispersion compared to placebo. This is perhaps not surprising as the 
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study was an acute study only and it was carried out at rest in normal healthy 
volunteers who are clearly very different compared to the CHF patient who is 
characterized by a complex and abnormal neurohomonal activated state. Furthermore 
it is likely that aldosterone- induced changes in the QT interval may only become 
observable chronically, once aldosterone has affected serum potassium. In Study 1, 
changes in QT dispersion have been shown to correlate with blood pressure changes 
and in Chapter 5, we found that aldosterone blunted the baroreflex change in heart 
rate. Hence a possible direct arrhythmogenic effect of aldosterone on the heart 
particular during an "activated" state (eg. during stress, exercise etc), remains to be 
clarified in future studies. 
At present however, we can conclude that aldosterone may contribute towards 
QT dispersion via a number of indirect mechanisms. Aldosterone may cause both 
increased afterload (by increasing vascular tone and potentiating vascular smooth 
muscle cell hypertrophy) and preload (salt and water retention), myocardial fibrosis, 
electrolyte depletion and sympathetic activation: all of which may potentially increase 
QT dispersion. Aldosterone also impairs the parasympathetic nervous system but the 
parasympathetic tone does not appear to contribute towards QT dispersion. 
7.4.4 Study Limitations 
There are several points worth discussing. Firstly, as mentioned above, the 
studies in this chapter are carried out in normal volunteers who are clearly different 
from CHF patients who may not respond in the same manner. The results of the 
studies will therefore need to be replicated in CHF patients. 
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Secondly, although Study 1 was designed primarily to assess the effects of 
afterload it must be borne in mind that any haemodynamic change in afterload will 
tend to affect pre -load as well. Although it is not possible to totally isolate the effects 
of one without changing the other in clinical studies, preload changes should be 
minimal in this study since phenylephrine is an alpha -adrenergic agonist which acts 
primarily on the arterial circulation. 
Thirdly, the technical difficulty of obtaining a precise and reproducible 
determination of the end of the T wave measurement is well recognised. Care has 
been taken to use consistent criteria to define the end of the T wave and to exclude U 
waves. We were careful not to miss any flat U waves which may have become more 
obvious following the phenylephrine infusion as this may produce an artifactually 
short QT interval when a flat U wave became more obvious. Fortunately, this was not 
a major issue as the T and U waves were essentially normal and easy to measure at 
baseline in a cohort of normal healthy subjects. Following phenylephrine infusion, 
both the T and U waves become more prominent making measurements even easier. 
If the end of T wave in any lead were in doubt, the lead was excluded from analysis. 
Finally, a direct electrophysiological effect of phenylephrine on the 
myocardium could not be entirely excluded. In isolated ferret Purkinje fibers, alpha - 
adrenergic stimulation has been shown to induce early afterdepolarizations (EAD) 
which may be a trigger for arrhythmia initiation [Drouin et al 1996]. However these 
effects are thought to be species specific, and have not been shown to occur in human 
myocardium [Jakob et al 1988]. Furthermore, EADs are heart rate dependent and 
only occur when there is prolongation of the action potential (ie. during bradycardia) 
[Charpentier et al 1993]. In our study, the effects of phenylephrine on QT dispersion 
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were independent of heart rate (ie. the effects were observed even when heart rate 
was kept constant). This means that a direct electrophysiological effect of alpha - 
adrenergic stimulation on QT dispersion is unlikely. 
7.4.5 Conclusions 
We have shown conclusively that there is a significant positive correlation 
between changes in afterload and changes in QT dispersion. The findings are clinically 
relevant and may account for part of the reason why there are such high rates of 
arrhythmic complications and sudden deaths in patients with conditions associated 
with increased afterload such as heart failure and hypertension. 
On the other hand, both an acute aldosterone infusion and acute changes in 





The therapeutic benefits of neurohormonal modulation in chronic heart 
failure are now well established as evident by the effects of ACE inhibitors and beta - 
blockers on mortality reduction in recent trials. Despite these favourable effects on 
mortality, CHF remains a deadly disease. It has become clear that ACE inhibitors do 
not completely suppress the RAAS system. Neurohormonal re- activation occurs with 
chronic ACE inhibition and the phenomenon of aldosterone "escape" is well 
described. 
Until recently, the clinical significance of aldosterone in congestive heart 
failure has been overlooked. The results of the recent Randomised Aldactone 
Evaluation Study (RALES) [Pitt et al 1999] clearly indicate that there is further 
therapeutic mileage to be gained by adding an aldosterone antagonist in patients with 
CHF already established on ACE inhibitors. In this study, the overall risks of death, 
death due to progressive pump failure, and sudden death from cardiac causes were 
reduced by approximately 30% among spironolactone- treated patients (compared to 
placebo), prompting early termination of the study. 
In this thesis, I have explored some of the potential adverse effects that 
aldosterone may have on the cardiovascular system. The results of these studies 
provide valuable mechanistic insights, which may account for some of the beneficial 
effects seen in the RALES trial. 
8.1 Summary of results 
In the first two studies, described in Chapters 3 and 4, the effects of 
spironolactone on cardiac autonomic tone, QT dispersion and arrhythmic activity 
were assessed in two different patient populations. In both studies, full diurnal 
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assessment of the autonomic tone including 24hr heart rate variability and 
noradrenaline kinetic studies were carried out. In Chapter 3, I investigated the effects 
of spironolactone in heart failure patients already established on ACE inhibitors. The 
cohort of patients chosen for the study was in fact, very similar to that of the RALES 
trial. The results of this study confirms that aldosterone, not unlike Angiotensin H, 
plays an important role in the regulation of the cardiac autonomic tone. The study 
suggest that spironolactone has important parasympathomimetic effects. Aldosterone 
blockade improved heart rate variability, particularly during the morning hours when 
aldosterone secretion is maximal. In addition aldosterone blockade had also been 
shown to reduce QT dispersion, a surrogate marker of sudden death. 
In Chapter 4, I explored the effects of aldosterone blockade in a cohort of 
chronic stable angina patients. The study was similar in protocol to that of the CHF 
study described in Chapter 3. In addition, the impact of spironolactone therapy on 
the total ischaemic burden was also assessed. The results of this study were 
disappointing. Aldosterone blockade did not appear to have any significant effect on 
ischaemic events. Similarly there was no significant effect on RRV, noradrenaline 
kinetics and QT dispersion measures compared to placebo in stable angina patients 
with preserved LV function. 
The subsequent chapters (Chapters 5 -7), consisted of a series of smaller 
mechanistic studies in healthy normal volunteers, designed to explore some of the 
possible mechanisms in which aldosterone may contribute to autonomic dysfuntion 
and increased dispersion of the QT intervals. The study described in Chapter 5 is the 
first study ever to describe the detrimental effects of aldosterone on the barorefiex in 
man. Baroreflex sensitivity was reduced in healthy subjects when intravenous 
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aldosterone infusion was administered until plasma concentration levels comparable 
to those seen in CHF patients were achieved. It attenuated the heart rate response to a 
vasopressor agent (phenylephrine) but did not have any significant effect on the 
reflex tachycardic (or cardiac sympathetic) response to a vasodilator, sodium 
nitroprusside. In Chapter 6, a head to head comparative study of the effects of 
losartan, an AT1 receptor antagonist and enalapril, an ACE inhibitor on baroreceptor 
dysfunction was described. Pharmacologically, the former is potentially an attractive 
class of drug as it works at the receptor level and should therefore, have the 
theoretical advantage of avoiding the neurohormonal escape phenomenon seen with 
ACE inhibitors resulting from Ang II production by non -ACE dependent pathways. 
However, in this study, there did not appear to be any significant differences between 
the two treatments as both therapies were equally effective in improving BRS in salt 
depleted normotensive subjects. 
In Chapter 7, I examined some of the mechanisms in which aldosterone may 
affect QT dispersion. Aldosterone may cause regional dispersion of the repolarisation 
phase of the action potentials in the myocardium via a number of potential 
mechanisms. Changes in QT dispersion appear to correlate strongly with acute 
changes in phenylephrine- induced cardiac afterload (or blood pressure). However, 
direct aldosterone infusion and vagal activity did not influence QT dispersion. 
8.2 Conclusions 
It is well recognised that the RAAS and the autonomic nervous system are 
inextricably linked in CHF. However, the interaction between the two 
neuroendocrine systems is not wholly understood. The studies in this thesis provide 
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important new insights into the role of aldosterone in cardiac autonomic regulation. 
The effects of aldosterone on the kidneys (salt and water retention, potassium 
and magnesium excretion) and the long -term detrimental effects on hypertension and 
myocardial fibrosis are well established. In addition, the studies in this thesis provide 
strong evidence that aldosterone also has detrimental effects on the parasympathetic 
nervous system. Like angiotensin II, aldosterone impairs the baroreflex response in 
man. This is a potentially important observation as baroreflex dysfunction 
predisposes the myocardium to arrhythmias. Indeed, baroreflex sensitivity (BRS) has 
recently been shown to correlate strongly with cardiac mortality in the large 
prospective ATRAI II study [La Rovere et al 1998]. The study suggest that 
aldosterone exerts its effects primarily on the parasympathetic tone with little impact 
on the sympathetic nervous system. Aldosterone blockade in CHF provided further 
evidence to support the above conclusion. Studying a similar cohort of CHF patients 
to that of the RALES trial, I found that spironolactone improved the high frequency 
(HF) component of heart rate variability, a marker of vagal activity. Noradrenaline 
kinetics on the other hand, were unaffected. 
Another interesting observation from the latter study was that QTc intervals 
and dispersion on the 12 -lead ECG were also reduced by spironolactone therapy. 
Both QTcmax and QTd have been identified as sensitive predictors of sudden death 
[Naas et al 1998, Schwartz and Wolf 1978, Barr et al 1994]. The dispersion of 
ventricular action potential provide a substrate for re- entrant circuits and the 
development of malignant arrhythmias [Han and Moe 1964, Kuo et al 1983]. 
Mechanisms in which aldosterone may contribute towards dispersion of the QT 
interval are not entirely known and may be multifactorial. It is well established in 
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experimental models that alterations in cardiac afterload may affect the action 
potential duration through mechano -electrical feedback [Lab 1982]. In this thesis, I 
have provided evidence that changes in cardiac load would alter QT dispersion. 
Aldosterone may cause both increases in cardiac afterload (by increasing vascular 
tone and potentiating vascular smooth muscle hypertrophy) and pre -load (salt and 
water retention). 
The effect of aldosterone on the parasympathetic nervous system is thought to 
be another possible mechanism, although in this thesis, I have demonstrated that 
vagal tone modulation itself did not contribute towards QT dispersion. Similarly, 
although the pro -arrhythmogenic effects of direct administration of aldosterone 
infusion has been demonstrated in experimental models [Arora and Somani 1962], an 
acute intravenous aldosterone infusion did not affect basal QT intervals or dispersion 
indices. Other potential mechanisms in which aldosterone may contribute towards 
QT dispersion include promotion of myocardial fibrosis and electrolyte depletion 
(hypokalemia, hypomagnesaemia), both of which may take time to develop. It was 
unfortunately beyond the scope of the thesis to explore these possibilities, which may 
represent ideas for future studies. 
It was also intriguingly observed in the CHF study (Chapter 3), that heart rate 
was reduced and the beneficial effects of aldosterone blockade on the various 
arrhythmic and autonomic surrogate markers (heart rate variability, QT dispersion) 
were maximal during the morning hours of the day (6- l0am), coinciding with the 
circadian pattern of cardiovascular events, such as sudden deaths and myocardial 
infarctions. 
Hence by exerting its maximal effects during these crucial hours, 
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spironolactone may particularly reduce the number of such events in the dawn period 
of the day. Indeed the heart rate reduction during these hours raises the possibility 
that aldosterone blockade may have anti -ischaemic properties. Unfortunately, when 
tested on a cohort of stable angina patients (Chapter 4), no such benefit was evident. 
There were a number of possible reasons that may account for the discrepancy in the 
findings between the two studies. The two cohort of patients studied were different - 
unlike CHF patients, stable angina patients with preserved left ventricular function 
had much lower circulating aldosterone levels, a larger proportion was established on 
beta -blockers (which may influence HRV and reduce myocardial ischaemia), and 
only a minority was taking concomitant ACE inhibitors. On the other hand, the 
beneficial effects of spironolactone therapy in both the RALES trial and the 
mechanistic study in Chapter 3 were described in CHF patients who were all fully 
established on ACE inhibitors. 
8.3 Clinical implications and future directions 
Spironolactone has been in clinical use for over 30 years, principally in the 
therapy of hypertension and congestive heart failure. Although simple and cheap, its 
use has often been neglected by physicians in the post -ACE inhibitor era, as it was 
thought that the latter class of drugs would provide adequate suppression of the 
RAAS, and hence reduce both circulating Ang II and aldosterone levels. We now 
know this is not the case. Combination therapy of low dose spironolactone (25- 
50mg/day) and an ACE inhibitor is well tolerated [Pitt et al 1999] and the results of 
the recent RALES trial indicate that the mortality benefits of aldosterone blockade in 
patients with CHF are additive to those of ACE inhibitors. This observation is an 
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important therapeutic advance and has lead to a resurgence of interest in the use of 
this old drug particularly, in the management of patients with severe CHF (NYHA 
grades III -IV). 
The studies in this thesis provide us with some mechanistic insights as to why 
aldosterone blockade may be beneficial in heart failure. The detrimental effects of 
aldosterone are most evident during the early morning hours when there is a shift in 
the sympathovagal balance. Aldosterone impairs the vagally- mediated baroreflex 
response and reduces heart rate variability in man. It would appear that its main 
effect is on the parasympathetic nervous system. Although there has been some 
previous animal data which suggests that it may also have detrimental sympathetic 
effects, I was unable to confirm this. 
Nonetheless, the observation that spironolactone has parasympathomimetic 
properties is a potentially important one. The parasympathetic nervous system plays 
an important role in the regulation of myocardial electrical stability. Reduced 
parasympathetic activity is associated with myocardial electrical instability and 
ventricular tachyarrhythmias, and may therefore play an important role in the 
pathophysiology of sudden death in CHF. Certainly reduced HRV and BRS have 
both been found to be good predictors of sudden deaths in CHF [Nolan et al 1998, La 
Rovere et al 1998]. This view is further strengthened by the fact that to date, all the 
other drugs that are known to reduce mortality in CHF (beta -blockers and ACE 
inhibitors), also regulate the autonomic tone and have been demonstrated to have 
favourable effects on the above surrogate markers. As the autonomic effects of 
spironolactone are maximal during the morning hours, it would be of interest to see if 
spironolactone- treated CHF patients have different diurnal pattern of deaths from 
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non -spironolactone treated patients. The timing of deaths were unfortunately not 
recorded in the RAZES study. 
So should we be prescribing spironolactone to all our heart failure patients? 
In the RALES trial, only those at the more severe end of the disease spectrum 
(NYHA Class III and IV) were studied. In this thesis, the beneficial effects of 
aldosterone blockade on cardiac autonomic regulation were also demonstrated in a 
similar cohort of patients. At present there is no data that spironolactone would 
benefit those with asymptomatic LV dysfunction or mild heart failure (NYHA H or 
less). Thus, extrapolation from RAZES cannot be made with confidence for non - 
severe heart failure. Indeed as suggested by the data from the study of stable angina 
patients (with normal or near -normal LV function) in this thesis, the ability of 
spironolactone to activate the renin- angiotensin system certainly argues against its 
use in the absence of ACE inhibition or angiotensin -receptor blockade, at least in 
angina patients. It remains to be seen if spironolactone would benefit patients with 
milder forms of heart failure (eg. asymptomatic LV dysfunction, where less 
circulating aldosterone levels are present). The effects of spironolactone on 
autonomic tone and mortality in these patients would certainly be interesting to 
explore in future studies. 
Similarly extrapolation from the RALES data cannot be made for diastolic 
heart failure. Theoretically, an agent that prevents myocardial fibrosis may have 
particular application in this setting. However this issue was not addressed in this 
thesis and the RALES trial only included patients with clear systolic dysfunction 
(LVEF <35 %). This topic too would be an interesting avenue for further research.. 
For the time being, the use of spironolactone is only indicated for patients 
216 
with severe systolic heart failure (NYHA Class III and IV). When and at what stage 
should the drug be introduced? The list of effective drug therapies in our 
armamentarium is growing rapidly. The benefits of ACE inhibitor therapy are well 
established, and this class of drugs should remain as first -line therapy for all patients 
with CHF. In both the RALES and heart failure studies carried out in this thesis, 
spironolactone was given as an add-on treatment in patients who had already been 
established on ACE inhibitors. What about the role of beta -blockers? The report from 
the RALES coincided with the now overwhelming evidence of benefit from beta - 
blockade for patients with NYHA Class II-III chronic heart failure. Should beta - 
blockers be introduced concurrently with spironolactone? Although only a small 
proportion of the RALES patients (11%) received beta- blockers, the RALES 
subgroup analysis did suggest that the use of both treatments may actually be 
synergistic in reducing mortality as the subgroup had the same proportional reduction 
in mortality as did those not receiving a beta- blocker. This is perhaps not too 
surprising as the main effect of beta- blocker therapy is on the sympathetic system 
whereas the main effect of spironolactone appears to be on the parasympathetic tone.. 
However these encouraging observations for combining both treatments require 
confirmation in further studies. Introduction of beta- blockers requires cautious, 
protracted dose -titration for CHF patients. Hence, until further data becomes 
available, separate stepped introduction of the two drugs would seem appropriate. 
Another issue worth exploring in future studies is 
between digoxin and spironolactone therapies. In RALES, 
observed that the patients receiving both spironolactone and '`goxín tir7-s áes far 
better than those on spironolactone only (no ) .. As it is weer ,d 
III ILI iI "9, I4i. LI, ,, 
digoxin has vagomimetic properties, it is not inconceivable that combining both 
therapies may be beneficial as they potentiate each other's autonomic effects. Studies 
evaluating the impact of the combined treatments on heart rate variability and 
baroreflex function, for instance, would clarify the issue. 
It is worth pointing out that although the main thrust of this thesis had been 
the exploration of its role in autonomic regulation, aldosterone clearly has other 
detrimental effects on the cardiovascular system. The effects of aldosterone blockade 
on QT interval and dispersion indices, for instance may be related to its effect on 
potassium. Although this was beyond the scope of this thesis, there is certainly 
evidence that intravenous potassium infusion improves QT dispersion in normal 
subjects [Choy et al 1997]. It would therefore be interesting to assess if the 
autonomic benefits of spironolactone are also shared by other potassium sparing 
diuretics such as amiloride. If indeed this was so, then there may be a case for new 
mortality trials with other potassium sparing diuretics in heart failure in the near 
future. 
In summary, there have been many new and exciting therapeutic advances in 
the management of chronic heart failure in recent years. Despite these developments, 
the pathophysiology of CHF remains complex and not fully understood; the work 
embodied in this thesis for example, highlights how inextricably linked the RAAS 
and the autonomic nervous system is. Neuroendocrine dysfunction contributes to 
haemodynamic decompensation and progression of the disease. Strategies aimed at 
limiting neuroendocrine disturbance in CHF are associated with an improvement in 
prognosis. Implementation of optimum treatment is challenging. 
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New therapies and innovations are currently being evaluated. These include 
endothelin antagonism, dual ACE and endopeptidase inhibition, and the combination 
of ACE inhibition and with angiotensin- receptor blockade. The mortality reduction 
seen with parasympathomimetic drug therapies, such as ACE inhibitors and 
spironolactone, suggest that enhancing the parasympathetic tone is cardioprotective 
and this may represent yet another therapeutic approach to the management of heart 
failure. Further studies should be aimed at evaluating the role of newer and more 
potent parasympathomimetic agents in CHF. 
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APPENDIX: 
Publications arising from this thesis 
European Heart Journal (1997) 18, 1860 -1864 
Can drug effects on mortality in heart failure be predicted 
by any surrogate measure? 
Introduction 
In chronic heart failure, the " impact of the drug 
therapy on mortality is a crucial issue that can best be 
answered by large expensive mortality trials. The 
need for these large expensive trials can act as a 
hindrance towards novel drug development. Indeed, 
the daunting prospect of such an expensive trial may 
explain why the pharmaceutical industry has .pro- 
duced 20 different ACE inhibitors rather than 20 
novel compounds all acting via different mechanisms. 
There are, however, surrogate markers which might 
help circumvent this problem. These non -invasive 
surrogate markers could help in two ways. Firstly, it 
may be possible for a marker to give a reasonably 
accurate indication of what effect the proposed new 
drug would have in any subsequent large mortality 
trial. We would then be able to select out promising 
drugs for these mortality studies from a large range of 
candidate novel therapies and avoid the current situ- 
ation where financial pressures may stifle novel drug 
development indiscriminately. Secondly, successful 
markers of mortality might themselves be potential 
targets for future drug development in the expec- 
tation that some of these markers represent key 
processes leading to mortality. 
However, in order for these markers to be 
accepted as surrogates for cardiac mortality, there 
must be sufficient evidence to show that drug therapy 
which alters mortality also causes a corresponding 
change in the surrogate. Not too long ago ejection 
fraction was considered a potential surrogate end- 
point for survival in patients with heart failure. 
However, its positive predictive value for sudden 
death is low and inotropic drug therapy such as 
milrinone, which improved ventricular function, had 
the opposite, adverse effect on mortality111. Hence; 
surrogates other than ejection fraction will need to be 
considered. Recent compelling evidence linking the 
autonomic nervous system and cardiac mortality 
including sudden death12 -51, suggests to us that para- 
meters such as heart rate variability, baroreceptor 
sensitivity and ventricular repolarization character- 
istics (QT dispersion) may well serve this purpose as 
potential surrogate markers. However, the predictive 
value of many of these autonomic markers is at 
present, uncertain. 
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The objective of this article is to assess how 
accurate these potential surrogate markers actually 
are at predicting drug effects on mortality in chronic 
heart failure. We have attempted to do this by 
reviewing the different drugs that have had an impact 
on mortality in heart failure and to see what their 
effects are on various potential surrogate markers. 
The markers that we have looked at include heart 
rate and its variability, baroreceptor sensitivity, QT 
dispersion, arrhythmias, late potentials and neuro- 
hormones. 
The effect of drug therapy on various 
surrogate markers in chronic heart 
failure (see Table 1) 
Drugs that have a favourable effect on 
mortality 
ACE inhibitors 
The mortality benefits of ACE inhibitors have been 
attributed to both neurohormonal suppression and 
vasodilatation161. Furthermore, it has been shown 
that the effect of ACE inhibitors on mortality reduc- 
tion was greater in those with a high baseline circu- 
lating norepinephrine level or an activated renin 
angiotensin system171. This reduction in mortality 
is paralleled by changes in various markers of 
autonomic tone, including a decreased heart rate181, 
increased heart rate variability19-111, increased baro- 
receptor sensitivity112 -141, decreased QT dispersion1151 
and a reduction in malignant ventricular arrhyth- 
miasl16-181. In summary therefore, all potential surro- 
gates are favourably altered by ACE inhibitors, 
which correspond with their favourable effect on 
mortality16,8,191 
Hydralazine-isosorbide dinitrate 
The vasodilator combination of hydralazine and 
isosorbide dinitrate has been shown to reduce mor- 
tality in the V -HeFT I studyr201. It has no impact on 
arrhythmic events in patients with left ventricular 
dysfunction and a history of inducible ventricular 
tachycardia1211. However, unlike ACE inhibitors, the 
hydralazine plus isosorbide dinitrate combination is 
associated with a small but significant rise in heart 
rate and an increased plasma norepinephrine concen- 
tration during the first year of follow- up161. However, 
the impact on autonomic markers such as heart rate 
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friability and baroreceptor sensitivity is not known. 
summary, unlike the situation with ACE inhibi- 
frs, there is a discrepancy here between their favour - 
ble effects on mortality and their unfavourable 
sects on heart rate and neurohormones. 
ka- blockers :: 
u addition to heart rate reductiont22.231, beta - 
iockers have consistently improved heart rate yaria- 
ty1 ' ,zs1 and plasma neurohormones (e.g. 'ANP, 
a techolanvnes)l'-6 
°273. Beta - blockers have also been 
rted to reduce ventricular tachyarrhyrhmias128,291. 
reports on the effects of beta -blockers on baro- 
tor sensitivity are, however, conflicting13o,321 
regard to QT dispersion, beta -blockers have 
been shown to reduce QT dispersion in the long 
syndromej33.341 This has been demonstrated by 
olitano et a1.1331 who found that beta -blockers 
d a greater reduction in those with higher base - 
values. Sotolol also reduces QT dispersion in 
-myocardial infarction patientsj351. 
In chronic heart failure, the corresponding 
on mortality are not entirely clear, although 
arable effects are likely. Metoprolol1221 and biso- 
Pl have produced favourable but not statisti- 
significant data on mortality. However, more 
fly, carvediloll361, a second generation beta - 
nergic antagonist with al- blocking effects, has 
shown to reduce mortality by 65% when com- 
to placebo in chronic heart failure. Therefore as 
rs beta- blockers are concerned, there is good 
between their effects on mortality and their 
on all surrogates. 
Drugs that have no overall impact on 
mortality 
recently the use of digoxin therapy in chronic 
failure and sinus rhythm has been controversial. 
Digoxin has been shown to reduce heart rate signifi- 
cantly in some studiesj37-381 but not in othersl39!. 
Furthermore, it has also been shown to have favour- 
able autonomic modulating properties; it restores 
heart rate variability137.381, improves baroreceptor 
sensitivityt4°1 and reduces circulating catechol- 
aminesl374t421 However despite these promising 
signs, digoxin had no impact on mortality in the DIG 
triall431 or on arrhythmic events in the DIMT 
studyl421. 
Calcium channel antagonists 
The use of Ca- channel blockers in heart failure has 
been controversial because of their potentially nega- 
tive inotropic activity and their ability to activate 
the neurohormonal systeml441. However, recent evi- 
dence has shown that the second generation dihydro- 
pyridines (e.g. amlodipine or felodipine) possess more 
favourable neurohormonal effectsl45.471. They appear 
to have no adverse effects on plasma norepinephrine 
levels in either normal subjectsl461 or- heart failure 
patientsl45.471. The Iong -term impact of these drugs on 
heart rate has not been reported from large trials. 
Although some dihydropyridines are known to cause 
an acute reflexogenic rise in heart rate, there are 
several small studies which show that the heart rate 
may subside in the long terml481. The effects of 
calcium antagonists on heart rate variability in 
chronic heart failure is not known, but felodipine has 
been shown to have no significant effect on heart rate 
variability in post -myocardial infarction patients1691. 
Similarly, Cook et aL1491 could not show any effect 
with diltiazem in normal subjects. Only verapamil, 
which is not used in heart failure, has been shown to 
improve heart rate variability in post - myocardial 
infarction patientst691. There are some data suggesting 
that calcium antagonists improve baroreceptor 
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sensitivityt505 1 in heart failure. In mortality trials, 
amlodipine and felodipine appear overall to have a 
neutral effect153.541 
Amiodarone 
Amiodarone deserves a separate mention. Low dose 
amiodarone was shown to reduce total mortality 
(including sudden death) by 28% over a 2 year period 
in the GESICA trials1551. However, controversy has 
arisen, as another trial, CHF- STATts61 showed no 
improvement in survival with amiodarone despite an 
improvement in LV ejection fraction. The discrep- 
ancy has not been fully explained, but may be par- 
tially accounted for by differences in doses and 
characteristics of the patients used in the two studies. 
Preliminary results from the recent EMIAT and 
CAMIAT trials of post -myocardial infarction 
patients (including those with LV dysfunction) have 
revealed a reduction in arrhythmic events, although 
total mortality was not reduced. Nonetheless, amio- 
darone appears to have a favourable effect on poten- 
tial surrogate markers; it has been shown to reduce 
heart rate significantly in both the GESICAt551 and 
CHF- STATt561 studies. Furthermore it also improves 
increase heart rate variability157M1 and reduces QT 
dispersionts9 -611 
Drugs with adverse effects on mortality 
Dopamine Receptors Agonists (Ibopamine) 
Ibopamine is an active dopaminergic prodrug which 
works primarily as a vasodilator with some inotropic 
activity. It has no significant effects on heart ratet371. 
Furthermore, it does not appear to have any signifi- 
cant proarrhythmic effects as documented by Holter 
monitoring and signal- averaged ECGst45,621 It has 
also been shown to modulate the autonomic tone 
favourably and to reduce circulating plasma neuro- 
hormonest42,631. An improvement in heart rate varia- 
bility (although not statistically significant) has also 
been documented in a substudy of the DIMT 
studyt371. Published long -term survival data are un- 
available at present but the multicentre trial PRIME 
II (second Prospective Randomised study of 
Ibopamine on Mortality and Efficacy) has apparently 
been terminated due to adverse effects on mortality. 
Ibopamine would appear to be the most worrying 
example of disagreement between survival data and 
the results with potential surrogate markers, with the 
latter suggesting favourable effects which were far 
from reproduced in the mortality trial. 
Flosequinan 
Flosequinan is a novel vasodilator with inotropic 
properties, no longer in use because of its adverse 
Eur Heart J, Voi. 18, December 1997 
effects on mortalityt64 °651. It caused an increase 
in heart rate1661 and is associated with increased 
norepinephrine levels1651. However, the worsened 
mortality is inconsistent with its effects on heart 
rate variability, where it appears to increase 
parasympathetic and decrease sympathetic tone, 
respectively1661. 
Positive inotropic agents ( milrinone) 
Despite their beneficial effects on the haemodynamics 
of heart failure, phosphodiesterase inhibitors such as 
milrinone have been shown to have adverse effects on 
mortalitytll. They are known to activate the neuro- 
endocrine systems, especially the renin -angiotensin 
system1671 and predipose the myocardium to arrhyth- 
mias1681. The effects of these inotropic agents on 
autonomic markers such as heart rate variability are 
unknown. 
Anti- arrhythmic therapy 
The use of antiarrhythmic therapy in chronic heart 
failure is limited. Apart from amiodarone, most 
antiarrhythmic drugs (especially Class I) have no 
significant effects on baseline heart rate but are 
associated with proarrhythmic effects, increased 
mortality and a deterioration in heart rate 
variability1571. 
Summary 
Clearly at present, the one perfect surrogate marker 
for mortality remains elusive. Chronic heart failure 
is a complex syndrome: as such it may perhaps be 
too simplistic to expect any single parameter to 
be universally predictive of drug effects on mor- 
tality, especially when each drug works by different 
mechanisms. 
Nevertheless, neurohormonal antagonists, 
such as ACE inhibitors and beta- blockers, seem to 
benefit both mortality and all surrogate markers 
of mortality. Equally, inotropic drugs and Class I 
antiarrhytbmics appear to worsen both mortality and 
many surrogates. This is encouraging. However, sig- 
nificant discrepancies exist, particularly for digoxin, 
ibopamine and hydralazine -nitrates, although it is 
only with the latter two that diametrically opposite 
effects occurred, whereby favourable surrogate effects 
turned into unfavourable mortality effects (or vice 
versa). It appears appropriate to have guarded opti- 
mism about the potential use of these surrogates to 
predict drug effects in chronic heart failure. Given 
our current understanding, none of the parameters 
discussed above is perfect when used alone. Perhaps a 
battery of surrogates would be more appropriate 
ether than there being any single surrogate. The 
lost promising surrogates are heart rate variability, 
iT dispersion and plasma neurohormones, the first 
vo for sudden death and the last one for death from 
rogressive disease. 
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Aldosterone blunts the baroreflex response 
in man 
K. M. YEE and A. D. STRUTHERS 
University Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medial School, 
Dundee DD 19SY, U.K. 
I. Recent animal evidence suggests that aidosterone, like angiotensin II, may possess detrimental 
autonomic modulating properties. Aldosterone has been shown to impair the baroreceptor 
response in animal models. This study is designed to test the hypothesis that aldosterone directly 
attenuates the baroreflex in vivo in man. 
.2. Fourteen healthy male volunteers [mean age (S.D.) 25 (9) years] received intravenous d- 
aldosterone (12 pmol min -I kg-I) and 5% dextrose (vehicle) in a double -blind crossover fashion, 
.co- infused with incremental doses of intravenous phenylephrine and sodium nitroprusside. 
Aldosterone had no significant effect on resting blood pressure, heart rate or baroreflex 
response to sodium nitroprusside. However, reflex responses to phenylephrine were impaired 
with aidosterone. (P < 0.01) while blood pressure responses were unaltered. Baroreflex 
sensitivity was significantly blunted in the aldosterone group [8.36 ±2.19 versus 10.12± 
2.27 ms /mmHg; P < 0.04]. 
3. This study confirms previous observations from animal models that aldosterone impairs the 
baroreflex response. High aldosterone levels may contribute to the baroreflex dysfunction in 
cardiovascular diseases such as hypertension and heart failure. 
INTRODUCTION 
It is well established that angiotensin II (ANG II) 
attenuates baroreflex control of heart rate and sym- 
pathetic activity [1,2], and that angiotensin- converting 
enzyme (ACE) inhibitors are able to improve baro- 
receptor sensitivity (MIS) [3,4]. However, it is now being 
appreciated that aldosterone too may influence the 
baroreflex, irrespective of ANG II. 
We recently found that spironolactone improves heart 
rate variability (as a measure of parasympathetic activity) 
inpatients with chronic heart failure (CHF) [5]. Although 
it remains inconclusive whether this was a direct effect of 
autonomic modulation by aldosterone blockade or due 
to the diuretic effect of spironolactone (which may 
potentially reduce right atrial stretch and improve heart 
rate variability by mechanoelectric feedback [6]), there is 
experimental data to suggest that aldosterone has major 
direct effects on the autonomic nervous system and the 
baroreflex. In an animal model, Wang et al. [7] showed 
that aldosterone infusion directly reduced baroreceptor 
discharge from the carotid sinus in dogs. 
However, no direct information has yet been reported 
on the effects of aldosterone on baroreflex responses in 
man. As with all animal studies, it is essential to determine 
if these observations also occur in man, especially since 
Key words: aldosterone, autonomic nervous system, baroreceptors, blood pressure, heart failure, heart rate. 
Abbreviations: ACE, angiotensin- converting enzyme; ANG II, angiotensin II; BP, blood pressure; BRS, baroreflex sensitivity; 
CHF, chronic heart failure; HR, heart rate. 
Correspondence: Dr K. M. Yee, at present address: Department of Cardiology, Bedford Hospital, South Wing, Kempston Road, 
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baroreceptor dysfunction is known to play a central 
regulatory role in the development of cardiac arrhythmia 
[8 -10]. Thus, we have designed this study to test the 
hypothesis that aldosterone attenuates the baroreflex 
control of heart rate in vivo in normal man. We have 
examined the effects of an acute intravenous infusion of 
aldosterone on the vagal and sympathetic limbs of the 
autonomic nervous system, by assessment of blood 
pressure and reflex heart rate responses to phenylephrine, 




Fourteen normal male volunteers [mean age (S.D.) 25 (9) 
years] were studied. None had a history of hypertension 
or cardiac disease, and physical examination, routine 
haematological and biochemical parameters, and 12 -lead 
ECGs were normal in all subjects. Each subject provided 
informed consent and the study was approved by the 
Tayside Committee on Medical Research. 
Protocol 
The subjects were studied on 2 separate days, at least 72 h 
apart, in a placebo -controlled, randomized, double -blind, 
crossover fashion. Subjects were asked to refrain from 
alcohol, caffeine and cigarettes for 24 h and to fast for 2 h 
before each study day. 
Subjects rested quietly in the supine position through- 
out the study. Two 18G intravenous cannulae were 
inserted into forearm veins, one in the right arm for blood 
sampling and one in the left arm for infusion of either 
aldosterone or 5 % dextrose solution (as vehicle). After 
45 min of bed rest, baseline values of blood pressure (BP) 
and heart rate (HR) were measured non -invasively in 
triplicate using a semi -automatic sphygmomanometer 
(Dinamap Vital Signs Monitor 1846; Critikon, Tampa, 
FL, U.S.A.) with the cuff placed around the subject's left 
arm. A 12 -lead ECG and venous blood (15 ml) for 
baseline aldosterone and angiotensin II assays were also 
obtained. 
After this, a continuous infusion of either vehicle or d- 
aldosterone (Tayside Pharmaceuticals ) in similar volumes 
was commenced in the left arm- The d- aldosterone was 
infused at a rate of 12 pinol min-1- kg-1. After 45 min of 
infusion, further triplicate recordings of BP, HR and 
continuous 12 -lead ECGs were obtained along with 
blood samples for aldosterone and angiotensin II assays. 
The haemodynamic study was then started, i.e. after- 
90 min of supine bed rest and 45 min after commence- 
ment of the infusion. The baroreflex response to a 
vasopressor agent, phenylephrine, was assessed in the 
first half of the study. Phenylephrine was given intra- 
© 1998 The Biochenùol Society ad die Medical kuawtb Society 
venously by infusion into the right forearm. It was 
administered in stepwise 10 -min infusions (0.2- 
3.6 pg min-1- kg -1) by use of an infusion pump (1MED, 
San Diego, CA, U.SA.). The infusion was stopped when 
a 35-40 mmHg rise in systolic arterial pressure had been 
achieved. The average systolic BP, HR and R -R interval 
obtained from continuous ECG recordings between 8 
and 10 min after each infusion dose were recorded. 
After completion of these measurements with phen- 
ylephrine, HR and BP were allowed to return to baseline 
values for 30 min before the second phase of the study 
began. Intravenous sodium nitroprusside was given in 
stepwise 5-min infusions (0.2-5.2 deg min-' kg -1) until a 
maximum drop in systolic BP of 25 mmHg was achieved. 
HR, BP and ECG recordings were obtained after4 -5 min 
of each infusion dose. 
Baroreflex sensitivity (BRS) assessment 
The R -R intervals were plotted against the systolic BP 
values on a graph, and a computerized curve fit was 
carried out to establish a linear portion of the line of best 
fit. Separate linear regression lines were plotted for the 
responses to phenylephrine and sodium nitroprusside. 
Traditionally, the slope derived from the linear regression 
line (ARR /dSBP) obtained from the vasopressor (phen- 
ylephrine) half of the haemodynamic study has been used 
as an index of BRS. As in previous studies [4,11], only 
regression lines that had a correlation coefficient of > 0.8 
were used. This method of assessment of the baroreflex 
using an infusion of phenylephrine has previously been 
shown to be reproducible [11]. 
Aldosterone and angiotensin Il assays 
Five -millilitre venous blood samples in lithium heparin 
tubes and 10 -ml venous samples in chilled glass tubes 
containing a solution of 0.05 mol /1 o- phenanthroline, 
2 g/1 neomycin, 0.125 mol /1 EDTA (disodium salt) and 
2 % ethanol, were collected for measurements of aldo- 
sterone and ANG H levels respectively. The samples 
were centrifuged at 4 °C and the plasma was separated 
and stored at -20 °C (aldosterone) and -70 °C (ANG 
II) until assayed. Commercially available radioimmuno- 
assay kits (Sorin Biomedica, Saluggia, Italy, and Nichols 
Institute Diagnostics B. F., Nieuweweg, The Nether- 
lands) were used for the aldosterone and ANG II assays 
respectively. 
Statistical analysis 
All data were analysed using the Statgraphics software 
package (STSC Softwear Publishing Group, Rockville, 
MD, U.S.A.). Analysis of variance at each dose increment, 
using subjects and treatment as within factors, and 
Bonferroni multiple range tests were performed to 
determine the significance of the effects of aldosterone on 
the hacmodynarnic response to phenylephrine and so- 
l6 Aue25 ere - dps art A5 3 (X 2) 
dium nitroprusside. The relationships between R -R 
intervals and systolic BP were studied by correlation and 
linear regression analyses; BRS between treatment 
groups was analysed using the paired Student's t -test. 
Differences were considered statistically significant if P 
< 0.05. 
RESULTS 
Baseline measurements (Table I) 
No significant differences in baseline measurements were 
seen between vehicle and aldosterone infusion days. 
Aldosterone infusion was painless. A significant rise in 
plasma aldosterone levels was noted after 45 min of 
aldosterone infusion compared with vehicle. There was a 
non -significant decrease in ANG H levels after aldo- 
sterone infusion compared with vehicle. 
Haemodynamic measurements (Figures 1 -3, 
Table 2) 
No significant changes in resting BP and HR recordings 
were observed during aldosterone infusion compared 
with vehicle. Systolic BP increased and decreased in a 
stepwise fashion in response to the phenylephrine and 
sodium nitroprusside in both 
groups; no significant differences in BP responses were 
observed in the aldosterone group compared with vehicle 
(Figures 1 and 2). Similarly, no significant differences in 
reflex HR responses to sodium nitroprusside were 
observed between the two groups. The slopes of the 
linear regression line in response to sodium nitroprusside 
(dRR /ASBP) were not significantly affected by aldo- 
sterone compared with vehicle [8.62 ±4.64 ms /mmHg 
(means ±S.D.) versus 9.07 ±2.11 ms /mmHg; P = 0.7] 
(Figure 3). 
However, reflex HR responses to phenylephrine were 
significantly impaired in the aldosterone group compared 
with vehicle (P < 0.05). BRS was significantly depressed 
in the aldosterone group [8.36 ±2.19 ms /mmHg versus 
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Figure I Change in heart rate (HR) and blood pressure (BP) 
responses ta incremental infusions of phenylephrine 























Figure2 Change in heart rate (HR) and blood pressure (BP) 
responses to incremental infusions of sodium nitroprusside 
Values are means ±S.E.M_ 
Table I Baseline values 
Results are expressed as means (S.D.). Statistical significance: "P< 0.05 compared with vehicle. 
Vehide 
Heart rate (beats/min) 
Systolic BP (mmHg) 
R-R interval (ms) 
Aldosterone levels (pg/ml) 
baseline 
45 min after start of infusion 
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Fgure3 Relationship between changes in RR interval and 
systolic blood pressure (SBP) 
Values are means ±S_E.M. Separate linear regression lines for responses to 
phenylephrine and sodium nitroprusside for the two treatments an shown. 
DISCUSSION 
The present study confirms previous observations from 
animal models that aldosterone impairs the baroreflex 
response. The sensitivity of the arterial baroreceptors to 
a change in BP is an important determinant of the ability 
of the autonomic nervous system to maintain cardio- 
vascular haemostasis. 
In this study, aldosterone has been shown to impair the 
HR response to phenylephrine. This is in keeping with a 
previous observation of ours that aldosterone halved the 
bradycardic response to infused noradrenaline, another 
vasopressor agent 112]. Although acting primarily on the 
arterial baroreceptors, it must be borne in mind that any 
change in afterload by vasopressor agents will also tend 
to cause a corresponding change in preload and thus 
influence the cardiopulmonary receptors as well. On the 
other hand, sodium nitroprusside results in vasodilatation 
and generalized unloading of arterial and cardiopul- 
monary baroreceptors leading to increased cardiac sym- 
pathetic activity [13,14]. It is interesting to note that 
aldosterone does not appear to have any significant effect 
on the reflex tachycardia (or cardiac sympathetic) re- 
sponse to sodium nitroprusside. These data together 
suggest that aldosterone exerts major effects on the 
parasympathetic limb of the autonomic nervous system. 
With regards to its specific mechanism of action, 
evidence from animal studies suggests that aldosterone 
may have a direct action on the arterial baroreceptors. 
Wang et aL [7,15] not only showed that aldosterone 
reduces the HR response to changes in BP, but also 
showed conclusively that aldosterone directly reduces 
baroreceptor discharge from the carotid sinus of dogs. 
These effects were seen with both acute and chronic 
administration of aldosterone. On a cellular level, the 
mechanism is less certain. Aldosterone may elicit part of 
its effect on the arterial baroreceptors by stimulation of 
the Na-- K+- ATPase activity [7,15] as it is known to be a 
potent Na +- K +- ATPase stimulant [16,17]. Depressed 
baroreceptor function after chronic aldosterone infusion 
in animal models has been shown to be partially reversed 
with a bolus injection of the Na+- K+- ATPase inhibitor, 
ouabain [15]. Similarly, digoxin, another cardiac glyco- 
side/Na +- K +- ATPase inhibitor, has also been shown to 
improve BRS in chronic hyperaldosteronaernic states 
such as CHF. [8,18]. However, such an effect of ouabain 
was not seen after acute administration of aldosterone [7], 
suggesting that other mechanisms may be responsible for 
the acute effects of the hormone. Interestingly, the 
impaired baroreflex response due CO acute administration 
of aldosterone could be prevented by denudation of the 
endothelial cells in the carotid sinus area, which has led to 
the suggestion that aldosterone may stimulate endothelial 
cells to release an unknown substance that depresses BRS 
activity. 
Although this study was not designed to determine the 
specific merhanism by which aldosterone impairs the 
baroreflex, it has important clinical implications as it is 
the first study as such to extend these observations to 
man. This study adds to the growing body of evidence 
Table 2 Change in haemodynamic parameters in response to phenylephrine infusion 
Values are means and 95% confidence intervals (in brackets). Statistic significance: 'P < 0.05, ji < 0.01 compared with vehicle_ Abbreviations: SBP. systolic blood 
pressure; HR, heart rate. 
Vehide Aldasierone 
dSBP (mmHg) dHR (beats/mio) dR-It interval (ms) dSBP (mmHg) dHR (bean/min) 4R4 interval (ms) 
Dose of phenylephrine 
(µg min-1- kg-i) 
0.2 35 (0.6 -6.4) 3.2 (1.9 -43) 51.9 (31.9 -831) 3.6 (0.7 -6.6) 2.7 (1.4-4.0) 50.2 (242 -16.2) 
0.6 125 (8.1 -16.9) 83 (6.1 -10.6) 163 (120 -206) 135 (9.0 -11.9) 33 (13 -5.8)f 63.9 (20.1 -101)f 
1.2 205 (14.4 -26.6) 13.9 (12.1 -159) 288 (241 -330) 24.6 (18.7 -301) 9.0 (1.1- 10.8)f 182 (141 -222)f 
2.4 43.1 (363 -49.8) 19.0 (113 -203) 435 (385-485) 44.1 (31.4 -50.9) 153 (13.8 -16.)f 343 (293 -393)- 
3.6 51.2 (51.7 -6L7) 211 (20.1 -242) 571 (533 -609) 60.4 (53.9 -41.0) 189 (16.4 -21.2)- 462 (416 -507)f 
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that aldosterone, like ANG II, has autonomic modulating 
properties. Aldosterone has been shown to block nor - 
adrenaline uptake in the heart in vivo in an animal study 
[19]. In accordance with this, we recently found that 
spironolactone, an aldosterone antagonist, increased 
myocardial noradrenaline uptake [19] and improved HR 
variability [5] in patients with CHF. Although in our 
study, aldosterone does not appear to have any significant 
effect on the reflex sympathetic response to sodium 
nitroprusside in healthy volunteers, this finding is not 
necessarily a contradiction to our previous findings since 
infusing nitroprusside into normal man clearly does not 
exactly reproduce the activated sympathetic system of 
patients with CHF, even though nitroprusside is a 
traditional way of assessing sympatho -activation in man. 
One important difference between the two is that filling 
pressures are high in CHF but are likely to be subnormal 
after nitroprusside unloading in normal man. 
There are, however, some limitations to our study 
worth discussing. First, the study was performed in 
healthy subjects and not in patient groups. Patients with 
CHF, for example, have a markedly abnormal and 
complex- haemodynamic and neurohormonal state. Al- 
though it would be of interest to assess the effects in these 
patient groups, they are not ideal for the purpose of this 
study which was to assess the effects of aldosterone on 
baroreceptor function in vivo in man. In our study of 
healthy subjects we were able to isolate the effects of 
aldosterone on the baroreflex (and thus confirm the data 
from animal models) while avoiding the many possible 
confounding factors present in patients with CHF who 
are characterized by the presence of other circulating 
neurohormones, impaired vascular tone and endothelial 
dysfunction. 
Secondly, salt intake was not controlled for in this 
study. Alterations in body salt status may potentially 
affect the renin-angiotensin- aldosterone axis. However, 
volunteers were advised to remain on their usual diet 
throughout the study and, as reflected by the baseline 
measurements, there were no significant differences in 
plasma neurohormones between the two study days. 
Finally, infusions rather than boluses of pressor and 
vasodepressor stimuli were used in this study, allowing 
for baroreceptor `resetting' to occur and hence reducing 
or dampening any change in baroreflex response. This 
may mean that small changes in baroreflex response to 
sodium nitroprusside, for example, may have gone 
undetected. On the other hand, one might expect, if 
anything, the blunting effect of aldosterone on baroreflex 
response to phenylephrine to be amplified if the bolus 
method had been used instead. BRS measurements by 
infusion method may not be equivalent to the bolus 
method, but the infusion method has been shown to be 
reproducible [11]. 
Infusions were used in this study because it allowed us 
to monitor HR and BP changes at steady state non- 
invasively at each incremental dose which has the 
advantage that our readings were taken in triplicate, 
which should minimize random measurement error. In 
addition, the bolus method requires either invasive intra- 
arterial measurements (more risk and discomfort to the 
subject using radial artery devices) or non- invasive beat - 
to- beat analysis using the Finapres, which is not possible 
at our institute as the Finapres devices are no longer 
available in the U.K. Furthermore, we were more 
interested in changes or differences in baroreceptor 
sensitivities between two treatments rather than in using 
absolute levels of BRS to compare one population with 
another. 
In summary, this study has established that in man in 
vivo, aldosterone has a detrimental effect on the para- 
sympathetic component of the baroreflex response. The 
effects of aldosterone on the autonomic nervous system 
have important clinical implications. In conditions such 
as CHF and hypertension, it is well documented that the 
suppressive effect of long -term ACE inhibitors on 
aldosterone is weak, variable and unsustained, whether or 
not ANG II itself remains suppressed [20 -22]. It is 
noteworthy that in our study, the plasma concentration 
of aldosterone [mean (S.D.) 489.8 (83.3) pg /ml] achieved 
on the treatment days was similar to those observed in 
patients with CHF [20]. 
Baroreflex dysfunction is thought to be a key process 
contributing to the development of ventricular arrhyth- 
miss and mortality in patients with CHF and ischaemic 
heart disease [8,9,23]. Thus, it follows that if residual 
aldosterone is partly responsible for the blunting of the 
baroreflex in these patients, there may well be a thera- 
peutic benefit in considering anti- aldosterone therapy in 
addition to ACE inhibitors. It must be borne in mind, 
however, that only the effects of acute aldosterone 
administration have been examined in this study, and 
whether these observations also extend to conditions 
characterized by chronic elevated aldosterone levels 
remains to be determined. The potential mortality bene- 
fits of giving spironolactone in addition to ACE in- 
hibitors are currently being evaluated in the multi- centre 
RALES study [24]. If the RALES study turns out to be 
positive, then this study will have highlighted an im- 
portant possible mechanism for such a beneficial effect 
on mortality. 
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Endogenous angiotensin II and baroreceptor dysfunction: a comparative 
tudy of losartan and enalapril in man 
M. Yee & A. D. Struthers 
búversily Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, Dundee DDI 9SY 
Aims To assess the role of direct AT1 receptor antagonism in baroreceptor 
modulation in man, and to perform a direct comparison of Ang II blockade at the receptor level with that of ACE inhibition. 
Methods Ten healthy male volunteers [mean age (s.d.) 23 (6.9)] pretreated with 
frusemide therapy (40 mg day -1 for 3 days prior to each visit) were studied on 3 
separate days, 10 days apart, in a placebo -controlled, randomized, double -blind, 
cross -over fashion. On each study day, subjects were randomly given either a single - 
dose of enalapril 20 mg, losartan 50 mg or placebo. Baroreceptor function was 
assessed by measuring changes in blood pressure (BP), pulse interval (RR Int) and 
heart rate (HR) in response to incremental doses of intravenous phenylephrine 
infusions (0.2 -3.6 µg kg- t min -1). 
Results In response to phenylephrine, no significant differences in BP responses 
were observed with any of the study medications but reflex heart rate responses 
were significantly increased with both enalapril and losartan compared with placebo 
(P<0.05). The (RR /AsBP ratio, taken as a measure of baroreceptor sensitivity 
(BRS) was significantly increased with enalapril [12.2 + 4.6 ins mmHg -1 
(mean +s.d.)] and losartan [11.9 +3.6 ms mmHg -1) compared with placebo 
[9.2 +4.5 ms mmH -1]; i.e. enalapril and losartan increased the (RR /(AsBP ratio 
by 3.0 ms mmHg (95 %CI 0.5, 5.6; P<0.05) and 2.8 ms mmHg -1 (95 %CI 0.6, 
5.0; P< 0.038), respectively. There were however, no significant differences between 
losartan and enalapril [mean difference 0.25 (95 %CI -1.6, 2.1)]. 
Conclusions The present study confirms observations from animal models that 
blocking endogenous angiotensin II in man improves baroreceptor function. Both 
strategies, AT1 receptor antagonism and ACE inhibition appear to be equally 
effective in restoring baroreceptor function in salt- depleted normotensive subjects. 
Keywords: angiotensin II, baroreceptor, enalapril, losartan 
troduction 
roreflex dysfunction is thought to be a key process leading 
ventricular dysrhythmias and sudden deaths in patients 
th CHF and in postmyocardial infarction patients [1 -3]. 
major component of baroreflex dysfunction is vagal 
ivity. In animal studies [4, 5], vagal stimulation dramati- 
ly improves survival and reduces dysrhythmias after 
.onary artery ligation. 
[t is well established that angiotensin II (Mg II) attenuates 
°reflex control of heart rate and increases sympathetic 
Ivity (6, 7]. Similarly, ACE inhibitors have been shown 
improve both heart rate variability and baroreceptor 
sitivity (BRS) in man [8 -10]. Indeed, the effect of ACE 
ibitors on BRS may well be instrumental in their ability 
snprove mortality in heart failure. 
:ompared with ACE inhibitors, Ang II type 1 receptor 
.1) antagonists offer a more selective and complete 
ckade of Ang II. The question naturally arises whether 
spondence: Dr K. M. Yee, University Department of Clinical Pharmacology, 
wells Hospital and Medical School, Dundee DDI 9SY. 
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AT1 receptor antagonists will also have favourable effects 
on BRS. Pharmacologically, they may even be more 
effective at boosting BRS because Ang II levels are not 
completely suppressed by ACE inhibitors [11]. However, 
although direct AT1 receptor antagonists have been shown 
to improve baroreceptor function in animal models [12, 13], 
the only study to examine this question in man found no 
effect of losartan on baroreflex sensitivity [14]. This whole 
question has been given added impetus by the recent 
Evaluation with Losartan in the Elderly (ELITE) trial results. 
Although designed primarily to assess safety and efficacy of 
the treatments and not mortality, it was intriguingly observed 
in the multicentre ELITE trial [15] that those randomized 
to losartan had a 46% reduction in all-cause mortality in 
comparison with captopril- treated patients, which was 
primarily due to a decrease in sudden cardiac deaths. 
The purpose of the present study was two fold. Firstly, 
the main aim was to assess if AT1 receptor antagonism really 
does improve baroreceptor function in man, as had been 
previously demonstrated in animal models although it did 
not appear to in the only human study of the matter [14]. 
The secondary aim was to perform a head to head 
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comparison of Ang II blockade at the receptor level with 
that of ACE inhibition to see if there were any major 
differences between them which might be relevant to the 
ELITE results. In this study, a comparison of a single oral 
dose of losartan potassium 50 mg was made with a single 
dose of an ACE inhibitor, enalapril maleate 20 mg. In 
particular, we performed this study in normal man in whom 
the endogenous renin angiotensin system (RAAS) had been 
activated as it would enable us to assess the activated RAAS 
of heart failure in isolation while avoiding the confounding 
influences of increased age, comorbidity and polypharmacy 
which would be present in CHF. 
Methods 
Subjects 
Ten normal male volunteers [mean age (s.d.) 23 (6.9)] were 
studied. None had a history of hypertension or cardiac 
disease. Physical examination, routine haematological and 
biochemical parameters, and 12 lead electrocardiograms 
(ECG)-were normal in all subjects. Each provided informed 
consent -in writing, and the study was approved by the 
Tayside Ethics Committee on Medical Research. 
Protocol 
Subjects were studied on 3 separate days, 10 days apart, in 
a placebo -controlled, randomized, double -blind, cross -over 
fashion. Three days prior to each study visit, subjects were 
pretreated with oral frusemide 40 mg day -1 to activate their 
endogenous renin- angiotensin system. The subjects were 
instructed to take the daily frusemide dose at 18.00 h and 
they were asked to maintain their usual diet for the duration 
of the study and to adhere to the same pattern of meals in 
the 48 h preceding each visit day. Subjects were also 
required to refrain from alcohol, caffeine and cigarettes for 
24 h and to fast for 2 h before each study day. 
On the study day (i.e. the day after they had completed 
each course of frusemide tablets), the subjects attended our 
department at 08.00 h. Each subject was given randomly, a 
different tablet on each visit day which comprised of either 
a placebo tablet, enalapril 20 mg or losartan 50 mg. 
Subjects rested quietly in the supine position throughout 
the study period. An 18G intravenous cannula was inserted 
into a right forearm vein for drug infusions and blood 
sampling. After 45 min of bedrest, baseline values of blood 
pressure (BP) and heart rate (HR) were measured noninvas- 
ively in triplicate using a semiautomatic sphygmomanometer 
(Dinamap Vital Signs Monitor 1846; Critikon, Tampa, FL, 
USA) with the cuff being placed around the subjects left 
arm. A 12 lead electrocardiogram and venous blood (15m1) 
for baseline aldosterone and Ang II assays were also obtained. 
The haemodynamic and baroreceptor assessments were 
carried out after 6 h following ingestion of the oral 
medication as the haemodynamic effects of both a single 
dose of Aral losartan and enalapril are known to peak after 
6 h [16, ,17]. Further triplicate recordings of resting blood 
pressure, heart rate and continuous 12 -lead ECGs were 
obtained before the reflex baroreceptor response to a 
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vasopressor agent, phenylephrine (PE), was assessed. 
Intravenous PE was administered in stepwise 10 min 
infusions (0.2 -3.6 µg kg -1 min-1) by use of an infusion 
pump (IMED, San Diego, CA). The infusion was stopped 
when a 35 -40 mmHg rise in systolic arterial pressure had 
been achieved. The average systolic BP, HR and R -R 
interval obtained from continuous ECG recordings between 
8 and 10 min after each infusion dose were recorded. After 
completion of these measurements with PE, HR and BP 
were allowed to return to baseline values. 
Barorefíexsensitivity (BRS) assessment 
The R -R intervals were plotted against the systolic blood 
pressure in a graph, and a computerised curve fit was then 
carried out to establish a linear portion of the line of best 
fit. As in previous studies [8, 9, 18], only regression lines 
that had a correlation coefficient of >0.8 were used; the 
slope of the linear portion of this relationship ((RR /t1sBP) 
was taken as an index of baroreflex sensitivity (BRS). The 
method of assessment of the baroreflex using an infusion of 
PE has been previously shown to be reproducible [18]. 
Aldosterone and angiotensin II assays 
Venous blood samples (5 ml) in lithium heparin tubes and 
10 ml venous samples in chilled glass tubes containing a 
solution of 0.05 mol 1 -1 o- phenantroline, 2 g l -1 neomycin, 
0.125 moll -1 EDTA (disodium salt) and 2% ethanol, were 
collected for measurements of aldosterone and Ang II levels, 
respectively. The samples were centrifuged at 4° C and the 
plasma was separated and stored at -20° C (aldosterone) 
and -70° C (Ang II) until assayed. Commercially available 
radioimmunoassay kits (Sorin Biomedica, Saluggia, Italy, 
and Nichols Institute Diagnostics B.F., Nieuweweg, The 
Netherlands) were used for the aldosterone and Ang II 
assays, respectively. 
Statistical analysis 
All data were analysed using the Statgraphics software 
package (STSC Softwear Publishing Group, Rockville, MD, 
USA). Multiple analysis of variance, using subjects and 
treatment as within factors, and Bonferroni multiple range 
tests were performed to determine the significance of the 
effects of losartan and enalapril on the haemodynamic 
response to phenylephrine. The relationships between R -R 
intervals and systolic BP were studied by correlation and 
linear regression analyses; BRS between the placebo and 
treatment groups were analysed using the paired Student's 




Resting haemodynamic and biochemical measurements were 
similar at all study visits prior to administration of the study 
medications (Table 1). As expected, basal plasma Ang II and 
aldosterone levels were elevated as a result of frusemide- 
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Angiotensin II and human barare flex 
Table 1 Baseline 
values. Results are expressed as means±s.d. Statistical significance: *P<0.004 compared with placebo. 
Placebo Enalapril Losartan 
Wart rate (beau 
min ') Pre -dose 67.6 (4.6) 66.6 (9.1) 69.1 (9.4) 
6 h post -dose 68.0 (7.4) 67.1 (8.4) 68.8 (7.1) 
Systolic BP (mmHg) Pre -dose 117.6 (9.9) 117.1 (7.6) 118.5 (7.1) 
6 h post -dose 119.3 (8.5) 107.5 (9.8)* 110.1 (7.4)* 
R -R interval (ms) Pre -dose 892 (62) 916.5 (122) 883 (115) 
6 h post -dose 892 (96) 907 (108) 881 (89) 
Plasma Ang 1I (pg m1-1) Pre -dose 42.6 (34.4) 40.7 (19.9) 44.9 (29.0) 
Plasma aldosterone (pgm1 -') Pre -dose 194 (189) 113 (63) 141 (79) 
induced salt depletion. At 6 h following ingestion of study 
medication, resting blood pressure was significantly reduced 






















0.6 1.2 2.4 3.6 
Phenylephrine (fig kg' min 1) 
Figure 1 Change in heart rate (AHR) and blood pressure (AsBP) 
responses to incremental infusions of phenylephrine. Values are 
mean ±s.d. placebo, enalapril, losartan *P<0.05 
compared with placebo. 
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12.6; P= 0.0038) and 9.6 mmHg (95% CI 4.6, 14.6; P= 
0.004), respectively, compared with placebo. However, 
there were no significant differences with resting heart rate 
either at the start or at 6 h after medication. 
Baroreceptor assessment (Figures 1, 2, Table 2) 
Systolic blood pressure and reflex heart rate increased and 
decreased, respectively, in a stepwise fashion in response to 
the phenylephrine infusion on all 3 study days. Whereas no 
significant differences in BP responses were observed with 
any of the study medications, reflex heart rate responses to 
phenylephrine were significantly increased with both enalap- 
ril and losartan compared to placebo (P<0.05). The 
(RR/(sBP ratio, taken as a measure of BRS was signific- 
antly increased with enalapril [12.2 -I-4.6 ms mmHg -1 
(mean ±s.d.)] and losartan [11.9-{-3.6 ms mmHg -1] 
compared with placebo [9.2 +4.5 ms mmHg -']; i.e. enalap- 
ril and losartan increased the (RR/AsBP ratio by 
3.0 ms mmHg -1 (95 %CI 0.5, 5.6; P <0.05) and 
2.8 ms mmHg -1 (95 %CI 0.6, 5.0; P<0.038), respectively. 
There were however, no significant differences 
between losartan and enalapril [mean difference 0.25 (95 %CI 













Enalapril Placebo Losartan 
Treatment 
Figure 2 Individual baroreflex sensitivity (BRS) data. The 
individual BRS indices (slope of the linear regression line 
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Discussion 
In this study, the haemodynamic effects of a single dose of 
oral losartan potassium and a single dose of oral enalapril 
maleate were examined in salt -depleted normotensive 
subjects pretreated with diuretics. Assessments were made 
6 h after oral administration of the respective medications 
i.e. at the tirne when the haemodynamic effects of the drugs 
are maximal [16, 17]. The hypotensive effect of a single 
dose of 50 mg losartan was comparable with that of 20 mg 
enalapril (systolic BP reduced by 8.4 mmHg [95% CI 4.2, 
12.6] and 9.6 mmHg [95% CI 4.6, 14.6], respectively). In 
accordance with data from other studies [16, 17, 19, 20] 
resting blood pressure was significantly reduced by both 
drugs but resting heart rate was unaffected. 
The absence of reflex tachycardia accompanying blood 
pressure reduction has been attributed to the parasympathetic 
activity of these drugs. The influence of Ang II on the 
cardiac vagal activity is well established in both animal 
studies [21, 22] and human studies involving steady state 
infusions of Ang II [7]. Although in disease states such as 
CHF, ACE inhibitors have been shown to enhance 
baroreceptor function [8, 9], the evidence for such a role 
for endogenous Ang II in healthy man has been conflicting. 
In sodium replete hypertensive subjects, captopril has been 
shown to cause displacement of the baroreceptor set -point 
but no modification of the BRS during activation by 
phenylephine [23, 24]. However, hypertensive patients are 
known to have a blunted baroreflex function [24, 25] which 
might confuse the picture. Hence, only studies in normotens- 
ive subjects will allow a true assessment of the effect of Ang 
II blockade per se on baroreceptor function. Amongst 
normotensive subjects, Ibsen et al. [20] found that enalapril 
improved BRS function whereas Giulicelli et al. [26] did 
not. In the only human study involving AT1 receptor 
antagonists, losartan had no effect on baroreflex sensitivity, 
although this was measured by the gain of the transfer 
function relating BP to pulse interval rather than by more 
standard techniques [14]. One of the possible reasons for the 
contradictory data in the literature may be related to the 
differences in the salt status and degree of endogenous Ang 
II activation in the different study populations. The latter 
two studies above [14, 26] were carried out in normotensives 
with normal salt status whereas in the study by Ibsen et al. 
[20], the subjects were mildly sodium depleted. This 
observation may be important suggesting that the influence 
of endogenous Ang II on the autonomic and vascular tone 
may only become prominent during an activated RAAS 
state e.g. during salt depletion. It has been shown in a recent 
animal model that Ang [I blockade improved the baroreflex 
response to a greater extent in rats fed with a sodium 
deficient diet compared with those on a high sodium diet 
[27]. The effects of raised endogenous Ang II is clinically 
relevant in a cardiovascular diseases such as CHF and 
hypertension where the RAAS is activated and may even 
be further exacerbated by diuretic therapy. Recent data 
even suggest that the RAAS is activated in hypercholesterola - 
emic patients [28] which may make our findings relevant to 
many disease groups. 
The effects of raised endogenous Ang II on reflex 
baroreceptor function were assessed in this study. The 
subjects in the study were pretreated with frusemide to 
activate the RAAS. The reflex bradycardic response to 
phenylephrine was significantly increased following treat- 
ment with enalapril and losartan. In addition, the slopes of 
the (RR AsBP linear regression line were also significantly 
increased. These observations support our hypothesis that 
raised endogenous Ang II levels do contribute to barorecep- 
tor dysfunction and that Ang II blockade, either by ACE 
inhibition or direct antagonism at the receptor level, would 
reverse it. These findings are also in agreement with 
observations from animal models where both losartan [27, 
29] and enalapril [29] have been shown to enhance 
baroreceptor sensitivity. 
It is also interesting to note in this study that the effects 
of losartan were comparable with those of enalapril. 
Although minor differences between the two clearly could 
not be excluded, we were able to exclude large or significant 
differences. Direct Ang II receptor antagonists such as 
losartan lack the bradykinin potentiation seen with ACE 
inhibition. Although there are beneficial effects associated 
with bradykinins, the lack of bradykinin- related adverse 
Dose PE 






20.6 ± 6.1 
38.1 +9.8 
45.6 + 6.0 





MIR (beats min -t) 
5.0+4.6 
19.5 ± 10.4 
34.6 ± 9.3 
43.6+6.4 
0.6 5.6 ±3.9 6.6 ±3.6 7.0 ±3.9 
1.2 14.0+ 5.4 12.5 ± 4.2 13.0 + 4.7 
2.4 15.4 ±5.1 19.0+4.4* 21.4 + 3.6* 
3.6 23.9 ± 4.4 28.6 ±5.8t 27.5 ±5.3* 
.IR -R interval (ms) 
0.6 86+645 1015+68 110 ± 79 
1.2 250± 127 222 ±113 224 ± 127 
2.4 280 ± 125 376 ± 142* 421 ± 149* 
3.6 517 ± 204 738 + 309* 644 +269 
586 
Table 2 Changes in haemodynamic 
parameters in response to phenylephrine 
infusion. Values are mean +s.d. Statistical 
significance: *P<0.01; tP<0.05 
compared with placebo. 
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effects makes AT1 receptor antagonists an attractive alterna- 
tive to ACE inhibitors. The recent ELITE trial [15] suggest 
that losartan may be even better than ACE inhibitors in 
terms of reducing mortality and in particular sudden deaths 
in heart failure. Although baroreflex dysfunction is thought 
to be a key process leading to ventricular dysrhythmias and 
sudden deaths, our study did not show any large differences 
in baroreceptor modulation between the two strategies. 
There may be several explanations for this. Firstly, the 
mechanisms for sudden death are multifactorial. Secondly, 
the number of deaths in the ELITE trial was small as it was 
not designed primarily as a mortality trial and the results 
may therefore occur by chance. Thirdly, there are inevitably, 
some limitations to our study. 
Infusions rather than boluses of pressor stimuli were used 
in this study, allowing for baroreceptor 'resetting' to occur 
and hence reducing or dampening any change in barorecep- 
tor response. This may mean that potentially small differences 
in baroreceptor response between the two treatments for 
instance, may have gone undetected. BRS measurements by 
infusion method may not be equivalent to the bolus method, 
but the infusion method has been shown to be reproduc- 
ible [18]. 
Infusions we're used in this study firstly, as it allowed us 
to monitor HR and BP changes at steady state noninvasively 
at each incremental dose, and hence avoiding the need for 
invasive beat -to -beat intra- arterial measurements as required 
by the bolus method. Secondly, noninvasive beat -to -beat 
analysis using the FINAPRES is now difficult in the United 
Kingdom as the FINAPRES machines are no longer 
available. Therefore, although our measurements may not 
exactly match the beat -to -beat method, our technique has 
the advantage that our readings were taken at steady state 
and more importantly still each of our readings were taken 
in triplicate, which should minimize random measurement 
error. Furthermore we were more interested in changes or 
differences in baroreceptor sensitivities between two treatments 
rather than in using absolute levels of BRS to compare one 
population with another. 
Despite these limitations, our data clearly indicate that 
blocking endogenous Ang II in man improves baroreceptor 
function. Both strategies, AT1 receptor antagonism and 
ACE inhibition appear to be equally effective in restoring 
baroreceptor function in salt- depleted normotensive subjects. 
This may be clinically relevant in conditions such as CHF; 
the long -term effects of these treatments are currently being 
evaluated in the ongoing mortality trial, ELITE II. 
Dr K. M. Yee is supported by a grant from the Scottish 
Office Home and Health Department. 
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Effect of Phenylephrine With and 
Without Atropine on QT Dispersion in 
Healthy Normotensive Men 
Kok -Meng Yee, MRCP, Pitt O. Lim, MRCP, Simon A. Ogston, MSc, and 
Allan D. Struthers, MD 
The present study examined if changes in cardiac after- 
load would affect QT interval dispersion. QT dispersion 
(QTd) on the 12 -lead electrocardiogram is believed to be 
a noninvasive measure of electrical inhomogeneity in 
the heart and has recently been identified as a sensitive 
predictor of sudden cardiac death. In experimental mod- 
els, an increase in cardiac afterload has been shown to 
alter action potential durations through mechanoelectri- 
cal feedback. This may result in an altered dispersion of 
action potential repolarization in the ventricle. Until 
now, there has been little evidence for this occurring in 
man in vivo. In the present study, the effects of afterload 
on QTd were examined in 10 healthy male volunteers 
(mean age [SD] 25 years (4.51) who received an intra- 
venous infusion of phenylephrine (0.2 to 3.6 ig /kg/ 
min) given in incremental doses, and placebo in a 
blinded, crossover fashion. Because phenylephrine is 
known to alter heart rate (HR) significantly (via a reflex 
vagal response), the study was performed with and 
without atropine. We found a significant positive corre- 
lation between acute changes in blood pressure (BP) and 
changes in all Old indexes (oQTd /e systolic BP and 
1QTcd /Asystolic BP r values 0.67 and 0.60, respec- 
tively; p <0.001). This relation was independent of HR 
changes or reflex vagal activity. Atropine had no signif- 
icant effect on Old. These observations have important 
clinical implications and may partly account for why 
sudden deaths and arrhythmic complications occur so 
frequently in conditions associated with increased after- 
load, such as hypertension and heart failure. ©2000 
by Excerpta Medica, Inc. 
(Am J Cordial 2000;85:69 -74) 
QT dispersion (QTd), the difference between the 
longest and shortest QT interval measured on the 
12 -lead electrocardiogram, has recently been identi- 
fied as a simple and easily measured predictor of 
sudden cardiac death.( -3 QTd is believed to be a 
measure of electrical inhomogeneity in the heart that 
decreases an individual's threshold for ventricular ar- 
rhythmias.4 Unraveling what factors actually contrib- 
ute to electrical inhomogeneity is essential if we are to 
develop specific therapies to overcome it, and thus 
reduce sudden death. One factor that may be impor- 
tant is cardiac afterload. In experimental models, an 
acute increase in cardiac afterload has been shown to 
be arrhythmogenic.5,6 An increase in cardiac loading 
with subsequent stretching of the ventricular myocar- 
dium causes shortening of the action potential dura- 
tion,7,8 and this may result in an altered dispersion of 
action potential repolarization in the ventricle.9 Until 
now, there has been little evidence for this occurring 
in man in vivo. We examined whether changes in 
cardiac afterload would alter QTd by examining the 
effects of an acute phenylephrine- induced increase in 
afterload on QTd in 10 healthy men. Because phen- 
ylephrine is known to alter heart rate (HR) signifi- 
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cantly (via a reflex vagal response), the study was 
performed with and without atropine. We also exam- 
ined whether atropine per se would alter the QTmax 
interval and QTd. 
METHODS 
Subjects: Ten normal male volunteers (mean age 
[SD] 25 years [4.5]) were studied. One patient was 
withdrawn from the study because he could not toler- 
ate the phenylephrine infusion (his systolic blood 
pressure (BP) increased by >50 mm Hg at the lowest 
dose administered). No patient had a history of hyper- 
tension or cardiac disease, and physical examination, 
routine hematologic and biochemical parameters, and 
12 -lead electrocardiograms were normal in all sub- 
jects. Each patient provided informed consent, and the 
study was approved by the Tayside Ethical Committee 
on Medical Research. 
Protocol: Subjects were studied on 2 separate days, 
at least 72 hours apart, in a placebo -controlled, ran- 
domized, single -blinded, crossover fashion. Subjects 
were requested to refrain from alcohol, caffeine, and 
cigarettes for 24 hours and to fast for 2 hours before 
each study day. Subjects rested quietly in the supine 
position throughout the study. A single 18 -gauge in- 
travenous cannula was inserted into a right forearm 
vein of each subject. After 30 minutes of bedrest, 
baseline values of BP and HR were measured nonin- 
vasively in triplicate using a semiautomatic sphygmom- 
anometer (Dinamap Vital Signs Monitor 1846; Cri- 
tikon, Tampa, Florida) with the cuff being placed 
around the subject's left arm. Baseline 12 -lead elec- 
trocardiograms were also obtained. Following this, a 
©2000 by Excerpta Medica, Inc. All rights reserved. 0002 -9149/00/5 -see front matter 69 
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TABLE I Baseline Hemadynamic and Electrocardiographic 
Measurements With Placebo Infusion 
Preinfusion 
(Start) Post- Atropine* p Value 
Systolic BP (mm Hg) 114 ± 10 116 ± 11 NS 
Diastolic BP (mm Hg) 64 ± 12 66 ± 9 NS 
HR (beats /min) 66 ± 12 109 ± 10 <0.001 
QTmax (ms) 401.5 ± 33 347 ± 19 <0.001 
QTmax (linear correction) 416 ± 19 421 ± 17 NS 
QTmax ( Bazett's correction) 412 ± 14 448 ± 15 <0.001 
QTmin (ms) 357 ± 20 301 ± 24 <0.001 
QTsmin (linear correction) 371 ± 15 375 ± 18 NS 
QTsmin (Bazett's correction) 365 ± 22 395 ± 21 <0.01 
QTd (ms) 45 ± 15 46 ± 6 NS 
QTd (linear correction) 45 ± 15 46 ± 6 NS 
QTd (Bazett's correction) 47 ± 15 54 ± 10 NS 
`Denotes values at rest following atropine before recommencement of pla- 
cebo infusion (see text). 
Expressed os mean ± SD. Statistical significance (p <0.05) refers to com- 
parison with preinfusion baseline values. Baseline values at rest during phen- 
ylephrine infusion are similar (see Table II). 
continuous infusion of either phenylephrine (Knoll 
Pharma, Nottingham United Kingdom) or placebo 
(5% dextrose) in similar volumes, was adminstered 
intravenously. Up to 6 incremental stepwise 10- 
minute infusions (0.2 to 3.6 pg/kg/min)) were admin- 
istered using an infusion pump (IMED, San Diego, 
California). The infusion was halted when a 35 to 40 
mm Hg increase in systolic BP had been achieved 
with the active treatment. Infusions of the placebo 
were performed in similar volumes and incremental 
steps as the active treatment. BP, HR, and electrocar- 
diographic recordings were obtained in triplicate be- 
tween 8 and 10 minutes after each infusion dose. After 
completion of these measurements, the infusion was 
discontinued and BP and HR at rest were allowed to 
return to baseline values for 30 minutes. 
Atropine 0.03 mg/kg was then administered by 
slow IV injection over 1 minute. Once HR and BP had 
restabilized following full vagal blockade, a repeat 
baseline 12 -lead electrocardiogram was obtained and 
the infusion of phenylephrine (or placebo) was re- 
started and the study repeated again as described 
above. Forty-five minutes after the injection of atro- 
pine, a further 0.6 mg od atropine was given intrave- 
nously to ensure continued vagal blockade. At the end 
of the study BP and HR at rest were allowed to return 
to normal. 
QT interval and dispersion analysis: Electrocardio- 
grams (with simultaneous 12 -lead acquisition) were 
recorded with a Hewlett- Packard 4700A electrocar- 
diographic machine (Palo Alto, California). All mea- 
surements were analyzed blindly by a single observer 
(KMY) on a Calcomp digitizing tablet (Twyford, 
Berkshire, United Kingdom) using customized soft- 
ware, as described elsewhere.z' The QT interval was 
taken from the onset of the QRS to the end of the wave 
(i.e., return to the T/P baseline). If U waves were 
present, the QT interval was measured to the nadir of 
the curve between the T and U waves. Three consec- 
utive cycles were usually measured for each lead. QT 
TABLE II Effects of Phenylephrine (- Atropine) on Heart Rate 
and QT Intervals 
Baseline 
(no atropine) Phe ' p Value 
HR 58 ± 11 42 ± 4 0.0004 
QTmax 418 ± 27 460 ± 26 0.0003 
QTmmax (linear correction) 415 ± 20 429 ± 25 0.017 
QTmax ( Bazett's correction) 410 ± 22 400 ± 28 NS 
QTmin 373 ± 25 396 ± 24 0.001 
QTmin (linear correction) 369 ± 20 364 ± 20 NS 
QTsmin ( Bazett's correction) 364 ± 24 332 ± 25 0.001 
Baseline 
(with atropine) Phe-Atr 
HR 104 ±13 106 ±13 NS 
QTmax 345 ± 27 348 ± 25 NS 
QTmax (linear correction) 422 ± 18 429 ± 13 NS 
QTmax ( Bazett's correction) 455 ± 24 465 ± 14 NS 
QTmin 299 ± 24 285 ± 17 0.038 
QTmin (linear correction) 376 ± 16 365 ± 14 NS 
QTmin (Bazett's correction) 398 ± 16 381 ± 12 0.02 
Measurements taken at baseline and after phenylephrine (Phe) infusion, with 
and without atropine (ATRI. 
intervals were corrected with both Bazett's formula 
(QT, = QT/RR "/z) and Hodges et al' s10 linear correc- 
tion formula (QT. = QT + 1.75 [HR - 60]). 
QTd was calculated in electrocardiograms in which 
?9 leads were measurable. QTd is defined as QT- 
max - QTmin. Corrected QT dispersion (QTad) is 
defined as QTmax - QTamin. The intra- and inter - 
observer variability were 6% and 7 %, 
measurements of QTd. 
Statistical analysis: All data were analyzed using the 
Statgraphics software package (STSC Software Pub- 
lishing Group, Rockville, Maryland). The relation be- 
tween variables were studied by Pearson's correlation 
and linear regression analyses. Differences between 
treatment groups were analyzed using the paired Stu- 
dent's t test. Results were expressed as mean -!- SD. 
Differences were considered statistically significant if 
p was <0.05. 
RESULTS 
Baseline measurements: BP, HR, and electrocardio- 
graphic parameters at rest were similar at the start of 
both study visits (Table I). On the placebo study day, 
there were no changes in either hemodynamic or QTd 
parameters before and after infusion. Following atro- 
pine, baseline HR increased significantly but BP at 
rest was unchanged. This was paralleled by a signifi- 
cant reduction in QTmax and an increase in the 
Bazett- corrected QTamax. The linearly -corrected 
QTmax did not increase significantly. Atropine, how- 
ever, did not appear to have any significant effect on 
either QTd or QTad. 
Correlation between alterations in blood pressure 
and QT dispersion: PELHNTYLEPHRINE ALONE: Phenyleph- 
rine given in incremental doses caused a gradual in- 
crease in BP paralleled by a significant decrease in 
reflex HR. Both QTmax and the linearly corrected 
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FIGURE I. Individual data: changes in QTd (AQTd) in response 
to changes in systolic blood pressure (A.SBP) following phenyl- 
ephrine (Phe) infusion olone (top) and Phe - atropine (Atr) 
(bottom). 
QTGmax significantly increased, but the Bazett-cor- 
rected QTmax was not significantly affected by the 
changes in BP induced by phenylephrine (Table II). 
The relation between changes in BP and QT interval 
and dispersion indexes in response to phenylephrine 
are displayed in Figures 1 to 5 and Table III. It is clear 
that phenylephrine caused a significant increase in 
QTd and QTcd and that this occurred in the presence 
or absence of atropine. 
Changes in QTd (AQTd) and QT0d (AQTcd) ap- 
pear to be significantly correlated with both changes in 
systolic and diastolic BP in a linear fashion. The 
relations between the variables, expressed as the slope 
of the linear regression line (e.g., AQTd /Asystolic 
BP), and their respective p values and correlation 
coefficients for each individual are displayed in Table 
III. Similar linear regression analysis made on the 
pooled data are displayed in Figures 1 to 3. 
PHENYLEPHRINE AND ATROPINE: Following pretreat- 
ment with atropine, phenylephrine had no significant 
effect on either HR, QTmax, or QTemax (Table II). 
The previously demonstrated relation between the dis- 
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FIGURE 2. Pooled scalterplot: relation between changes in QTd 
(AQTd) and changes in systolic BP (A.SBP) (top) and diastolic BP 
(.ïDBP) (bottom) in response to phenylephrine (Phe) ± atropine 
(Atr). The correlation coefficient, r, and p value for each linear 
relation are displayed. 
unaffected by atropine pretreatment. There were no 
significant differences in the slope, AQTd /Asystolic 
BP before and after atropine (mean difference -0.003 
[95% confidence intervals (CI) -0.558 to 0.552] 
ms /mm Hg; p = 0.9). Similarly, atropine did not 
affect AQTd/Adiastolic BP (mean difference -0.271 
[95% CI -1.060 to 0.517] ms /mm Hg; p = 0.45), 
AQTcd/Asystolic BP (mean difference -0.404 
ms /mm Hg [95% CI -1.066 to 0.258] ms/mm Hg; 
p = 0.2), or AQT5d/Adiastolic BP (mean difference 
-0.383 [95% CI -1.214 to 0.449] ms /mmHg; p = 
0.32). 
DISCUSSION 
In the present study, we found a significant positive 
correlation between changes in cardiac afterload and 
changes in all QTd indexes. Importantly, our atropine 
data showed that this relation was independent of HR 
changes or reflex vagal activity. Phenylephrine is a 
vasopressor, acting principally on the arterial bed. The 
increase in afterload is accompanied by a decrease in 
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FIGURE 3. Pooled scaferplot: relation between changes in Ba- 
zeit- corrected QTd (AMA) and changes in systolic BP (oSBP) 
(top) and diastolic BP (ADBP) (bottom) in response to phenyleph- 
rine (Phe) ± atropine (Atr). The correlation coefficient, r, and p 
value for each linear relation ore displayed. 
HR, resulting from reflex vagal activation. Pretreat- 
ment with atropine not only enabled us to assess the 
contributory role of vagal blockade on QTd, but also 
allowed us to control for HR. Due to the varying Hits, 
the effects of phenylephrine on Bazett's rate corrected 
QT intervals were significantly different from uncor- 
rected values in our study (Tables I and II). As can 
clearly be seen, the QTmax values were not only 
significantly different between corrected and uncor- 
rected values, but they moved numerically in opposite 
directions as a result of over -correction with the Ba- 
zett's formula.' 1.12 This has led many investigators to 
question the appropriateness of HR correction formu- 
las such as Bazett's. 
However, despite this, the relation between 
changes in QTd and changes in BP was unaffected by 
HR (Figures 2 to 3). Although it appears that acute 
cardiac afterload increases QTd, there does not appear 
to be any significant correlation with QTmmax (Figure 
4). The impact of these major hemodynamic pertur- 
bations appears to be mainly on the QTcmin (Table II, 
Figure 5). The reduction in QTcmin with afterload is 
consistent with experimental data where stretching of 
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FIGURE 4. Pooled scalterplot. relation between changes in Ba- 
zett- corrected QT,max (AQTcmax) and changes in systolic BP 
(eSBP) (tap) and diastolic BP (ADBP) (bottom) in response to 
phenylephrine (Phe) ± atropine (Atr). The correlation coefficient, 
r, and p value for each linear relation are displayed. 
the ventricular myocardium has been shown to shorten 
action potential duration.7 -9 
Afterload and QT dispersion: Our findings are con- 
sistent with the results of a recent study by Sun et a1,13 
who found a 22% increase (although nonsignificant) 
in dispersion of the QT interval following phenyleph- 
rine infusion in normal subjects. It is well established 
from experimental models that alterations in cardiac 
afterload may affect the action potential duration 
through mechanoelectrical feedback.7 From the law of 
Laplace, an increase in afterload should result in an 
increase in wall stress. Stretching of the ventricular 
myocardium has been shown to shorten the action 
potential duration in a number of studies.7-9 Impor- 
tantly, however, these changes in effective refractory 
period may not be homogenous throughout the myo- 
cardium. Dean and Lab9 found that in an in situ pig 
heart model, there was a greater change in refractory 
period occurring at the apex compared with the base in 
response to an increase in load by aortic clamping. 
The effects of afterload on QTd have important 
JANUARY 1, 2000 
TABLE III Effect of Changes in Blood Pressure on QT Dispersion: Individual Data 
Patient 
AQTd /ASBP 
(ms /mm Hg) 
AQTd /ADBP 
(ms /mm Hg) 
¿QTd /ASBP 
(ms /mm Hg) 
AQTcd /ADBP 
(ms /mm Hg) 
Phe (r) Phe -Atr (r) Phe (r) PheAtr (r) Phe (r) Phe -Atr (r) Phe (r) PheAtr (r) 
1 0.610 (0.61) 0.685 (0.98) 0.788 (0.60) 0.952 (0.98) 0.533 (0.80) 1.019 (0.99) 0.678 (0.78) 1.398 (0.96) 
2 0.891 (0.98) -0.190 (0.98) 1.700 (0.96) -0.395 (0.93) 0.622 (0.98) -0.226 (0.79) 1.169 (0.96) -0.218 (0.36) 
3 1.130 (0.84) 0.640 (0.68) 1.821 (0.88) 0.726 (0.40) 0.755 (0.85) 0.642 (0.45) 1.154 (0.77) 1.394 (0.76) 
4 0.460 (0.98) 2.071 (0.95) 1.022 (0.99) 1.538 (0.90) 0.354 (0.99) 2.728 (0.95) 0.775 (0.98) 2.027 (0.90) 
5 0.512 (0.81) 0.320 (0.64) 0.520 (0.80) 0.520 (0.70) 0.179 (0.28) 0.383 (0.55) 0.174 (0.26) 0.632 (0.62) 
6 0.490 (0.81) 0.780 (0.75) 0.819 (0.80) 0.461 (0.20) 0.307 (0.79) 1.017 (0.75) 0.581 (0.89) 0.572 (0.19) 
7 0.311 (0.86) 0.395 (0.96) 0.987 (0.95) 0.176 (0.99) 0.238 (0.85) 0.626 (0.99) 0.752 (0.95) 0.258 (0.96) 
8 0.550 (0.74) 0.381 (0.99) 0.806 (0.82) 0.516 (0.96) 0.335 (0.47) 0.559 (0.98) 0.524 (0.56) 0.714 (0.90) 
9 0.625 (0.98) 0.525 (0.98) 0.706 (0.99) 2.234 (0.62) 0.495 (0.99) 0.706 (0.98) 0.550 (0.98) 3.024 (0.62) 
Mean 0.619 0.623 1.019 0.748 0.424 0.828 0.706 1.089 
95% CI (0.429 -0.809) (0.152- 1.093) (0.676- 1.362) (0.159- 1.336) (0.279 -0.570) (0.21 1- 1.445) (0.466 -0.946) (0.329 -1.849) 
p Value <0.0001 0.016 0.0001 0.019 0.0001 0.015 0.0001 0.011 
Relation between changes in systolic BP (ASBP) and diastolic BP (ADBP), and QTd are expressed in terms of the linear regression slope (AQTdABP) for each 
individual, in response to phenylephrine (Phe) (± atropine [Air)). r (in brackets) denotes the linear correlation coefficient. p <0.05 denotes a statistically significant 
relationship between the 2 variables. 
clinical implications. A number of previous studies 
have shown that an increase in afterload is arrhyth- 
mogenic.5.6 Furthermore, patients with conditions asso- 
ciated with an elevated afterload have an increased inci- 
dence of ventricular arrhythmías and sudden deaths.14 -'6 
Angiotensin -converting enzyme (ACE) inhibitors, a va- 
sodilator drug, in contrast, has been shown to reduce 
mortality, including sudden death.' 7,' 8 It is also intrigu- 
ing to note that although QTd is increased in these 
cardiac diseases,'2 the reduction in mortality by drug 
therapies such as ACE inhibitors is paralleled by a sim- 
ilar reduction in QTd.19 It is generally believed the in- 
creased QTd in these conditions occurs as a result of 
chronic changes in the myocardium, such as left ventric- 
ular hypertrophy.20'21 We believe that our study is the 
first to show that QTd may also be affected by acute 
changes in BP. 
Vogel activity and QT dispersion: In our study, at- 
ropine reduced the resting QTmax (and QTmin) but 
increased the Bazett- corrected QTamax (and QTamin) 
significantly, an effect that has also been observed in 
other studies. ".22 However, the QT intervals were not 
significantly changed when linearly corrected. 
Changes in QT intervals are highly dependent on HR 
changes with QT interval shortening occurring as HR 
increases with atropine. As discussed in the previous 
section, the increase in Bazett- corrected QTamax is 
believed to be due to over -correction by the Bazett 
formula) 1,12 As such, it remains uncertain whether 
vagal activity does indeed modulate ventricular repo - 
larization; although some experimental data suggest 
that the cholinergic effects on ventricular repolariza- 
tion are minima1,23 others have found that atropine 
shortens the ventricular effective refractory period and 
QTmax interval during fixed atrial pacing.' 1.12 
QTd, unlike the QT interval, is not HR dependent 
(as reflected by the fact that we have found no dis- 
crepancy between our results with QTd, Bazett cor- 
rected QT0d, or linear corrected QT0d). In our study, 
QTd was unaffected by atropine. Our results are con- 
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FIGURE 5. Pooled scatferplot relation between changes in QTmin 
(top) and 8azeit- corrected QTmin (.QTmini (bottom) and 
changes in systolic BP {:ISBP) in response to phenylephrine {Phe) 
atropine. The correlation coefficient, r, and p value for each 
linear relation are displayed. 
the only study that we know of that has directly 
examined the effects of atropine on QTd in man. 
The reflex vagal response to phenylephrine has 
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been previously investigated by Kautzner et a1.25 This 
group used boluses instead of infusions of phenyleph- 
rine to assess if rapid vagal stimulation altered QTd. 
Boluses did not produce sustained increases in after - 
load. Hence, it is not surprising that Kautzner et al25 
did not find any change in QTd. The finding that reflex 
vagal activity did not influence QTd is consistent with 
our observations. 
Study limitations: First, although the study was de- 
signed primarily to assess the effects of afterload, any 
change in afterload will tend to affect preload as well. 
Although it is not possible to totally isolate the effects 
of one without changing the other, preload changes 
should be minimal because phenylephrine is an a -ad- 
renergic agonist that acts primarily on arterial circu- 
lation. 
Second, the technical difficulty of obtaining a pre- 
cise and reproducible determination of the end of the 
T -wave measurement is well recognized. Care was 
taken to use consistent criteria to define the end of the 
T wave and to exclude U waves. We were careful not 
to miss any flat U waves that may have become more 
obvious following the phenylephrine infusion, be- 
cause this may produce an artifactually short QT in- 
terval when a flat U wave becomes more obvious. 
Fortunately, this was not a major issue because the T 
and U waves were essentially normal. and easy to 
measure at baseline in a cohort of normal, healthy 
subjects. Following phenylephrine infusion, both the 
T and U waves became more prominent, making mea- 
surements even easier. If the end of T wave in any lead 
was in doubt, the lead was excluded from analysis. 
Third, a direct electrophysiologic effect of phenyl - 
ephrine on the myocardium could not be entirely 
excluded. In isolated ferret Purkinje fibers, a- adren- 
ergic stimulation was shown to induce early after 
depolarizations that could have been a trigger for 
arrhythmia initiation 26 However, these effects are be- 
lieved to be species specific, and have not been shown 
to occur in human myocardium.27 Furthermore, early 
after depolarizations are HR dependent,28 but in our 
study, the effects of phenylephrine on QTd were in- 
dependent of HR. This means that a direct electro- 
physiological effect of a- adrenergic stimulation on 
QTd was unlikely. Finally, the study was performed in 
healthy normotensive subjects and not in patient 
groups. It remains to be seen if our observations also 
apply to the hypertensive population. 
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